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Introduction
INCIDENCE OF CUTANEOUS MELANOMA
Cutaneous melanoma is developing into a major public health problem worldwide. 
Incidence differs greatly across the world with high incidence rates in the Unites states, 
Europe and especially in Australia and New Zealand, but relatively low incidence rates in 
Central and South America, Asia and Africa (figure 1). 
In Europe, melanoma incidence is rising, especially in the Northern and Western Euro-
pean countries2. This is also true for the United States, where melanoma is one of the few 
cancer types which showed continuously increasing incidence rates from 1975 onward3. 
Also in the Netherlands, incidence of melanoma keeps increasing (figure 2)4. Although 
incidence in Australia and New Zealand remains the highest in the world1, incidence 
has been observed to stabilize in younger individuals in both Australia5, as well as in 
Canada6.
Differences across gender in melanoma incidence have been noted for a long time. 
These differ considerably across the world (figure 3). In Australia and New-Zealand, men 
Figure 1. Melanoma Incidence across the world
Estimated age-standardized incidence rate per 100,000 for Melanoma of the skin (both sexes, all ages)
Source: Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality 
Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available 
from: http://globocan.iarc.fr, accessed on 30/11/20131.
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have a higher incidence than women: the age standardized incidence rate (ASR) is 42 
per 100,000 in males versus 32 per 100,000 in females. This higher incidence in males 
is also found in Northern America: with an ASR of 16 in males versus 13 in females. In 
Europe the contrary is true: incidence is higher in females than in males (7.8 vs 7.6 per 
100.000)1. Gender differences in incidence differ per European region: males have a 
higher incidence in Central and Eastern Europe, while females have a higher incidence 
in Northern and Western Europe. There is an equal incidence across gender in southern 
Europe (figure 3). However, when we take a closer look at Europe, we see that these 
differences are even more differentiated within these regions: male incidence is espe-
cially higher in countries in Central and Southern Europe while incidence is higher in 
females in Western, South-Western, but also various Eastern European countries (figure 
3A). Melanoma incidence in Asia and Africa is low (figure 1) but slightly higher in males, 
except for Eastern Africa with a higher incidence in females, and South-Central and 
Eastern Asia with an equal incidence rate (figure 3)1. In the Netherlands, incidence of 
melanoma has been consistently higher in females since 1990 and incidence is rising in 
both males and females (figure 2)4. 
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Figure 2. Incidence trends for cutaneous melanoma in the Netherlands across gender
ESR: European Standardized Rate. Data Source: www.cijfersoverkanker.nl, Dutch Cancer Registry, accessed on 22-05-2013.
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TREATMENT OF MELANOMA
The primary treatment for a primary melanoma of the skin is surgical excision, preferably 
by an immediate excisional biopsy which is evaluated by the pathologist for tumor-free 
margin and prognostic features. As recommended by the European Interdisciplinary 
consensus-based  guideline, excision margin depends on the Breslow thickness of the 
primary tumor and varies from 0.5 cm in in situ melanoma and 2 cm for melanomas 
with a thickness of >2 mm7. Clear guidelines for further staging of patients are lacking. 
In general, staging examinations can be omitted in ‘low-risk’ patients, but ‘high-risk’ 
patients should be evaluated for lymph node and distant metastasis by sonography of 
regional lymph nodes and CT or PET-CT scans. In the Dutch guidelines however further 
staging with PET-CT or more preferably CT scan is only recommended for stage IIIB 
(lymph node micrometastasis in a ulcerated primary or lymph node macrometastasis 
in an non-ulcerated primary) or higher8.  However, the definitions for high and low risk 
patients vary7. Sentinel lymph node dissection (SLND) can be used as a staging tool 
M : F M : F
1.  Eastern Africa      1.7 : 2.0
2.  Middle Africa      1.7 : 1.4
3.  Northern Africa     0.4 : 0.3
4.  Southern Africa     7.7 : 4.2
5.  Western Africa     1.2 : 1.1
6.  Caribbean        0.7 : 0.6
7.  Central America    1.5 : 1.5
8.  South America     2.1 : 1.8
9.  Northern America  15.8 : 12.5
10. Eastern Asia      0.3 : 0.3
11.  South-Eastern Asia     0.6 : 0.5
12.  South-Central Asia       0.2 : 0.2
13.  Western Asia          1.5 : 1.2
14.  Central-Eastern Europe   4.4 : 4.3
15.  Northern Europe      12.3 : 13.4
16.  Southern Europe           6.5 : 6.5
17.  Western Europe    10.6 : 12.0
18.  Australia/New Zealand 41.8 : 32.1
19.  Melanesia         4.0 : 2.7
20. Micronesia/Polynesia    0.6 : 2.1
Male : Female incidence ratio’s in 20 world regions
Fig. 3A Detailed view of Europe
higher male incidence
equal male:female incidence
higher female incidence
Figure 3. Male versus female incidence ratios across the world.
Incidence Rates are presented as Age Standardized Rates (World Population) per 100,000. In figure 3A, gender incidence 
ratios are shown across countries instead of regions.
Source: Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality 
Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available 
from: http://globocan.iarc.fr, accessed on 18/6/2013 1.
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to evaluate micro-metastasis in the sentinel lymph nodes after diagnosis of a primary 
melanoma and is of great prognostic significance. In the Netherlands, SLND is advised 
in patients with stage IB (i.e. melanoma of ≤1 mm with ulceration or a mitotic rate of 
≥1) or higher with the purpose of optimal staging and therefore informing patients of 
their prognosis as best as possible8  No effect on overall survival has been found for a 
sequential complete lymph node dissection (CLND) in SLND positive patients9. However, 
when SLND is positive, a CLDN is often recommended as non-sentinel nodes might be 
affected7. A CLND is also recommended when macroscopic lymph node metastases are 
found by routine clinical examination or imaging techniques. In several randomized 
trials in adjuvant settings, interferon-α has shown a benefit in disease-free survival but 
none or a very small benefit in overall survival, with significant toxicity. Interferon can 
therefore be considered for high risk stage II or stage III melanoma patients7. 
Until recently, there were virtually no treatment options for patients diagnosed with 
distant metastasis who had a dismal prognosis with a median survival of 6-9 months. 
Complete surgical resection of metastases is recommended if technically feasible. 
Isolated limb perfusion with melphalan with or without Tumor Necrosis Factor is recom-
mended for numerous or extensive metastatic skin lesions in one limb not amenable to 
surgery, but has mainly palliative value7. Radiation therapy is mainly used for the pallia-
tion of brain and bone metastases. Chemotherapy (mainly dacarbazine monotherapy) 
has been used in metastatic disease but showed a low remission rate of 5-12% and has 
very limited effect on survival.
However, after decades of disappointing results in the research for new treatment 
modalities, the European Medicines Agency recently approved two new drugs for the 
treatment of patients with metastatic melanoma. Firstly, in 2011 Ipilimumab was ap-
proved. Ipilimumab is a CTLA-4 antibody which leads to continued activation of lympho-
cytes which in turn leads to a continued specific immunoresponse killing tumor cells. 
Ipilimumab showed a benefit in overall survival in two randomized controlled phase 
III trials with significant Hazard Ratio’s (HRs) of 0.68 and 0.7210,11. Adverse autoimmune 
reactions do occur but are manageable in a specialized centre7. Secondly, vemurafenib 
was approved in 2012. Vemurafenib is a selective inhibitor of the BRAF V600E mutation 
which is present in approximately 50% of all melanomas. BRAF is a key regulator in the 
Mitogen-Activated Protein Kinase (MAPK) pathway. Vemurafenib showed an overall 
response rate of 48%-53% in patients carrying this mutation, although these mainly 
consisted of partial responses12,13. In one trial, vemurafenib substantially improved over-
all survival (Hazard Ratio 0.37, 95% Confidence Interval 0.26-0.55)12. However, this initial 
survival benefit is largely attenuated by acquired resistance to BRAF-inhibitors: after 
some time the majority of patients progresses despite initial response to treatment12. 
This acquired resistance to therapy is now a major focus of research. Moreover, several 
other BRAF-inhibitors e.g. dabrafenib, as well as inhibitors for molecules downstream of 
13
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BRAF in the MAPK-pathway e.g. MEK-inhibitors, are being investigated for their effect as 
mono- and combination therapies in an effort to overcome this therapy resistance7,14-16. 
Although the benefit for patients is presently limited, with these new treatment options 
in metastasized melanoma a new era in melanoma seems to have begun, in which both 
our understanding of melanoma biology as well as our treatment options will hopefully 
be expanded. 
PROGNOSTIC FACTORS IN MELANOMA
The main prognostic indicators for localized melanoma are Breslow thickness (as mea-
sured by the maximal vertical depth of the tumor), histologically recognized ulceration, 
mitotic rate (number of mitosis per mm square), and level of invasion (Clark’s level). 
Other indicators for prognosis include localisation of the primary tumor (trunk, limbs, 
head/neck), age and gender7. Furthermore, findings on SLND are of major prognostic 
significance. Although our increased understanding of melanoma carcinogenesis, im-
mune response and mutational status have led to new treatment options in patients 
with advanced melanoma as described above, we have surprisingly little understanding 
of the biological significance of most of these prognostic indicators17. For example, 
the biological explanation for the major importance of ulceration remains almost 
completely unknown17. Another unresolved mystery –and the subject of this thesis– is 
the prognostic role of gender in melanoma progression and survival. In 1959, Medical 
Oncologist L.P. White published a study in the New England Journal of Medicine on “an 
important feature about the behavior of melanomas in human beings — namely, that the 
chances of five-year survival are distinctly greater in females than in males”18. Furthermore, 
pathologist W.H. Clark jr. (to whom the Clark levels of melanoma invasion were named) 
mentioned in his 1969 study on the behaviour of melanoma that “As has been noted by 
several workers, the disease is somewhat less malignant in the female when compared with 
the male”19. This gender difference in survival was confirmed by other studies around 
1970 on melanoma survival20,21. More recently, several authors noted that this survival 
advantage for female patients persisted after adjustment for several other prognostic 
indicators such as age, Breslow thickness, ulceration and localisation of the primary 
tumor22-26. 
14
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THE GENDER EFFECT IN MELANOMA COMPARED TO OTHER TYPES OF 
CANCER
Melanoma is not the only cancer for which a better outcome for females has been 
noted. Two large studies investigated the female advantage in different cancer types. In 
Europe, Micheli et al. found a significant female advantage in 16 out of 26 different types 
of cancer after adjustment for age and region (figure 4). Only 3 types of cancer showed 
a significant male advantage. For all cancers combined, females showed a survival ad-
vantage of 5% compared to males27. In the United States, Cook et al. found a significant 
advantage for females in 18 out of 34 types of cancer, after adjustment for age and, if 
available, stage of the tumor (figure 5)28. Although the results of Micheli et al. and Cook et 
al. differ for several types of cancer, there are also some remarkable similarities (figure 4 
and 5): both confirm the male survival advantage in cancer of the urinary bladder29. Both 
studies observed a small male survival advantage in cancer of the gallbladder, although 
this did not reach significance in the study of Cook et al. Furthermore, both show a small 
but significant female advantage in cancer of the pancreas, colon and rectum, lung, 
nasal cavities & sinuses and the brain. A somewhat larger female advantage was found 
in lymphoma (Hodgkin & non-Hodgkin), cancer of the bones & cartilages, and cancer of 
the salivary gland. Most important for this thesis is however that the category contain-
ing melanoma of the skin shows the largest female advantage in both studies (Cook et 
al. used a category of skin cancer excluding basal call and squamous cell carcinoma, of 
which melanoma could be expected to be the majority of tumors). Therefore, it seems 
that although a large variety of cancer types show better survival in females than males, 
this female advantage is the largest for patients with melanoma of the skin. 
Remarkably, this gender difference in survival of melanoma seems to be restricted 
to the cutaneous variant: several studies showed no gender differences in survival of 
ocular (uveal or choroidal) melanoma20,27,30,31, except one study32. In mucosal melanoma, 
no gender differences in survival were found33-36. 
HYPOTHESES ON MECHANISMS BEHIND THE FEMALE SURVIVAL ADVANTAGE 
In general, there are two categories of hypotheses concerning these observed gender 
differences in melanoma survival: (1) gender differences in behavior explain the female 
survival advantage and (2) biological gender differences underlie this improved survival 
in females. 
For the first hypothesis, several behavioral differences across gender have been put 
forward as an explanation. The most important behavioral hypothesis states that females 
might visit their health care worker sooner when they observe a suspicious skin lesion 
15
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compared to males37, resulting in earlier detection and therefore melanomas of earlier 
stage which have a favorable prognostic outlook38-40. Another possibly behavior-linked 
aspect of melanoma associated with gender is the site of the primary melanoma. For 
long it has been noted that females have more melanomas on the extremities whereas 
males have more melanomas on the trunk (especially the back), presumably because 
of changes in clothing and sun exposure22,23,41,42. This has been hypothesized to explain 
the survival advantage in females40,41, possibly linked to the assumption that extrem-
ity melanomas, especially of the legs, are more readily visible to the patient and are 
therefore diagnosed earlier than melanomas on the trunk43. 
The second category of hypotheses state that a biological difference across gender 
explains their differences in survival. This hypothesis consists of two subcategories: the 
difference might be explained by more aggressive tumors in males, or the male host is 
less able to ‘resist’ the disease. In other words: it might be the tumor or it might be the 
-40% -30% -20% -10% 0% 10% 20% 30% 40% 50% 60%
Melanoma of skin
Salivary gland
Thyroid
Head and neck
Bone and cartilages
Pleura
Hodgkin's disease
Non-hodgkin's lymphoma
Nasal cavities and sinuses
Lip
Stomach
Brain
Soft tissue
Multiple myeloma
Oesophagus
Lung, bronchu, trachea
Colon and Rectum
Pancreas
Kidney
Small intestine
Melanoma of choroid
All cancers combined
Liver
Leukaemia
Larynx
Gallbladder and Biliary Tract
Bladder
Females betterMales better
Figure 4. Gender differences in survival for different types of cancer according to Micheli et al.
Adapted from Micheli et al.27 
The female advantage in different cancer types using EUROCARE-4 data. Percentages indicate female advantage as com-
pared to males as Relative Excess Risk, adjusted by age and region. 
Light grey bars indicate the female advantage was not significant, dark grey bars represent a significant difference across 
gender (P<0.05), a positive percentage indicates a female advantage, a negative percentage indicates a male advantage 
in survival.
16
Chapter 1
host. In literature, these hypotheses have mainly been stated ‘per exclusionem’: several 
studies noted that the female survival advantage persisted after adjustment for the 
factors which are presumably linked to the behavioral differences across gender (most 
importantly tumor thickness and primary site). This then leaves an unknown biological 
explanation for the female advantage17,22,44. However, so far no candidates have been 
investigated as such a possible biological explanation for the gender differences in 
melanoma survival.
-30% -20% -10% 0% 10% 20% 30% 40%
Skin excl BCC+SCC
Floor of mouth
Retroperitoneum
Salivary gland
Small intestine
Trachea, mediastinum, and other respirotaroy organs
Lymphoma
Nasal cavities and sinuses and middle ear
Lung, bronchu, trachea
Liver
Gum and other mouth
Bone and cartilages
Brain and other nervous system
Nasopharynx
Soft tissue
Anus, anal, anorectum
Colon and Rectum
Tonsil
Ureter
Eye and orbita
Oesophagus
Pancreas
Leukaemia
Larynx
Oropharynx
Multiple myeloma
Other biliary tract
Hypopharynx
Stomach
female advantage in different cancer types 
(According to Cook et al. ) 
Kidney
Tongue
Lip
Bladder
Females betterMales better
Galbladder
Figure 5. Gender differences in survival for different types of cancer according to Cook et al. 
Adapted from Cook et al.28 
BCC: Basal Cell Carcinoma, SCC: Squamous Cell Carcinoma.
The female advantage in different cancer types using SEER data (USA). Percentages indicate female advantage as com-
pared to males which originally reported in hazard ratios. Adjusted by age and if available, stage of the tumor (not available 
for Brain and other nervous system, lymphoma, myeloma and leukemia). 
Light grey bars indicate the female advantage was not significant, dark grey bars represent a significant difference across 
gender (P<0.05), a positive percentage indicates a female advantage, a negative percentage indicates a male advantage 
in survival.
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AIMS OF THIS THESIS
The aim of this thesis is to investigate the female advantage in melanoma survival and to 
identify possible explanations for this phenomenon. To achieve this, we investigated the 
female advantage in different large databases, adjusting it for as many other prognostic 
factors as possible. These studies are presented in chapter 2. Using both trial-based 
and population-based approaches we searched for epidemiological clues related 
to possible underlying mechanisms. In chapter 2.1, we were able to use the Munich 
Cancer Registry (MCR) to investigate gender differences in survival, but also in different 
pathways of melanoma progression. The MCR is a population-based cancer registry for 
the Bavarian region in Germany, uniquely registering not only incidence and survival, 
but also progression (e.g. metastazation). In chapter 2.2, we used data from patients 
with localized (Stage I or II) melanoma which participated in four past trials on adjuvant 
treatment (mainly interferon) of the European Organisation for Research and Treatment 
of Cancer (EORTC) Melanoma Group. As these trial patients were so meticulously fol-
lowed up and had complete information for all other factors, we were able quantify the 
female advantage adjusted for all other important prognostic factors and investigate 
different endpoints and subgroups. In chapter 2.3, we used the same approach using 
five trials of the EORTC Melanoma in stage III and IV patients, i.e. metastasized mela-
noma. The persistence of the female advantage in metastasized melanoma would be an 
argument in favor of a biological rather than a behavioural explanation. In chapter 2.4, 
we used the database of the Melanoma Institute of Australia (MIA) to investigate the 
female advantage in relation with the mitotic rate of the primary melanoma, a measure 
for primary tumor proliferation. This could give a clue whether the primary tumor differs 
across gender and explains the survival differences.  
In chapter 3, we performed extensive literature searches to find factors which are 
both linked to gender as to melanoma survival and therefore might offer an explanation 
for the observed female advantage. In chapter 3.1, we present a hypothesis based on 
extensive literature research that the different handling of reactive oxygen species across 
gender might be an explanation for the gender differences in progression and survival. 
In chapter 3.2, we summarized the findings of our literature research resulting in nu-
merous other possible explanations of the female advantage in melanoma survival. This 
thesis is concluded with a general discussion (chapter 4) and a summary (chapter 5). 
18
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ABSTRACT
Female melanoma patients generally exhibit significantly longer survival than male 
patients. This populationbased cohort study aimed to investigate gender differences 
in survival and disease progression across all stages of cutaneous melanoma. A total 
of 11,774 melanoma cases extracted from the Munich Cancer Registry (Germany), 
diagnosed between 1978 and September 2007, were eligible to enter the study. 
Hazard ratios (HRs) and 95% confidence intervals (CIs), adjusted for tumor and 
patient characteristics, were estimated for the end points of survival, regional and 
systemic progression, and survival after progression. A significant female advantage 
was observed for melanoma-specific survival (adjusted HR 0.62; 95% CI 0.56–0.70). 
Women were at a lower risk of progression (HR 0.68; 95% CI 0.62–0.75), including a 
lower risk of lymph node metastasis (HR 0.58; 95% CI 0.51–0.65) and visceral me-
tastases (HR 0.56; 95% CI 0.49–0.65). They retained a significant survival advantage 
after first progression (HR 0.81; 95% CI 0.71–0.92) and lymph node metastasis (HR 
0.80; 95% CI 0.66–0.96), but this became borderline significant (HR 0.88; 95% CI 
0.76–1.03) after visceral metastasis. Localized melanomas in women had a lower 
propensity to metastasize, resulting in a better survival when compared with men, 
even after first disease progression. These results suggest differences in tumor-host 
interaction across gender.
Abbreviations used: 
AJCC, American Joint Committee on Cancer; CI, confidence interval; HR, hazard ratio; 
MCR, Munich Cancer Registry
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INTRODUCTION
In 1967, Wallace H Clarknoted that melanoma was more aggressive in males1. Since 
then, numerous studies have consistently confirmed gender to be an independent 
prognostic factor after adjustment for, e.g., age, Breslow thickness, histological subtype, 
body site2-4 ulceration5,6, vascular invasion7, mitotic rate, Clark level6, and sentinel lymph 
node positivity3,8. Hence, a biological basis was suggested to underlie this female-
survivaladvantage3,4. Several investigators hypothesized female melanoma patients 
to be somehow protected against metastasis9-11. However, the precise differences in 
metastatic patterns across gender remain unclear. Some have stated that gender influ-
ences only local cancer invasion12; others have hypothesized that the effect is limited to 
lymphogenous13 or hematogenous8 metastasis. Given the conflicting results5,9,14, it also 
remains controversial whether the superior female survival is restricted to early-stage 
melanoma or also pertains to patients diagnosed with metastatic disease. 
This observational study assessed gender differences in several phases of melanoma 
progression and across all melanoma stages. We used data from the Munich Cancer 
Registry (MCR).
MATERIALS AND METHODS
Setting
The MCR has been registering incident cancers in Munich since 1978, gradually extend-
ing to the surrounding region of Bavaria (3.8 million inhabitants), becoming population 
based in 1988. Incidence and primary tumor information (i.e., tumor–lymph node–me-
tastasis (TNM) stage and histological tumor characteristics) are ascertained through 
pathology laboratories. Furthermore, clinicians complete standardized forms concern-
ing patient characteristics, tumor diagnosis, TNM stage, information about therapy, and 
follow-up. Vital status is recorded by physicians and validated by yearly checks with the 
Bavarian registry of death certificates and the municipal registration offices. 
Case ascertainment and available data
All melanomas diagnosed between 1978 and 2008 were extracted from the MCR data-
base (n=15,859). The last complete check of vital status was performed on 20 September 
2007; hence, melanoma cases diagnosed after 20 September 2006 were excluded so 
that atients. For patients with multiple melanomas, only the first invasive melanoma was 
used as the starting point of follow-up. In situ melanoma, lentigo maligna, noncutaneous 
melanoma, unknown primaries, and patients without follow-up were excluded (Table 
1). For all eligible cases (n=11,734), date of diagnosis, patient characteristics, primary 
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tumor characteristics, last known vital status, and cause of death were available. During 
follow-up, the occurrence of first progression (if any) and four distinct types of disease 
progression (local recurrence, in-transit/satellite metastasis, lymph node metastasis, 
and distant metastasis) were recorded (Table 2). Distant metastasis was subcategorized 
into visceral (i.e., lung, liver, brain, and other organs), distant skin, distant lymph nodes, 
and “not otherwise specified” metastasis. Because the diagnosis date was available only 
for the first distant metastasis diagnosed (marking progression to stage IV), subgroup 
analyses using the sites of distant metastasis (e.g., liver and lung) were based on the first 
distant metastasis only. Variables indicating the time from diagnosis to progression were 
calculated for all types of disease progression, and were coded ‘0’ if patients presented 
with metastasis at the time of diagnosis. Death due to melanoma was defined using 
information obtained from the death certificate or from the clinics, or if a distant mela-
noma metastasis was recorded prior to death of unknown cause. 
Statistical analysis
We used χ2 and Student’s t-test to compare categorical and continuous variables, 
respectively. Kaplan-Meier tables were used to calculate crude 10-year overall survival 
rates. Cox regression models were used to calculate crude and adjusted HRs and 95% 
CIs for females compared with males, censoring cases that were lost to follow-up 
Table 1. Exclusion of patients with melanoma recorded in the MCR 1978-2008
Number of 
melanomas
%
Total melanoma patients 15,859 100
Exclusion Criteria
Diagnosis after 20-09-2006 1,128 7.1
In Situ melanoma a 1,969 12.4
Non-skin melanoma b 129 0.8
Unknown Primary c 312 2.0
Assumed unknown primary d 154 1.0
Multiple melanomas e 432 2.7
No follow-up available 1 <0.0
Included patients 11,734 74.0
MCR: Munich Cancer Registry
a Coded as In Situ in TNM stage variable or coded as ‘In situ melanoma’, ‘Lentigo Maligna’ or ‘Nevus’ in the histological clas-
sification variable.
b Coded as mucosal or genital melanoma in Body Site classification
c Coded ‘Unknown Primary’, or as a visceral primary location in the Body Site classification 
d When no data was available for all of the following variables: TNM T-stage, Breslow thickness, Body site and Histological 
subtype, the melanoma was excluded, and were assumed to be unknown primaries
e The second, third, fourth etc. primary melanomas of one patient extracted from the registry were excluded, i.e. only the 
first invasive melanoma was included. 
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and, if applicable, cases with a non-melanoma-related cause of death. These survival 
analyses were performed separately for different phases in melanoma disease progres-
sion: (i) from diagnosis to overall or melanoma-specific death, (ii) from diagnosis todif
ferentendpointsofdiseaseprogression,and (iii) from diagnosis of disease progression to 
melanoma-specific death. For survival between visceral metastases and death, overall 
survival instead of melanoma-specific death was used as an end point to increase power, 
assuming that virtually all patients diagnosed with visceral metastases ultimately die of 
melanoma. The proportional-hazard assumption was checked by plotting log-minus-
log plots for all confounders in all analyses, followed, if necessary, by landmark analysis 
to check the extent of nonproportionality15. This yielded one minor violation: gender 
effect showed some variation over time in log-minus-log plots, but only in the analysis 
concerning overall survival. Landmark analysis revealed that the effect of gender on 
overall survival was most profound in the early years after diagnosis (HR 0.60 for 0–4 
years after diagnosis) and decreased significantly over time (HR 0.78 for44–20 years after 
diagnosis, data not shown). For all other analyses, the proportional hazard assumption 
was not violated. All statistical tests were two-sided. P-values <0.05 were considered 
significant. Statistical analysis was performed using SPSS 15.0.0 (SPSS, Chicago, IL).
Confounders
Available confounders for melanoma progression included age (continuous variable), 
year of diagnosis (continuous variable), Breslow thickness categorized according to 
the AJCC 2002 staging system16, histological subtype, primary tumor body site, N and 
M classification at the time of diagnosis, and -after disease progression- the type of 
progression or site of distant (visceral) metastasis. For categorical variables, categories 
are described in Table 2. As recommended by the STROBE (Strengthening of Reporting 
of Observational Studies in Epidemiology) guidelines for reporting of epidemiological 
studies17, and to determine which confounders influence the gender difference, all avail-
able and appropriate confounders for each survival analysis were first separately tested 
in bivariate Cox models along with gender. If a confounder adjusted the HR of gender 
by ≥10%, it was included in the multivariable Cox regression model. To confirm that the 
nonincluded confounders indeed did not influence the gender estimate, a second mul-
tivariable ‘‘fully adjusted’’ model was performed, adjusting for all available confounders.
Ulceration of the primary tumor, which is an important factor in the current AJCC 
staging system16, was excluded from our main analyses, as it was unknown for 63% of 
cases, especially in the earlier years of the study. However, subgroup analyses using only 
patients with known ulceration status(n=4,313) were performed to explore the effect 
of this important prognostic indicator on melanoma gender differences. Furthermore, 
to explore the potential influence of menopause, subgroup analyses were performed 
adjusting the gender estimate for a proxy of female menopausal status using age at 
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diagnosis: premenopausal was defined as ≤45 years old (n=3,239), menopausal as >45 
and <60 years old (n=3,312), and postmenopausal as ≥60 years old (n=5,183).
To validate the MCR database and the influence on survival of important prognostic 
factors included in the AJCC staging system, survival plots of all MCR cases stratified 
by stage I through IV were compared with those published by the AJCC melanoma 
group5,16. This was repeated for survival plots stratifying for AJCC substages according 
to ulceration -if available- in stages I and II (IA–IIC) and site of metastasis in stage IV 
(M1–M3). Unfortunately, stage III patients could not be substaged because of missing 
information on the number of positive lymph nodes.
This cohort study is reported according to the STROBE guidelines17.
Table 2. Descriptive data of study population: newly diagnosed patients with cutaneous melanoma 
recorded in the MCR
  _____Males____ ____Females___   
  N % N % p value
Total 5779 49.3% 5995 50.7%
Variable
Patient Characteristics
Age
median (yrs) 58.5 55.9
mean (yrs) 57.2 55.9 <0.001
Year of MM diagnosis overall <0.001
1978-1982 313 5.4% 438 7.4% <0.001
1983-1987 610 10.6% 673 11.3% 0.20
1988-1992 922 16.0% 1,063 17.9% 0.01
1993-1997 1,059 18.3% 970 16.3% <0.01
1998-2002 1,557 26.9% 1,475 24.8% 0.01
2003-2006 1,318 22.8% 1,336 22.4% 0.63
Primary Tumor Characteristics
Breslow Thickness
median (mm) 0.84 0.75
mean (mm) 1.81 1.70 0.23
In categories: overall <0.001
<1.0 mm 2,942 50.9% 3,261 54.4% <0.001
1.01-2.0 mm 1,003 17.4% 1,007 16.8% 0.52
2.01-4.0 mm 695 12.0% 560 9.3% <0.001
>4.0 mm 415 7.2% 355 5.9% 0.01
Missing 724 12.5% 772 12.9% 0.48
Histology overall <0.001
SSM 3,085 53.4% 3,091 51.9% 0.11
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Table 2. (Continued)
  _____Males____ ____Females___   
  N % N % p value
NM 1,313 22.7% 1,295 21.7% 0.21
LMM 377 6.5% 500 8.4% <0.001
ALM 121 2.1% 216 3.6% <0.001
Other / NOS 883 15.3% 853 14.3% 0.15
Site overall <0.001
Head and Neck 945 16.4% 881 14.8% 0.02
Trunk 2,503 43.3% 1,259 21.1% <0.001
Upper extremity 1,301 22.5% 1,311 22.0% 0.52
Lower Extremity 933 16.1% 2431 40.8% <0.001
NOS 97 1.7% 73 1.2% 0.04
Ulceration overall 0.13
No 1,896 32.8% 1,913 32.1% 0.09
Yes 267 4.6% 237 4.0% 0.43
Missing 3,616 62.6% 3,805 63.9% 0.14
N-Stage at diagnosis overall <0.001
N0/NX 5,481 94.8% 5,776 97.0%
N1+ 298 5.2% 179 3.0%
M-stage at diagnosis overall 0.01
M0 5,682 98.3% 5,891 98.9%
M1 97 1.7% 64 1.1%
Disease Progression During Follow-up
Disease Progression? overall <0.001
Yes ,1257 21.8% 934 15.7%
No 4,522 78.2% 5,021 84.3%  
Local Recurrence?       overall 0.50
Yes 266 4.6% 290 4.9%  
No 5,513 95.4% 5,665 95.1%  
In transit / satellite metastasis? a    overall 0.10
Yes 52 0.9% 72 1.2%  
No 5,727 99.1% 5,883 98.8%  
Lymphnode metastasis?    overall <0.001
Yes 805 13.9% 516 8.7%  
No 4,979 86.1% 5,439 91.3%  
Distant metastasis?    overall <0.001
Visceral metastasis 675 11.7% 406 6.8% <0.001
Distant skin / LN metastasis 274 4.7% 247 4.1% 0.13
No distant metastasis 4,830 83.6% 5,302 89.0% <0.001
a Of the total of 124 in transit / satellite metastases, n=119 were in transit and n=5 were satellites.
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RESULTS
Study population
Of the total of 11,734 patients analyzed, 49.3% were male (Table 2). Between 1978 and 
1992 most of the newly registered melanoma patients were female, but after 1992 there 
was a higher incidence of male patients. Men exhibited a disadvantaged distribution 
for almost all prognostic indicators (Table 2), being significantly older at diagnosis, hav-
ing thicker melanomas, and having more melanomas localized on the trunk or head 
and neck. In analyses of histological subtypes, females had significantly more lentigo 
maligna melanomas and acral lentiginous melanomas, but the incidence of SSM and 
nodular melanoma did not differ across gender. Males more often presented with lymph 
node metastases or distant metastasis at diagnosis than did females (5.2 vs. 3.0% and 
1.7 vs. 1.1%, respectively). Whereas overall disease progression, lymph node metastasis, 
and distant metastasis occurred significantly more often in males than in females, local 
recurrence and in-transit/satellite metastases were equally common. Median follow-up 
time of the total study population was 6.7 years (80 months). 
Survival 
Of the total 11,734 patients, 3,469 died during follow-up, including 1,398 registered mel-
anoma deaths. The crude 10-year overall survival rate was 70% and considerably higher 
in females than in males (76 vs. 65%). Similarly, adjusted overall survival for females was 
much better than for males (adjusted hazard ratio (HR) 0.71; 95% confidence interval 
(CI) 0.66-0.75; Table 3), which was even more pronounced in melanoma-specific survival 
(adjusted HR 0.59; 95% CI 0.53–0.66). Breslow thickness was the only confounder affect-
ing the gender survival difference. Subgroup analyses showed that neither ulceration 
nor the proxy for menopausal status considerably affected survival differences across 
gender (data not shown). Comparing our survival plots according to stages I to IV with 
those of the American Joint Committee on Cancer (AJCC) 2001 classification validation 
resulted in an almost complete overlap. In the subgroup with known ulceration status, 
the presence of ulceration upstaged melanomas classified in Breslow thickness catego-
ries. The best prognosis in stage IV patients was observed for skin and distant lymph 
node metastases, followed by lung metastases; the poorest prognosis was for other 
visceral metastases. These observations are in accordance with AJCC validation studies.
Progression after localized melanoma diagnosis
Females were at a lower risk of disease progression as recorded at follow-up (adjusted 
HR 0.69; 95% CI 0.63–0.75; Table 4). No significant differences across gender were ob-
served for local recurrence or in-transit/satellite metastases. However, the probability of 
progressing to stage III (lymph node metastasis) and stage IV (distant metastasis) was 
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significantly lower in women as compared with men (adjusted HRs 0.58; 95% CI 0.51–
0.65 and 0.64; 95% CI 0.57–0.71, respectively). Among distant metastasis subcategories, 
gender did not significantly affect the occurrence of skin metastases or distant lymph 
node metastasis. However, the progression to visceral metastases was highly influenced 
by gender (adjusted HR 0.53; 95% CI 0.46-0.61), with similar estimates for the occurrence 
of liver, lung, and brain metastases. Breslow thickness and primary tumor body site were 
the only confounders consistently included in the multivariable analyses. Subsequent 
Table 3. Survival after melanoma diagnosis: Multivariable analysis comparing females to males.
ENDPOINT Events (%)a 
_Crude HR_ _______Adjusted HRb_______ Fully adjusted HRc
HR 95% CI HR 95% CI
Included 
Confounder(s) b HR 95% CI
Overall Survival
  Males 1929 (33.3) 1.00 Ref 1.00 Ref
Breslow
1.00 Ref
  Females 1540 (25.7) 0.67 0.63-0.72 0.71 0.66-0.75 0.69 0.64-0.74
Melanoma-specific Survival
  Males 851 (14.7) 1.00 Ref 1.00 Ref
Breslow
1.00 Ref
  Females 547 (9.1) 0.55 0.50-0.62 0.59 0.53-0.66 0.62 0.56-0.70
Abbreviations: CI, confidence interval; HR, hazard ratio.
a Absolute numbers of deaths that were observed and the percentages within the male/female groups.
b The following confounders were tested: age, year of diagnosis (YOD), primary tumor Breslow thickness (in AJCC (American 
Joint Cancer Classification System) categories), histology and body site, and N-stage and M-stage at the time of diagnosis. 
If a confounder adjusted the male excessive risk of death by ≥10%, it was considered an eligible confounder and was 
added to the adjusted Cox proportional hazards model.
c Adjusted for all confounders: age, year of diagnosis, primary tumor Breslow thickness, histology and localization, and 
N-stage and M-stage at the time of diagnosis.
Melanoma
Diagnosis
First relapse
(Any disease
progression) Death
Visceral
metastasis
HR 0.59;
95% CI (0.53-0.66)
HR 0.52;
95% CI (0.45-0.59)
HR 0.87;
95% CI (0.75-1.01)
HR 0.69;
95% CI (0.63-0.59)
HR 0.84;
95% CI (0.74-0.95)
Figure 1. The female advantage in survival as well as before and after first progression and visceral 
metastasis. 
CI: Confidence IntervaI, HR: Hazard Ratio.
Hazard ratios for females as compared with males, presented in several time periods of melanoma progression related to 
diagnosis, disease recurrence, visceral metastasis, and death. Lighter gray arrows represent borderline significance; darker 
gray arrows represent a significant female advantage as compared with males. 
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full adjustment with all available confounders did not greatly affect gender estimates 
for disease progression (Table 4), nor did adjusting for ulceration or menopausal status 
in the subgroup analyses (data not shown).
Survival after melanoma progression
Out of 2,191 patients who progressed, 1,110 died from melanoma (Table 5). After first 
progression of disease, women retained a survival advantage of 16% as compared with 
males (adjusted HR 0.84; 95% CI 0.74-0.95). This advantage was also significant after in-
transit/satellite and lymph node metastasis, but borderline significant for survival after 
Table 4. Disease progression after melanoma diagnosis: Multivariable disease free survival analysis 
comparing females to males a
ENDPOINT Events (%)b _Crude HR_ Adjusted HR c Fully adjusted HR d
HR 95% CI HR 95% CI
Included 
Confounder(s) c HR 95% CI
Any first melanoma 
recurrence
2191 (18.7) 0.66 0.61-0.72 0.69 0.63-0.75 Breslow, Body site 0.68 0.62-0.75
-Local recurrence 476 (4.1) 0.95 0.80-1.14 0.86 0.71-1.03 All confounders 
were included
0.86 0.71-1.03
-In transit/
satellite 
metastasis
124 (1.1) 1.28 0.90-1.83 0.92 0.63-1.34 YOD, Breslow, 
histology, body site 
0.90 0.62-1.32
-Lymph node 
metastasis
1321 (11.3) 0.58 0.52-0.65 0.58 0.51-0.65 Breslow, body site 0.58 0.51-0.65
-Distant 
metastasis
1602 (13.7) 0.61 0.55-0.67 0.64 0.57-0.71 Breslow, body site 0.64 0.58-0.71
* Distant skin 
metastasis
321 (2.7) 0.83 0.66-1.03 0.75 0.59-0.94 Breslow, histology, 
body site
0.74 0.59-0.94
* Distant LN 
metastasis
200 (1.7) 0.76 0.58-1.01 0.67 0.50-0.90 Breslow, Body site 0.68 0.51-0.92
* NOS 182 (1.6) 0.75 0.56-1.00 0.82 0.61-1.09 Breslow 0.85 0.63-1.16
* Visceral 899 (7.7) 0.50 0.43-0.57 0.53 0.46-0.61 Breslow 0.56 0.49-0.65
- Liver 220 (1.9) 0.49 0.37-0.64 0.53 0.40-0.70 Breslow 0.54 0.40-0.72
- Lung 344 (2.9) 0.44 0.36-0.57 0.47 0.40-0.60 Breslow 0.50 0.40-0.64
- Brain 188 (1.6) 0.49 0.36-0.66 0.53 0.39-0.71 Breslow 0.58 0.42-0.79
- Other 
visceral
147 (1.3) 0.66 0.48-0.92 0.73 0.52-1.03 Breslow, body site 0.74 0.53-1.05
 AJCC cats: American Joint Cancer Classification System categories, CI: Confidence Interval, HR: Hazard Ratio, LN: lymph 
node, NOS: not otherwise specified, YOD: year of diagnosis 
a All HR’s were calculated for females compared to males as reference category. 
b Absolute number of events and the percentages of the total of 11,734 pts.
c The following confounders were tested: age, YOD, primary tumor Breslow thickness (in AJCC categories), histology and 
body site. If a confounder adjusted the male excessive risk of death with ≥10%, it was considered an eligible confounder 
and was added to the adjusted Cox proportional hazards model.
d Adjusted for age, YOD, primary tumor Breslow thickness, histology and body site.
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local recurrence and distant metastasis. Overall, no significant adjusted gender effects 
were observed for survival after any of the subtypes of distant metastasis. However, the 
effect of gender on survival after visceral metastasis also pproached significance (ad-
Table 5. Survival after melanoma progression: Multivariable analysis comparing females to males a
DISEASE 
PROGRESSION b
Events 
/ nr. of 
patients c
_Crude HR_ Adjusted HRd Fully Adjusted HRg
(%) HR 95% CI HR 95% CI
Included 
Confounder(s)d HR 95% CI
Any first 
melanoma 
recurrence
1110 / 2191 0.75 0.66-0.84 0.84 0.74-0.95 Body Site 0.81 0.71-0.92
-Local 
recurrence
191 / 476 40.1 0.69 0.52-0.92 0.73 0.54-1.00 Age, Breslow, Body 
Site
0.77 0.56-1.05
-Intransit/
satellite 
metastasis
39 / 121 32.2 0.54 0.29-1.02 0.39 0.16-0.95 All confounders 
were eligible
0.39 0.19-0.95
-Lymphnode 
metastasis
552 / 1321 42.8 0.77 0.65-0.92 0.82 0.68-0.99 Breslow, Body Site 0.80 0.66-0.96
-Distant 
metastasis
1005 / 1602 62.7 0.78 0.69-0.89 0.90 0.78-1.03 Body Site, Site of 
metastasis e
0.89 0.78-1.03
* Distant skin 
metastasis
162 / 321 50.5 0.79 0.58-1.07 0.84 0.60-1.17 Breslow, Body Site 0.82 0.58-1.16
* Distant LN 
metastasis
91 / 200 45.5 0.96 0.63-1.45 1.08 0.67-1.74 All confounders 
were eligible 
1.08 0.67-1.74
* NOS 128 / 182 70.3 0.79 0.55-1.12 0.84 0.56-1.26 YOD, Breslow, 
Histology
0.88 0.58-1.35
* Visceral f 822 / 899 91.4 0.84 0.73-0.97 0.87 0.74-1.01 Body Site 0.88 0.76-1.03
-Liver f 206 / 220 93.6 1.01 0.76-1.35 1.06 0.76-1.48 All confounders 
were eligible
1.06 0.76-1.48
-Lung f 311 / 344 90.4 0.84 0.66-1.07 0.80 0.63-1.02 YOD, Breslow 0.84 0.65-1.09
-Brain f 176 / 188 93.6 0.79 0.58-1.07 0.76 0.55-1.06 Age, Histology, 
Body Site 
0.78 0.56-1.09
-Other 
visceral f
129 / 147 87.8 0.70 0.49-1.00 0.84 0.58-1.22 Age, YOD 0.85 0.58-1.25
 AJCC cats: American Joint Cancer Classification System categories, CI: Confidence Interval, HR: Hazard Ratio, NOS: not 
otherwise specified, YOD: year of diagnosis
a All HR’s were calculated for females compared to males as reference category. 
b Follow-up starts at Disease Progression, and ends at lost to follow-up, MM specific death or death from other causes. 
Hazard ratios across gender are calculated for melanoma-specific death (= the event), except for distant visceral metasta-
sis, where HRs for overall survival (death of all causes) were calculated.
c Nr of observed deaths / nr. of patients with Disease Progression.
d The following confounders were tested: age as continuous variable, YOD as continuous variable, Primary tumor Breslow 
thickness (in AJCC categories), Histology and Body site. For ‘First progression’, the type of progression was also tested. For 
‘distant metastasis’, ‘distant metastasis (visceral/NOS)’ and ‘Visceral metastasis’, a variable containing the subdivision of sites 
of these metastases was also tested. If a confounder adjusted the male excessive risk of death with ≥10%, it was considered 
an eligible confounder.
e Site of distant metastasis (in categories: skin / distant lymph node / visceral / NOS).
f Survival analysis was performed for the endpoint overall survival instead of melanoma-specific survival
g Adjusted for age, YOD, primary tumor Breslow thickness, histology and body site and site of metastasis (if applicable).
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justed HR 0.87; 95% CI 0.74–1.01). Full adjustment for all available confounders did not 
considerably change the adjusted gender estimate. Owing to lack of power, subgroup 
analyses were not performed after disease progression.
DISCUSSION
Although the female melanoma survival advantage has been well established, there is 
little information on the gender effect on progression patterns. To our knowledge, this is 
the first study that not only analyzes gender survival differences but also simultaneously 
takes into account all types of melanoma progression. There have been speculations 
that gender might influence distinct phases of disease progression, namely, only local 
primary tumor invasion12, lymphogenous metastasis13, or hematogenous metastasis8. 
However, we demonstrate that females are at a significantly lower risk of both lymph 
node and distant metastases when compared with males, even when adjusted for 
relevant prognostic factors. The largest gender difference was a >50% risk reduction 
of visceral (mostly liver, lung, and brain) metastases (Table 4). This lower risk for visceral 
metastases explains the largest part of the female survival advantage, as the gender HR 
for melanoma-specific survival after first diagnosis (HR 0.62; Table 4) decreases consid-
erably after the occurrence of visceral metastasis (HR 0.88; Table 5). Even after lymph 
node metastasis, females remain at a lower risk for subsequent distant metastasis, as 
indicated by their persisting survival advantage. Our results confirm the hypothesis that 
melanoma cells in females are at lower risk of disseminating, overcoming circulation, 
and establishing metastases at any site9-11. Importantly, male gender is also associated 
with rapid growth of the primary melanoma18,19, although this was linked to a higher 
proportion of nodular melanoma, which we did not observe among males (Table 2). 
The female survival advantage may persist even after spread to visceral organs, as 
suggested by our finding of a borderline significant effect of gender (HR 0.88, 95% CI 
0.76–1.03, Table 4). Unfortunately, this analysis in stage IV patients was limited by the 
small sample size and missing information on important confounders, i.e., tumor burden 
and performance score. A few studies using stage IV trial databaseswere able to adjust 
forthese confounders, but they yielded conflicting results: one meta-analysis (n=813) 
did not reveal a significant effect of gender, but five of nine reviewed studies reported 
gender as a prognostic indicator20. Another meta-analysis (n=1,278) showed a positive 
effect of female gender on prognosis of patients with stage IV melanoma (HR 0.78; 
P<0.0001)21. Female patients with brain metastases have also been reported to exhibit 
better survival14. On the basis of both our results and the literature, we believe that a 
small independent female survival advantage persists in stageIV that is significant when 
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a study sample is large enough. According to our results, however, this might not be true 
for survival after liver metastasis (HR 1.06; Table 5).
In summary, either a protective factor in females or a melanoma-stimulating factor in 
males seems to be responsible for an overall less aggressive course of the melanoma in 
females, and, although affecting progression throughout all melanoma stages, this gen-
der factor seems to have the largest effect on the risk of visceral metastases. It is known 
that males, as compared with females, are less likely to self-detect their melanomas18, 
have a lower awareness of skin cancer risk22, make fewer visits to health-care providers, 
and are less likely to engage in preventive behaviors23. This results in diagnostic delays 
in males that probably explain their thicker tumors, older age, and higher AJCC stage at 
diagnosis, as observed in our population (Table 2) and consistently reported throughout 
the literature3,4. These differences in detection might also explain the known gender 
differences in body-site distribution, i.e., more truncal melanomas in males and limb 
melanomas in females4,9 (Table 2). Gender differences in survival have long been thought 
to result from these differences in detection. Our results, using the bivariate approach 
with the ‘‘10% rule,’’indeed indicate that Breslow thickness and body site considerably 
influenced the gender effect (Tables 2.1.3–5), reflecting these differences in detection. 
However, gender remains an independent prognostic indicator after adjustment for 
these factors. Therefore, we conclude that the female survival advantage is indepen-
dent of gender differences in detection or diagnostic delay. Another argument for this 
conclusion can be found in a comparison of regions worldwide. Although male/female 
incidence ratios differ greatly across continents, the female survival advantage has been 
very consistently reported in Europe2-4,24, Australia6, and the United States5,8,9. Therefore, 
incidence patterns are unlikely to explain the female survival advantage. Other proposed 
explanations for the gender difference in melanoma survival include differences in the 
distribution confounders, such as age and ulceration; influence of estrogen in females; 
and the overall longevity of women. However, all other confounders—including age 
and ulceration and inclusion of menopausal age groups in the subgroup analyses—did 
not considerably change the gender estimates for survival or progression and therefore 
do not seem to contribute to the explanationof this phenomenon. Regarding meno-
pausal status, this is consistent with recent conclusions that estrogens do not seem 
to affect melanoma25. Finally, given that the effect of gender was more pronounced in 
melanoma-specific survival than in overall survival, the overall superior longevity of 
women is unlikely to explain their survival advantage in melanoma. 
A major strength of our study is that we used a large population-based cancer registry 
that uniquely recorded different types of disease progression during follow-up through 
a meticulously refined system of follow-up. Illustrating the accuracy and validity of the 
MCR, the survival rates and effect of known confounders on survival within the registry 
highly resembled the results of the AJCC validation studies5,16. 
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Our study is limited by a lack of information on some confounders, including sentinel 
node biopsy and, for a large group of patients, ulceration. However, for the analyses with 
the subgroup with known ulceration status, survival curves were very similar to those in 
the AJCC 2001 validation study5, bolstering their validity. Furthermore, we did not have 
information concerning mitotic rate of the primary, number of involved lymph nodes, 
and lymph node tumor burden, which are all included in the latest AJCC staging sys-
tem26. The 30% of all melanoma specific deaths without a distant metastasis registered 
during follow-up suggests a 30% rate of underreporting of metastasis. However, this is 
common in melanoma and unlikely to be associated with gender (i.e., a nondifferential 
misclassification bias). 
Although the female advantage is consistently significant, the effect on prognosis is 
modest. For example, the 10% difference across gender for 10-year overall survival is 
small compared with the 50% higher survival rate for thin versus thick melanomas(<1 
mm and >4 mm; 10-year survival rates 84 vs. 34%). Illustratively, Balch et al. ranked 
gender as the sixth most important prognostic indicator5. However, the gender effect 
is intriguing because it is so consistent and the cause remains unknown. To date, only 
one hypothesis has been published proposing that reactive oxygen species underlie this 
phenomenon27.
CONCLUSION
In our population-based study, gender independently affected melanoma in all progres-
sion phases, reflected mainly in a reduced risk in females of visceral metastases (Figure 
1), resulting in a significantly higher survival rate in females as compared with males. 
These results suggest a biological difference across gender in the disease and/or in the 
disease–host interaction. Research aimed at unraveling the underlying mechanisms 
may be of therapeutic relevance.
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ABSTRACT
Purpose: Several studies observed a female advantage in the prognosis of cutane-
ous melanoma, for which behavioral factors or an underlying biologic mechanism 
might be responsible. Using complete and reliable follow-up data from four phase 
III trials of the European Organisation for Research and Treatment of Cancer (EORTC) 
Melanoma Group, we explored the female advantage across multiple end points 
and in relation to other important prognostic indicators. 
Patients and Methods: Patients diagnosed with localized melanoma were in-
cluded in EORTC adjuvant treatment trials 18832, 18871, 18952, and 18961 and ran-
domly assigned during the period of 1984 to 2005. Cox proportional hazard models 
were used to calculate hazard ratios (HRs) and 95% CIs for women compared with 
men, adjusted for age, Breslow thickness, body site, ulceration, performed lymph 
node dissection, and treatment.
Results: A total of 2,672 patients with stage I/II melanoma were included. Women 
had a highly consistent and independent advantage in overall survival (adjusted HR, 
0.70; 95% CI, 0.59 to 0.83), disease-specific survival (adjusted HR, 0.74; 95% CI, 0.62 
to 0.88), time to lymph node metastasis (adjusted HR, 0.70; 95% CI, 0.51 to 0.96), 
and time to distant metastasis (adjusted HR, 0.69; 95% CI, 0.59 to 0.81). Subgroup 
analysis showed that the female advantage was consistent across all prognostic 
subgroups (with the possible exception of head and neck melanomas) and in pre- 
and postmenopausal age groups.
Conclusion: Women have a consistent and independent relative advantage in all 
aspects of the progression of localized melanoma of approximately 30%, most likely 
caused by an underlying biologic sex difference.
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INTRODUCTION
Although it is known that female patients with melanoma have higher survival rates than 
their male counterparts, the cause of this phenomenon remains a mystery1. Generally, 
there are two hypotheses: one, differences in behavior, detection, diagnostic delays, and 
screening lead to more advanced melanomas in men, resulting in worse survival2-5, and 
two, unknown biologic sex differences affect melanoma progression and survival3,6,7. 
The first hypothesis seems to be refuted by numerous studies showing that the 
prognostic effect of sex is independent of other (presumed) behavior-, detection-, or 
diagnosis-related prognostic factors (eg, stage, Breslow thickness, and body site)3,6,8-11. 
However, to truly refute this hypothesis, a careful look at the interactions of sex and 
other prognostic factors would be useful; if behavior causes the female advantage, 
the magnitude of this advantage should differ between thicker and thinner tumors, 
for example. If the second hypothesis holds (ie, some female trait inhibits melanoma 
progression), it would be interesting to study whether this equally affects all types of 
melanoma progression (e.g., both lymph node and distant metastasis). 
To answer these questions, we performed Dutch6 and German12 population-based 
analyses of sex differences in melanoma survival and progression. In both studies, 
a significant female advantantage was observed. The German study also showed 
significant sex differences in risk of metastasis. However, these studies were limited; 
registration of progression by cancer registries might have been unreliable, and data on 
important confounders were missing (ie, ulceration and lymph node dissections [LNDs]).
To overcome these limitations and adequately confirm and quantify the female advan-
tage, we used four large randomized trial databases to perform an elaborate analysis on 
sex differences in localized melanoma. We studied different end points: overall (OS) and 
disease-specific survival (DSS) and different types of disease progression. The influence 
of other prognostic factors on the prognostic impact of sex was analyzed by estimating 
the magnitude of the sex effect in different subgroups.
PATIENT AND METHODS
Setting
Data were extracted from four adjuvant randomized controlled trials performed by the 
European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group 
investigating isolated limb perfusion (18832)13, interferon alfa and Iscador M (mistletoe 
extract; Hiscia Laboratories, Arlesheim, Switzerland; 18871)14, high- and intermediate-
dose interferon alfa (18952)15, and ganglioside GM2-KLH21 vaccination (18961)16. 
Trial characteristics are summarized in Table 1. After random assignment, patients were 
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routinely observed for occurrence of local recurrence, in-transit metastasis, lymph node 
metastasis, distant metastasis, and death, including cause of death. Follow-up continued 
after first recurrence (e.g. lymph node metastasis) to register subsequent recurrences 
(e.g. first distant metastasis).
Patient and Variable Selection
Clinical and tumor characteristics were analyzed in relation to sex. Patients with lymph 
node metastasis at random assignment or missing data on sex, Breslow thickness, 
ulceration, or tumor localization were excluded (F). For some patients, two discrepant 
values existed for Breslow thickness or ulceration: one from the local pathologist, the 
other from the EORTC pathology review committee. Tests using the Akaike information 
criterion17 showed that the value with the worst prognostic implication should be used 
in the analysis (ie, highest value of Breslow thickness, presence of ulceration). Because 
only a few patients with thin melanomas were available, Breslow categories were 
coded combining the lowest two categories of the American Joint Committee on Cancer 
classification18 in to one(0.1 to 2.0mm). Unfortunatley, data on menopausal status (e.g. 
estrogen levels)were not available. Therefore, in concordance with our previous publica-
tions6,12, we assessed the impact of menopause by categorizing women into menopausal 
categories based on age at diagnosis: premenopausal (≤45years), postmenopausal (≥60 
years), and unknown (46 to 59 years). Prognoses of these female groups were then 
compared with those of men of the same age. 
Table 1: EORTC Trials used
Trial Ac-
crual
Database 
closed
Trial arms Main inclusion criteria Total nr. ran-
domized
Reference
nr.
18832 1984-
1994
Oct 1996 wide excision + ILP 
vs. wide excision
5-75 yrs, only melanomas 
localized at 
or distal to middle of 
thigh or arm, stage II 
>1.5mm
852 13
18871a 1988-
1996
Sep 2001 IFN-α2b vs. IFN-γ 
vs. Iscador vs. Observa-
tion
14-80 yrs, AJCC stage II 
>3 mm 
melanomas & stage III
830 14
18952 1996-
2000
Jan 2005 High-dose IFN-α2b vs. 
intermediate-
dose IFN-α2b vs. Obser-
vation
16-75 yrs. AJCC stage II ≥ 
4mm & Stage III
1388 15
18961 2002-
2005
Sep 2009 Ganglioside GM2-KLH/
QS21 
vaccination vs. observa-
tion
18-80 yrs, AJCC Stage II 
>1.5mm
1314 16
AJCC: American Joint Cancer Committee, EORTC: European Organization for Research and Treatment of Cancer, IFN: 
Interferon, ILP: Isolated Limb Perfusion, yrs: years old.
a Trial 18871-DKG80-1 was performed by the EORTC in collaboration with the German Cancer Society.  
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Statistical Considerations
Impact of sex on outcome was investigated using seven end points: OS, DSS, relapse-
free survival (RFS), time to local recurrence, time to in-transit metastasis, time to lymph 
node metastasis, and time to distant metastasis (TTDM) from random assignment. In 
concordance with Punt et al.19, events were defined as follows: OS, death as a result of 
any cause; DSS, death as a result of melanoma or of unknown cause after melanoma 
distant metastasis; and RFS, any melanoma recurrence or death as a result of any cause. 
The specific recurrence types of times to local recurrence and in-transit and lymph node 
metastasis were considered events; other recurrences were ignored, and patients who 
died without experiencing the specified event were censored. For TTDM, death as a 
result of melanoma without a registered distant metastasis was considered an event as 
Stage III 
exclusion: 
Trial 18952
n=1,388
Trial 18871
n=830
Trial 18961
n=1,314
Trial 18832
n=852
Total
n=2,787
Total Included:
n=2,672
Excluded: 
Missing data
n=115b
n=1,032 n=483 n=61 
Total
n=2,808
Excluded: 
Possible Stage III
n=21a
Figure 1. Flow-chart with study in- and exclusion 
a: 1 patient was reported to have a therapeutic lymph node dissection, 20 patients were reported to have positive lymph 
nodes although staged as stage I/II.
b: Excluded due to missing data on gender, Breslow thickness, Ulceration or primary tumor localisation.
44
Chapter 2.2
well as a registered distant metastasis. For all end points, patients who did not experi-
ence the specified event were censored at date of last contact.
We used χ2 and t-tests to compare the distribution of categoric and continuous variables 
between men and women. Survival distribution curves were plotted using the Kaplan-
Meier method. For DSS and TTDM endpoints, cumulative incidence curves for death as a 
result of melanoma and TTDM, respectively, were plotted as well, with death unrelated to 
melanoma considered a competing event. In this analysis, cumulative incidence was cal-
culated as a function of the hazards of all competing events instead of solely the hazard of 
the event of interest20. For all endpoints, crude and adjusted HRs with 95% CIs for sex (with 
male sex as reference) were calculated using Cox proportional hazards models, stratified 
by trial (i.e. allowing the baseline hazard function to differ by trial). 
The proportional hazards assumption for all variables was checked using graphic 
(categoric variables) and time-interaction models (continuous variables); no major 
violations were found. In subgroup analysis, we estimated sex HRs within categories of 
prognostic importance (eg, separate sex HRs for categories of Breslow thickness). This 
analysis is presented using forest plots. 
Multivariate sex HRs were adjusted for age (continuous), Breslow thickness, ulceration, 
localization of primary melanoma, treatment type, and whether sentinel lymph node 
biopsy (SLNB) or elective LND (ELND) was performed. These dissections were negative 
by definition because only patients with stageI/II melanoma were included. Histologic 
subtype was not included in the multivariate analyses because this was unknown for 
>50% of patients and is generally considered not to independently affect prognosis21. 
However, to rule out associations between histology and sex effect, histology was in-
cluded in the univariate subgroup analyses.
Kaplan-Meier and cumulative incidence curves (using a macro20) were plotted using 
STATA/SE 11.1 (STATA, College Station, TX). For all other analyses, SPSS PASW 17.0.2 
(SPSS, Chicago, IL) was used.
RESULTS 
Study Population
From the four trial databases, 1,597 patients diagnosed with stage III melanoma and 115 
patients with missing data were excluded (Figure 1). These 115 excluded patients with 
stage I/II disease did not differ in distribution of sex or important prognostic indicators (if 
known) from included patients. Finally, 2,672 patients with stage I/II disease were includ-
ed in this study: 48% men and 52% women. Confirming numerous other studies3,6,12,21,22 
men showed a worse distribution of all prognostic indicators (Table 2). At diagnosis, they 
were older, were more likely to have an ulcerated or thicker primarytumor, and more 
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often had melanomas on the head, neck, or trunk and fewer melanomas on extremities. 
Sex was unequally distributed across trials; women were overrepresented in trial 18832, 
which included distal extremity melanomas only (Table 1). Men underwent significantly 
more SLNBs, where as women more often underwent ELND. Women more often had 
superficial spreading melanomas; men more often had an unknown histologic subtype. 
Table 2. Descriptive data for study population
    ___Males __ __Females__  p-value 
Total Study population; n (%) 1274 (47.7%) 1398 (52.3%)  
VARIABLE          
EORTC Trial           <0.001
18832 n (%) 237 (18.6%) 506 (36.2%)  
18871 n (%) 157 (12.3%) 132 (9.4%)  
18952 n (%) 178 (14.0%) 164 (11.7%)  
18961 n (%) 702 (55.1%) 596 (42.6%)  
Treatment Type           0.16
Observation n (%) 553 (43.4%) 619 (44.3%)  
Interferon n (%) 226 (17.7%) 210 (15.0%)  
Other treatment n (%) 495 (38.9%) 569 (40.7%)  
Age Mean (SD) 52.5 (13.7) 50.1 (13.7) <0.001
Age in Menopausal Categories           0.002
Premenopausal age (≤45 yo) n (%) 383 (30.1%) 498 (35.6%)  
Menopausal age (46-59 yo) n (%) 465 (36.5%) 509 (36.4%)  
Postmenopausal age (≥60 yo) n (%) 426 (33.4%) 391 (28.0%)  
Age in 5 categories           <0.001
15-39 yr n (%) 231 (18.1%) 305 (21.8%)  
40-48 yr n (%) 229 (18.0%) 306 (21.9%)  
49-56 yr n (%) 261 (20.5%) 302 (21.6%)  
57-64 yr n (%) 294 (23.1%) 267 (19.1%)  
65-88 yr n (%) 259 (20.3%) 218 (15.6%)  
Breslow Thickness Mean (SD) 4.3 (3.0) 3.8 (3.3) <0.001
Breslow Thickness in categories           <0.001
0.01-2.00 mm n (%) 215 (16.9%) 290 (20.7%)  
2.01-4.00 mm n (%) 565 (44.3%) 682 (48.9%)  
>4.00mm n (%) 494 (38.8%) 426 (30.5%)
Ulceration           0.003
Absent n (%) 644 (50.5%) 787 (56.3%)
Present n (%) 630 (49.5%) 611 (43.7%)
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Effect of Sex on End Points
Univariately, men had a clear disadvantage for the endpoints OS, RFS, DSS, and TTDM in 
Kaplan-Meier curves (Figures 2.A to 2.D). Cumulative incidence curves for DSS and TTDM 
taking death unrelated to melanoma into account as competing risk yielded comparable 
sex differences (Figures 3.A and 3.B). After adjusting for all confounders, there was no sex 
difference in experiencing local recurrence (adjusted HR, 1.10; 95% CI, 0.73 to 1.64; Table 
3). However, women exhibited an independent, significant, and consistent advantage of 
approximately 30% for all other endpoints: OS (adjusted HR,0.70; 95% CI, 0.59 to 0.83), 
DSS (adjusted HR 0.74; 95% CI, 0.62 to 0.88), RFS (adjusted HR, 0.69; 95% CI, 0.61 to 
0.79), time to in-transit metastasis (adjusted HR 0.70; 95% CI, 0.51 to 0.96), lymph node 
metastasis (adjusted HR 0.70; 95% CI, 0.59 to 0.83), and distant metastasis (adjusted HR 
0.69; 95% CI, 0.59 to 0.81; Table 3).
Effect of Sex in Prognostic Subgroups
When examining crude HRs for DSS across different subgroups (Figure 4), the sex effect 
was consistent in all groups except thin melanomas head and neck melanomas, and 
patients who underwent SLNB. The HRs for RFS showed even greater consistency, with 
a female advantage for thin melanomas (although nonsignificant) and SLNB. For the 
small subpopulation (n= 228) with head and neck melanomas, no sex impact on either 
Table 2. (Continued)
    ___Males __ __Females__  p-value 
VARIABLE          
Body Site           <0.001
Head and Neck n (%) 152 (11.9%) 76 (5.4%)
Trunk n (%) 539 (42.3%) 273 (19.5%)
Upper Extremity n (%) 194 (15.2%) 255 (18.2%)
Lower Extremity n (%) 389 (30.5%) 794 (56.8%)
Lymph node Dissection           0.001
No n (%) 813 (63.8%) 867 (62.0%)
Yes, SLNB n (%) 324 (25.4%) 307 (22.0%)
Yes, ELND n (%) 126 (9.9%) 208 (14.9%)
Unknown n (%) 11 (0.9%) 16 (1.1%)
Histology           <0.001
SSM n (%) 183 (14.4%) 325 (23.2%)
NM n (%) 270 (21.2%) 329 (23.5%)
Others n (%) 63 (4.9%) 67 (4.8%)
Unknown n (%) 758 (59.5%) 677 (48.4%)  
ELNB: Elective Lymph Node Biopsy, EORTC: European Organization for Research and Treatment of Cancer, NM: Nodular 
Melanoma, SLNB: Sentinel Lymph Node Biopsy, SSM: Superficial Spreading Melanoma, yo: years old.
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DSS or RFS was observed (Figure 4). The relatively small shift of crude compared with 
adjusted HRs (Table 3) confirms the consistency and independence of the sex effect 
across subgroups. 
Table 3. Crude and adjusted HRs for females vs. males comparisons for all endpoints
_ _events __ adjusted 
HRbEndpoint male female crude HRa 95%CI 95% CI
Overall Survival 366 267 0.61 0.52-0.71 0.70 0.59-0.83
Disease Specific Survival 319 243 0.64 0.54-0.76 0.74 0.62-0.88
Relapse Free Survival 569 438 0.62 0.55-0.71 0.69 0.61-0.79
Time to Local Recurrence 48 60 1.00 0.68-1.48 1.10 0.73-1.64
In Transit Metastasis Free Survival 92 79 0.70 0.51-0.95 0.70 0.51-0.96
Lymph Node Metastasis Free Survival 333 260 0.66 0.56-0.78 0.70 0.59-0.83
Time to Distant Metastasis 402 291 0.60 0.52-0.70 0.69 0.59-0.81
HR: Hazard Ratio, CI: Confidence Interval
a Cox Regression HR’s for females vs. males and stratified by trial.
b Cox Regression HR’s HR’s for females vs. males, stratified by trial and adjusted for age (continuous), Breslow thickness, ul-
ceration, localization of primary melanoma, treatment type and lymph node dissection. See Table 2 for all categorizations.
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Pre- and Postmenopausal Age Groups
Stratifying patients into premenopausal, menopausal, and postmenopausal age groups, 
the female advantage versus that of men of the same age was equal in the postmeno-
pausal age group (≥60 years), compared with the advantage observed in the premeno-
pausal age group (≤45 years) regarding the endpoints RFS, time to lymph node metasta-
sis, and TTDM (Table 4). For OS, the relative female advantage was borderline significant 
and only slightly smaller in the postmenopausal age group (adjusted HR 0.77) compared 
with the premenopausal age group (adjusted HR 0.66). However, in contrast to the other 
endpoints, the female advantage for DSS decreased significantly (test for interaction, 
P= .02) and lost significance in the postmenopausal age group (adjusted HR, 0.91; 95% 
CI, 0.65 to 1.28) compared with the premenopausal age group (adjusted HR 0.67; 95% 
CI, 0.50 to 0.91; Table 4). Because competing risks might influence DSS outcome, we 
compared inversed Kaplan Meier curves with cumulative incidence curves where death 
unrelated to melanoma was a competing risk (Figures 5.A to 5.F). We observed high 
consistency in the results of these two methods, including within the postmenopausal 
age category (Figures 5.E and 5.F).
DISCUSSION
The most intriguing result of this study is undoubtedly the highly consistent 30% rela-
tive prognostic advantage of female compared with male patients with melanoma. This 
applied for both OS and DSS and is thus unlikely to have been caused by overall better 
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For Disease specific survival, dying of a non-melanoma or unknown cause of death was considered a competing event. For 
Time to Distant Metastasis, dying of a non-melanoma or unknown cause of death without experiencing a distant metas-
tasis was considered a competing event.
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female longevity. As expected, the female survival advantage was preceded by a 30% 
lower chance of experiencing distant metastasis. However, women also had a 30% lower 
chance of experiencing relapses as in-transit or lymph node metastasis (Table 3). There-
fore, the 30% advantage extends to the whole spectrum of melanoma disease behavior. 
As Clarket al.22 observed in 1969, the disease truly behaves “somewhat less malignant” 
22(p712) in females.
This 30% relative advantage is remarkably consistent with those reported in published 
literature. Our population-based study observed similar adjusted HRs of 0.68 (95% CI, 
0.62 to 0.75) for RFS and 0.64 (95% CI, 0.58 to 0.71) for TTDM12. When considering large 
(N>10,000) studies reporting sex HRs for localized melanoma, a consistent pattern 
emerges; apart from two studies reporting sex estimates of 0.846 and 0.5323, all studies 
have observed a female adjusted survival advantage of approximately 30% (Table 5). 
Were the hypothesis of an explanation by sex difference in detection, screening, and 
diagnostic delays true, one would expect to see marked differences in the sex HR across 
prognostic subgroups presumably associated with these delays, particularly Breslow 
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thickness and primary location. However, sex HRs are roughly the same in these sub-
groups (Figure 4), and taking these confounders into account caused only a minor shift 
from crude to adjusted HRs (Table 3). Even primary location, which so markedly differed 
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For KM curves (cumulative rates) dying of a non-melanoma or unknown cause of death was considered as a censored ob-
servation, whereas for cumulative incidence curves dying of a no-melanoma or unknown cause of death was considered 
a competing event.
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across sex, does not explain this phenomenon; women had a survival advantage for 
both truncal and lower limb melanomas. It is also worth noting that a study analyzing 
diagnostic delays in melanoma did not observe significant sex differences27. Moreover, 
because we used trial data, delays were determined by trial protocol rather than by 
patient. Therefore, it is unlikely that differences in follow-up or compliance explain these 
sex differences.
Stage migration could contribute to the female advantage; more women might have 
opted for SLNB or ELND and migrated to stage III as a result of microscopic lymph node 
metastasis, resulting in a female advantage in stage I/II, because more occult metasta-
ses are filtered out in women. However, especially for RFS, the female advantage was 
observed in SLND, ELND, and no-LND groups, making selective stage migration unlikely 
(Figure 4). Furthermore, population-based studies including all patients (stages I to IV) 
and thus unaffected by stage migration have reported highly similar results (Table 5)6,12. 
Only head and neck melanoma showed no sex differences for both OS and RFS (Figure 
4). This might be a chance finding resulting from a large number of subgroup analyses 
with increasingly smaller subgroups. This seems likely because a large study consider-
ing head and neck melanomas did observe a female advantage of 30% (HR, 0.70; 95% 
CI, 0.63 to 0.77; Table 5)26. Alternatively, the divergent pathways hypothesis argues 
that head and neck melanomas differ biologically from lesions on other sites, because 
they are associated with chronic sun exposure and have lower BRAF mutation rates28,29. 
Therefore, they might constitute a different disease, possibly with a different prognostic 
effect of sex. 
Table 4. Outcome comparisons of females vs. males according to three age groups
Premenopausal age (≤45 yrs) Menopausal age (46-59 yrs) Postmenopausal age (≥60 yrs)
Total nr of 
patients
383 males; 498 females 465 males; 509 females 426 males; 391 females
Endpoint Events
(Males)
Events
(Females)
HRa 95% CI Events
(Males)
Events
(Females)
HRa 95% CI Events
(Males)
Events
(Females)
HRa 95% CI
Overall 
Survival
108 77 0.66 (0.49-0.89) 126 91 0.62 (0.46-0.82) 132 99 0.77  (0.56-1.04)
Disease 
Specific 
Survival
105 76 0.67 (0.50-0.91) 117 87 0.66 (0.49-0.88) 97 80 0.91  (0.65-1.28)
Relapse Free 
Survival
166 139 0.73 (0.58-0.93) 204 153 0.63 (0.51-0.79) 199 146 0.65  (0.51-0.83)
Time to LN 
Metastasis
110 89 0.70 (0.52-0.93) 123 96 0.67 (0.50-0.88) 100 75 0.71  (0.50-0.99)
Time to Dis-
tant Meta’s
125 93 0.67 (0.51-0.89) 146 106 0.63 (0.48-0.82) 131 92 0.73  (0.54-0.99)
a Cox Regression HR’s for females vs. males adjusted for age (continuous), Breslow thickness, ulceration, localization of 
primary melanoma, treatment type and lymph node dissection, and stratified by trial. See Table 2 for all categorizations.
HR: Hazard Ratio, CI: Confidence Interval
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When examining the Kaplan-Meier curves (Figures 1.A to 1.D), women exhibited not 
only a longer delay before relapse but also a higher cure rate compared with men (ie, 
persistent separation of curves after long follow-up). This observation is confirmed by a 
population-based study with longer follow-up6. Therefore, it seems that whatever the 
cause of the female advantage may be, it causes both a delay in progression and a larger 
subset of melanomas being cured in women compared with men. 
Table 5: Gender Risk Estimates in studies using patient samples of n>10,000 with (a majority of) localized mela-
noma
Reference End-
point
Country n (% local 
MM)
Confounders in multivariate 
analysis
Adj. Risk 
Estimatea 95% CI
Balch et al., 
200123
DSS USA 13,581 (100%) Sex, Age, Breslow, Site, Ulcer-
ation, Invasion
HR 0.84 0.76-0.92
de Vries et al., 
20086
RS Nether-
lands
10,538 (95%) Sex, Age, Breslow, Histology, 
Site, Stage
RERb 0.53 0.48-0.61
Xing et al., 
201010 (Stage I)
DSS USA (SEER) 32,430 (100%) Sex, Age, Race, Marital status, 
Histology, Site
HRb 0.67 0.60-0.75
(Stage II) DSS USA (SEER) 5,089 (100%) Sex, Age, Race, Marital status, 
Histology, Site
HRb 0.67 0.60-0.75
Joosse et al. 
201012
OS Germany 11,734 (95%) Sex, Age, Breslow, Site, Histol-
ogy, N-stage, M-stage, Year
HR 0.69 0.64-0.74
DSS Germany 11,734 (95%) Sex, Age, Breslow, Site, Histol-
ogy, N-stage, M-stage, Year
HR 0.62 0.56-0.70
Collins et al. 
201147
OS USA (SEER) 142,653 (56+30%)
d
Sex, Age, Stage, Site, Ulceration, 
Histology, satellites, LN meta’s, 
Year, Ethnicity
HR 0.71b 0.68-0.73
DSS USA (SEER) 142,653 (56+30%)
d
Sex, Age, Stage, Site, Ulceration, 
Histology, satellites, LN meta’s, 
Year, Ethnicity
HR 0.65b 0.62-0.68
Thompson et al. 
201146
DSS Interna-
tional 
AJCC con-
sortium
10,233 Sex, Age, Breslow, Site, Ulcer-
ation, Mitotic Rate, Clark
HR 0.69 0.61-0.79
Tseng et al. 
201025
OS USA (SEER) 27,097 (98%) Sex, Age, Breslow, Site (within 
head/neck), Histology, Ulcer-
ation, Clark, N-stage, ethnicity, 
surgery type, radiation
HR 0.76 0.72-0.80
DSS USA (SEER) 27,097 (98%) Sex, Age, Breslow, Site (within 
head/neck), Histology, Ulcer-
ation, Clark, N-stage, ethnicity, 
surgery type, radiation
HR 0.70 0.63-0.77
DSS: Disease-Specific Survival; MM: Malignant Melanoma; OS: Overall Survival; RS: Relative Survival (an estimate of disease 
specific survival); SEER: Surveillance, Epidemiology and End Results database
a Relative risk of females compared to males
b Value reported here is the inverse of the original risk estimate, as males were compared to females in the cited publication.
c For patients who underwent surgery
d 56% local melanoma, 30% in situ melanoma, 10% regional or distant metastasis, 4% unknown
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When reviewing all the evidence, a consistent picture emerges: For localized mela-
noma, not only do men have worse characteristics at time of diagnosis (Table 2), but 
after diagnosis, they continue to have an approximate 30% disadvantage compared 
with women. This advantage is consistent across trials and population-based studies, 
countries (Table 5), and prognostic parameters (Figure 4) and is independent of con-
founders (Table 3). This further refutes the first hypothesis of an explanation by behav-
ioral differences. Therefore, it is likely that fundamental biologic sex differences, either 
tumor- or host-related, cause this female advantage. 
There are no indications that the primary melanoma truly differs across sex (eg, there 
are no sex differences in the mutation rate of important genes such as BRAF30-32 NRAS32 
or KIT33). Furthermore, this study provides evidence that tumor characteristics (eg, thick-
ness or ulceration), even if disadvantageously distributed in men versus women, do not 
explain sex survival differences. 
Therefore, host factors are more likely to be involved in the explanation of this phenom-
enon. Sex steroids, especially estrogens, are often mentioned as a possible contributing 
factor. However, for most end points in our study, sex differences were approximately 
equal in pre- and postmenopausal age groups (Table 4), when estrogen levels drop 
significantly in women. The female advantage seems to disappear only for DSS. This 
finding is difficult to explain, because postmenopausal women do have a lower chance 
of distant metastasis compared with elderly men.We hypothesized that this result for 
DSS in the oldest age group could have been caused by sex-specific competing risks 
(more non–melanoma-related deaths in men), but this was not found when comparing 
Kaplan-Meier with cumulative incidence curves (Figures 5.A to 5.F). This might have 
resulted from differences in follow-up for elderly men compared with women. It could 
also have been a chance finding resulting from multiple subgroup analyses with smaller 
sample sizes and fewer events (Table 4). However, despite this finding for DSS,the overall 
picture clearly shows a persistent female advantage in the postmenopausal age group 
(Table 4). Conflicting results are also found in the literature; although some studies have 
observed the female advantage to disappear3,11 a majority of studies have reported a 
persisting female advantage in older (postmenopausal) agegroups6,12,34-37 even for stage 
III melanoma38. Furthermore, overall consensus is that hormones do not profoundly af-
fect melanoma39,40. Interestingly however, melanomas do express estrogen receptor β41 
which seems to be related to progression but does not differ across sex42. Nevertheless, 
this receptor might still be related to the female advantage. Because estrogen does 
not clearly emerge as a candidate to explain this phenomenon, other factors may be 
involved. Our study could not assess possible contributing factors other than differences 
in pre- and postmenopausal age groups. However, several sex-related factors have been 
linked to melanoma. For example, androgen receptors have been observed in mela-
noma cell lines43. Sex differences in oxidative stress could be involved7, as could known 
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sex differences in vitamin D metabolism44, because vitamin D levels seem to influence 
melanoma prognosis45. Finally, because melanoma is immunogenic46, sex differences in 
immune homeostasis47 might play a role.
A major strength of this study is the meticulous follow-up associated with EORTC trials 
in contrast to cancer registry data. This includes continued follow-up after first relapse 
of disease (eg, after lymph node metastasis follow-up continues for distant metastases). 
This eliminates possible sex differences in screening and health care behavior and 
enables reliable research for surrogate end points (e.g. TTDM). However, trial-based 
databases have smaller sample sizes compared with population-based series. Another 
disadvantage is inclusion criteria–based selection, which is inherent to trials. Most im-
portantly, this leads to an overrepresentation of thick (>2 mm) melanomas compared 
with population-based series (Table 2). Furthermore, a large subset of our patient 
population was randomly assigned in trial 18832, which included only patients with 
distal extremity melanomas. These inclusion criteria led to a selected population, and 
therefore, results cannot be generalized to the population. However, even with these 
differences in study population, our results (30% relative difference) highly resemble 
those of large population-based studies (Table 5). 
Another strength was the completeness of data on important confounders (e.g. 
thickness, body site, and ulceration). Unfortunately, data on tumor mitotic rate were 
missing in these trials. It is, however, not likely that this factor would have consider-
ably influenced our results, because a large study that included mitotic rate reported a 
similar 30% female advantage25.
To summarize our results and those in the published literature, women have a clear 
30% relative advantage over men in stage I/II cutaneous melanoma prognosis. This is 
independent of other prognostic factors and persists at older (postmenopausal) age. 
Unraveling the underlying cause could be of therapeutic relevance. Future work will 
focus on sex differences in metastasized melanoma, which could further affirm the 
biologic explanation hypothesis. 
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ABSTRACT
Purpose To study sex differences in survival and progression in patients with stage 
III or IV metastatic melanoma and to compare our results with published literature.
Patients and Methods: Data were retrieved from three large, randomized, con-
trolled trials of the European Organisation for Research and Treatment of Cancer 
in patients with stage III and two trials in patients with stage IV melanoma. Cox 
proportional hazard models were used to calculate hazard ratios (HRs) and 95% 
CIs for females compared with males, adjusted for different sets of confounders for 
stage III and stage IV, respectively.
Results: In 2,734 stage III patients, females had a superior 5-year disease-specific 
survival (DSS) rate compared with males (51.5% v 43.3%), an adjusted HR for DSS of 
0.85 (95% CI, 0.76 to 0.95), and an adjusted HR for relapse-free survival of 0.86 (95% 
CI, 0.77 to 0.95). In 1,306 stage IV patients, females also exhibited an advantage in 
DSS (2-year survival rate, 14.1% v 19.0%; adjusted HR, 0.81; 95% CI, 0.72 to 0.92) as 
well as for progression-free survival (adjusted HR, 0.79; 95% CI, 0.70 to 0.88). This 
female advantage was consistent across pre- and postmenopausal age categories 
and across different prognostic subgroups. However, the female advantage seems 
to become smaller in patients with higher metastatic tumor load. 
Conclusion: The persistent independent female advantage, even after metastasis 
to lymph nodes and distant sites, contradicts theories about sex behavioral differ-
ences as an explanation for this phenomenon. A biologic sex trait seems to pro-
foundly influence melanoma progression and survival, even in advanced disease.
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INTRODUCTION
The biology behind many of the prognostic factors available for melanoma remains 
poorly understood1. One of the most intriguing prognostic factors in melanoma is sex. 
Although female sex is associated with a survival advantage in many different cancer 
types, studies in both Europe and the United States found this advantage for females 
to be considerably higher in melanoma than in virtually anyother type of cancer2,3. In 
stage I or II (localized) melanoma, the independent prognostic value of sex has been 
confirmed by multiple large studies, both trial-based and population-based, and ad-
justed for all other known prognostic factors4. However, the prognostic role of sex has 
not been studied extensively in metastatic melanoma. If sex remained an independent 
prognostic value in advanced melanoma, this would be another argument against the 
hypothesis that diagnostic delays or behavioral differences explain the worse survival in 
males. This study aimed to evaluate the role of sex in patients with melanoma metasta-
sized to regional lymph nodes (LNs) and to distant sites, concurring with American Joint 
Committee on Cancer (AJCC) staging system stage III and IV, respectively, carried out in 
five large European randomized controlled trials.
PATIENTS AND METHODS
Setting
Data were retrieved from five randomized trials of the European Organisation for 
Research and Treatment of Cancer (EORTC) Melanoma Group: three adjuvant stage III 
(188715, 189526, and 189917) and two stage IV (189518 and 180329) trials. Trial charac-
teristics are summarized in Table 1. In all trials, routine active follow-up was performed 
according to EORTC Head quarters protocols and, if applicable, date and cause of death 
were registered. In stage III patients, disease relapse was monitored, including relapse in 
the LN basin or spread to distant sites. In stage IV patients, progression was monitored 
by using Response Evaluation Criteria in Solid Tumors (RECIST)10, defining disease pro-
gression as an increase of at least 20% of the sum of the largest diameters of the target 
lesions (TLs). TLs were defined by the local physician on the basis of the possibility of 
evaluating the lesions by using conventional imaging techniques. 
Patients with stage I or II melanoma (n=703) were excluded from this analysis be-
cause these patients were included in our previous study on localized melanomas4. 
This pertained only to trials 18871 and 18951 because trial 18991 included only stage 
III patients. In total, 2,771 stage III patients were available from these three trials, and 
1,315 stage IV patients were available in trials 18032 and 18951. Patients with missing 
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important prognostic information for advanced melanoma as defined by the AJCC stag-
ing system11 were excluded from the analyses.
Statistical Considerations
According to definitions by Punt et al12, four endpoints were defined for stage III patients: 
overall survival (OS), disease-specific survival (DSS), relapse-free survival (RFS), and time 
to distant metastasis (TTDM). In stage IV, OS, DSS, and progression-free survival (PFS) 
were used. Per endpoint, the following events were defined: for OS, death as a result 
of any cause; for DSS, death as a result of melanoma; for RFS, any disease recurrence 
and death as a result of any cause; for TTDM, occurrence of the first distant metastasis; 
and for PFS, progression of disease as defined by RECIST and death as a result of any 
cause. For all endpoints, patients were censored at the last follow-up date if the event 
of interest did not occur. For DSS, patients who died as a result of causes not related to 
melanoma were censored at their date of death. For TTDM, disease recurrences other 
than distant metastases were ignored.
To compare the distribution of categorical variables across sex, we used the χ2 test; 
for ordered categorical variables (eg, age), we used the χ2 test for linear trend and the t 
test for continuous variables. The Kaplan-Meier method was used to estimate survival-
type distributions according to sex, with the log-rank test to test the difference between 
these distributions. For multivariate analysis, Cox proportional hazard models stratified 
by trial were used to calculate adjusted hazard ratios (HRs) with 95% CIs for sex (females 
compared with males). Graphical methods for categorical variables and timeinteraction 
models for continuous variables were used to check the proportional hazards assump-
tion for all variables. This did not give reason to suspect violations of this assumption.
To adjust the effect of sex on melanoma prognosis, separate sets of confounders were 
available for stage III and stage IV. For stage III, sex HRs were adjusted for the follow-
ing categorized variables: treatment (observation v interferon v other treatment), age 
(≤45 v 46 to 59 v  ≥60 years), Breslow thickness (0 to 1 v >1 to 2 v >2 to 4 v > 4 mm v 
unknown), ulceration (absent v present v unknown), body site (head and neck v trunk v 
upper extremity v lower extremity v unknown), nodal metastatic volume (microscopic 
v macroscopic), and number of positive LNs (1 v 2 to 3 v ≥4). Unknown values were 
allowed for primary tumor characteristics (Breslow thickness, ulceration, and body site) 
but not for LN metastasis characteristics (nodal metastatic volume, number of positive 
LNs).
For stage IV, sex HRs were adjusted for the categorized variables treatment (dacar-
bazine [DTIC] v temozolomide v DTIC, interferon, cisplatin v DTIC, interferon, cisplatin, 
interleukin-2), age (≤45 v 46 to 59 v  ≥60 years), Eastern Cooperative Oncology Group 
performance score (ECOG PS; 0v 1v 2), AJCC categories of metastatic sites (subcutane-
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ous and distant LNs v lung v other visceral sites), lactate dehydrogenase (LDH) serum 
level (≤upper limit of normal [ULN] v ULN to ≤2 X ULN v >2 X ULN), sum of baseline 
diameter of all TLs (1 to 50, 51 to 100, >100 mm, unknown). Two continuous variables 
were included in the multivariate models for stage IV: number of distant sites involved 
in metastatic disease and number of TLs.
Crude sex HRs were also estimated separately for different important patient sub-
groups. These analyses were presented by using forest plots. To test whether sex HRs 
differed across these subgroups, an interaction term between sex and the subgroup 
variable was used. A variable indicating synchronous diagnosis of LN metastasis at time 
of diagnosis of the primary melanoma versus patients who were diagnosed with an LN 
metastasis after their primary melanoma diagnosis (nonsynchronous) was included in 
the subgroup analysis. As a result of a large proportion of missing data (Table 2), we 
decided not to include this variable in multivariate analyses. Statistical analyses were 
performed with STATA/SE 11.1 (STATA, College Station, TX) and SPSS 17, PASW Statistics, 
Version 17.0.2 (IBM, Armonk, NY).
Table 1: Trial characteristics
EORTC 
Trial Accrual
Database
closed Trial arms Main inclusion criteria
Total nr.
random-
ized
Refer-
ence
Stage III
18871a 1988-
1996
Jan 2004 IFN-α2b vs. IFN-γ 
vs. Iscador vs. Observa-
tion
Any age, AJCC stage II >3 mm 
& stage III CM, after wide exci-
sion and curative LN resection
830 5
18952 1996-
2000
Sep 2003 High-dose IFN-α2b vs. 
intermediate-
dose IFN-α2b vs. Obser-
vation
16-75 yrs. AJCC stage II ≥ 4mm & 
Stage III  CM, after wide excision 
and curative LN resection
1388 6
18991 2000-
2003
Sep 2006 PEG-IFN vs. Observation 18-70 yrs, Microscopic or 
macroscopic stage III melanoma, 
unknown primary allowed, LDH 
<2x ULN. 
1256 7
Stage IV
18951 1995-
2002
May 2004 DTIC + cisplatinum + 
IFN-α vs. 
DTIC + cisplatinum + 
IFN-α + IL-2
18-70 yrs, Histologically con-
firmed melanoma, ECOG 0-2. 
Brain metastases, prior immuno- 
or chemotherapy excluded.
457 8
18032 2004-
2007
Dec 2007 DTIC vs. Temozolomide Histologically confirmed stage 
IV melanoma, Evaluable disease, 
LDH <2x ULN, ECOG 0-1. Brain 
metastases and prior chemo-
therapy excluded.
859 9
AJCC: American Joint Cancer Committee, CM: Cutaneous Melanoma, EORTC: European Organization for Research and 
Treatment of Cancer, IFN: Interferon, LN: lymph node, PEG: Pegylated, ULN: Upper Limit of Normal, yrs: years old.
a Trial 18871-DKG80-1 performed in collaboration with the German Cancer Society.  
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Table 2. Study Population and Descriptive Data
Stage III Stage IV
  ___MALES _  _FEMALES _ p ___MALES _ _FEMALES _ p
                   
Total Study population; 1572 (57.5%) 1162 (42.5%) 765 (58.6%) 541 (41.4%)  
Clinical Variables
EORTC Trial         .77         1.00
18871 271 (17.2%) 205 (17.6%)    
18952 577 (36.7%) 438 (37.7%)    
18991 724 (46.1%) 519 (44.7%)    
18951   263 (34.4%) 186 (34.4%)  
18032   502 (65.6%) 355 (65.6%)  
Treatment Type         .51         .99
Observation 556 (35.4%) 414 (35.6%)    
Interferon 982 (62.5%) 730 (62.8%)    
Other treatment 34 (2.2%) 18 (1.5%)    
DTIC   253 (33.1%) 177 (32.7%)  
Temozolimide   249 (32.5%) 178 (32.9%)  
DTIC, IFN, Cisplatin   105 (13.7%) 72 (13.3%)  
DTIC, IFN, Cisplatin, IL-2   158 (20.7%) 114 (21.1%)  
Age         <.001b         .07b
Premenopausal (≤45 yrs) 584 (37.2%) 496 (42.7%) 188 (24.6%) 150 (27.7%)  
Menopausal (46-59 yrs) 581 (37.0%) 426 (36.7%) 251 (32.8%) 188 (34.8%)  
Postmenopausal (≥60 yrs) 407 (25.9%) 240 (20.7%) 326 (42.6%) 203 (37.5%)  
ECOG performance status                   .15b
0   504 (65.9%) 337 (62.3%)  
1   251 (32.8%) 194 (35.9%)  
2   10 (1.3%) 10 (1.8%)  
Primary Tumor Characteristics
Thickness         .002          
0.01-1.00 mm 272 (17.3%) 196 (16.9%)    
1.01-2.00 mm 138 (8.8%) 107 (9.2%)    
2.01-4.00 mm 334 (21.2%) 313 (26.9%)    
>4.00mm 459 (29.2%) 332 (28.6%)    
Unknown 369 (23.5%) 214 (18.4%)    
Ulceration         .53          
Absent 752 (47.8%) 579 (49.8%)    
Present 481 (30.6%) 349 (30.0%)    
Unknown 339 (21.6%) 234 (20.1%)    
Body Site         <.001          
Head and Neck 160 (10.2%) 75 (6.5%)    
Trunk 778 (49.5%) 378 (32.5%)    
Upper Extremity 183 (11.6%) 130 (11.2%)    
Lower Extremity 342 (21.8%) 526 (45.3%)    
Unknown 109 (6.9%) 53 (4.6%)    
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Table 2.  (Continued)
Stage III Stage IV
  ___MALES _  _FEMALES _ p ___MALES _ _FEMALES _ p
LN metastatis variables
Nodal metastatic volume         .46          
Micrometastasis 544 (34.6%) 418 (36.0%)    
Macrometastasis 1028 (65.4%) 744 (64.0%)    
nr of Positive LNs         <.001b          
1 Lymph Node 728 (46.3%) 631 (54.3%)    
2-3 Lymph Nodes 492 (31.3%) 344 (29.6%)    
4 or more Lymph Nodes 352 (22.4%) 187 (16.1%)    
Timing of LN metastasis         .02          
Synchronous 181 (11.5%) 97 (8.3%)    
Non-synchrounous 786 (50.0%) 619 (53.3%)    
Unknown 605 (38.5%) 446 (38.4%)    
Distant metastasis variables
M-stage site categories                   .61
(Sub)cutaneous, nodal   85 (11.1%) 67 (12.4%)
lung   167 (21.8%) 125 (23.1%)
Other visceral sites   513 (67.1%) 349 (64.5%)
LDH in categories                   .95b
<=ULN   490 (64.1%) 350 (64.7%)
<= 2x ULN   242 (31.6%) 163 (30.1%)
> 2x ULN   33 (4.3%) 28 (5.2%)
Nr of involved sitesa                  
Continuous: Mean (SD) 2.3 (1.2) 2.2 (1.1) .24c
1 site involved   210 (27.5%) 162 (29.9%) .48b
2 sites involved   281 (36.7%) 189 (34.9%)
3 or more sites involved   274 (35.8%) 190 (35.1%)
Nr of TLs                  
Continuous: Mean (SD) 2.9 (2.0) 2.8 (2.0) .31c
Categorical: 0-2 TLs   384 (50.2%) 273 (50.5%) .93b
3 or more TLs   381 (49.8%) 268 (49.5%)
Diameter of TLs                   .15
1-50 mm   237 (31.0%) 191 (35.3%)
51-100 mm   267 (34.9%) 163 (30.1%)
>100 mm   223 (29.2%) 152 (28.1%)
Unknown   38 (5.0%) 35 (6.5%)  
NOTE. Categorical variables presented as number of patients (percentage of total in sex group). Continuous variables 
presented as the mean and SD.
Abbreviations: DTIC, dacarbazine; ECOG, Eastern Cooperative Oncology Group; EORTC, European Organisation for 
Research and Treatment of Cancer; IFN, interferon; IL-2, interleukin-2; LDH, lactate dehydrogenase; LN, lymph node; SD, 
standard deviation; TL, target lesion; ULN, upper limit of normal.
a No. of known sites involved in metastatic disease. The maximum sites possible to register in the trials amounted to 11. 
These included target and nontarget lesions. Possible sites to register were primary location, lymph nodes, lung, liver, 
bone, brain, skin, other soft tissues, ascites, pleural effusion, and other.
b P values for ordered variables were calculated by using the χ2 test for linear trend.
c P value calculated using the t test.
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RESULTS
Study Population
Of 2,771 stage III patients, 36 were excluded because of an unknown number of posi-
tive LNs and one patient because of missing information on the nodal tumor burden. 
Of 1,315 stage IV patients, nine were excluded: sex was unknown for one patient, and 
eight patients had no reported site of distant metastasis. Finally, 2,734 stage III and 1,306 
stage IV patients were included in the analyses. Patient characteristics are described 
in Table 2. Sex was evenly distributed across trials and treatment arms. Males were 
significantly overrepresented in the older age groups in stage III (P < 0.001) but only 
marginally in stage IV (P= 0.07) disease. Among stage III patients, males were more likely 
to have unknown tumor thickness and more often had a history of primary truncal and 
head and neck melanoma, although women more often had a primary melanoma on 
the lower extremity. Compared with females, males had higher numbers of positive LNs 
(P < 0.001). There was no sex difference in nodal volume of LN metastases (microscopic 
v macroscopic; P = 0.46). In stage IV patients, none of the analyzed variables differed 
across sex: males were comparable to females for ECOG PS, metastatic site, number of 
TLs, number of affected sites, LDH level, and sum of TL diameters at baseline.
Effect of Sex on End Points
A clear and significant female advantage was apparent in the Kaplan-Meier curves for 
OS, DSS, and RFS in stage III (Fig 1). Even with the dismal prognosis of stage IV patients, 
this significant advantage persisted for OS, DSS, and PFS (Fig 1). This was also reflected 
in superior survival rates; for example, for DSS in stage III, the 5-year survival rates for 
males versus females were 43.3% versus 51.5% and in stage IV, the 2-year survival rates 
were 14.1% versus 19.0% (Table 3). After adjustment for all available confounders, this 
advantage for females remained statistically significant for all end points in both stage III 
and IV disease (Table 3). In stage III, the significant HRs for sex were highly comparable: 
0.81 for OS, 0.85 for DSS, 0.86 for RFS, and 0.87 for TTDM. In stage IV, comparable HRs of 
0.82 for OS, 0.81 for DSS, and 0.79 for PFS were observed (Table 3). For DSS, the complete 
Cox proportional hazard model is presented in Table 4. Along with sex, localization of 
the primary, number of positive LNs, and metastatic burden were significantly associ-
ated with survival in stage III disease. PS, LDH levels, baseline sum of TL diameters, and 
number of involved sites were significantly associated with survival in stage IV.
Effect of Sex in Subgroups
Forest plots of the subgroup analyses of the sex difference for DSS are presented in 
Figure 2, including P values for interaction of these subgroups with the sex effect. In 
stage III, none of the investigated subgroups showed a significant interaction with the 
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sex effect (Fig 2A). In stage IV, the female advantage was consistent in the majority of 
subgroups (Fig 2B). Only treatment showed a significant interaction with sex (P = 0.01), 
caused by a small but insignificant female disadvantage (HR 1.13; 95% CI 0.90 to 1.42; 
Fig 2B) in the temozolomide group; this altered sex effect was not confirmed for PFS (HR 
0.93; 95% CI 0.76 to 1.13; data not shown). There seemed to be no sex difference in the 
group with distant (sub)cutaneous and nodal metastases (HR, 1.00; 95% CI, 0.68 to 1.48); 
but this was a small subgroup (n = 152), and the interaction term was not significant (P 
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Figure 1 Kaplan-Meier Curves for sex in stage III and IV.
Kaplan-Meier curves of (A, B) overall, (C, D) disease-specific, (E) relapse-free, and (F) progression-free survival separated 
for sex for stage III (A, C, and E) and stage IV (B, D, and F) across different end points. P values were calculated by using the 
log-rank test.
68
Chapter 2.3
= 0.51). Females seemed to have equal advantage with a high or low number of TLs (Fig 
2B). However, results in other subgroups suggested that the female advantage might 
disappear with higher tumor load: the HRs shifted toward 1 for the subgroup with three 
or more metastatic sites and the subgroup with a sum of TL diameters more than 100 
mm compared with subgroups with smaller tumor burden (Fig 2B). However, these 
observations were not statistically significant (P for interaction for number of TLs = 0.81 
and P for interaction for sum of TL diameters = 0.49, respectively). 
When stratifying patients across menopausal age categories, no clear differences were 
observed between the adjusted sex HRs in the three age groups for both stage III and IV 
melanoma (Fig 2; Table 5).
DISCUSSION
Recently, we published a similar analysis of EORTC trials for stage I and II (localized) 
melanoma that showed a highly consistent and independent advantage for females 
Table 3. HRs for females compared to males for different endpoints
Stage III (n=2734)
nr. of events 5-year survival / progression-free 
rates
Adjusted Cox regression 
modela
Male
(n=1572)
Female
(n=1162) Male Female HR 95% CI p-value
OS 871 526 40.6% 51.0% 0.81 (0.72-0.91) <0.001
DSS 822 517 43.3% 51.5% 0.85 (0.76-0.95) <0.01
RFS 1033 672 31.7% 40.7% 0.86 (0.77-0.95) <0.01
TTDM 937 607 38.1% 45.3% 0.87 (0.78-0.97) 0.01
Stage IV (n=1306)
nr. of events 2-year survival / progression-free 
rates
Adjusted Cox regression 
modelb
Male
(n=765)
Female
(n=541) Male Female HR 95% CI p-value
OS 630 427 12.5% 17.5% 0.82 (0.72-0.93) <0.01
DSS 597 402 14.1% 19.0% 0.81 (0.72-0.92) <0.01
PFS 739 499 2.2% 5.3% 0.79 (0.70-0.88) <0.001
NOTE. All models were stratified by trial.
Abbreviations: DSS, disease-specific survival; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; RFS, 
relapse-free survival; TTDM, time to distant metastasis.
a Multivariable Cox regression model with the following variables included, in order of prognostic importance (for OS): 
No. of positive lymph nodes, size of lymph node metastasis, Breslow thickness, sex, body site of primary melanoma, age, 
ulceration, and treatment.
b Multivariable Cox regression model with the following variables included, in order of prognostic importance (for OS): lac-
tate dehydrogenase level, No. of involved sites (continuous), baseline sum of target lesion diameter, Eastern Cooperative 
Oncology Group status, sex, No. of target lesions (continuous), M-stage site categories, age, and treatment.
69
2.3
Gender Differences in Metastasized Melanoma (EORTC trials)
Ta
bl
e 
4.
 M
ul
ti
va
ri
at
e 
m
od
el
s 
fo
r D
is
ea
se
 S
pe
ci
fic
 S
ur
vi
va
l
St
ag
e 
III
St
ag
e 
IV
Va
ri
ab
le
Ca
te
go
ry
H
R
95
%
 C
I
p
Va
ri
ab
le
Ca
te
go
ry
H
R
95
%
 C
I
p
G
en
de
r
M
al
e
1.
00
Re
fe
re
nc
e
G
en
de
r
M
al
e
1.
00
Re
fe
re
nc
e
Fe
m
al
e
0.
85
(0
.7
6-
0.
95
)
<0
.0
1
Fe
m
al
e
0.
82
(0
.7
2-
0.
93
)
<0
.0
1
Tr
ea
tm
en
t
O
bs
er
va
tio
n
1.
00
Re
fe
re
nc
e
Tr
ea
tm
en
t
Te
m
oz
ol
om
id
e
1.
00
Re
fe
re
nc
e
In
te
rf
er
on
0.
98
(0
.8
7-
1.
10
)
0.
70
D
TI
C
0.
97
(0
.8
3-
1.
13
)
0.
70
O
th
er
 
1.
33
(0
.9
4-
1.
90
)
0.
11
D
TI
C,
 In
te
rf
er
on
, C
is
pl
at
in
0.
88
(0
.7
1-
1.
08
)
0.
22
Ag
e
≤4
5 
yr
s
1.
00
Re
fe
re
nc
e
D
TI
C,
 In
te
rf
er
on
, C
is
pl
at
in
, I
L-
2
0.
82
(0
.6
8-
1.
00
)
0.
05
46
-5
9 
yr
s
1.
00
(0
.8
7-
1.
10
)
0.
96
Ag
e
≤4
5 
yr
s
1.
00
Re
fe
re
nc
e
≥6
0 
yr
s
1.
07
(0
.9
4-
1.
90
)
0.
37
46
-5
9 
yr
s
0.
88
(0
.7
5-
1.
03
)
0.
11
Br
es
lo
w
 th
ic
kn
es
s
0-
1 
m
m
1.
00
Re
fe
re
nc
e
≥6
0 
yr
s
0.
97
(0
.8
3-
1.
14
)
0.
75
1.
01
-2
 m
m
1.
18
(0
.9
3-
1.
49
)
0.
17
EC
O
G
0
1.
00
Re
fe
re
nc
e
2.
01
-4
 m
m
1.
28
(1
.0
2-
1.
61
)
0.
03
1
1.
29
(1
.1
3-
1.
47
)
<0
.0
01
>4
 m
m
1.
72
(1
.3
6-
2.
19
)
<0
.0
01
2
1.
45
(0
.9
0-
2.
34
)
0.
13
U
nk
no
w
n
1.
16
(0
.8
8-
1.
55
)
0.
30
Si
te
Sk
in
, l
ym
ph
 n
od
es
, s
of
t t
is
su
e
1.
00
Re
fe
re
nc
e
U
lc
er
at
io
n
A
bs
en
t
1.
00
Re
fe
re
nc
e
Lu
ng
0.
85
(0
.6
8-
1.
08
 )
0.
18
Pr
es
en
t
1.
12
(0
.9
9-
1.
28
)
0.
08
O
th
er
 v
is
ce
ra
l s
ite
s
0.
82
(0
.6
6-
1.
02
)
0.
07
U
nk
no
w
n
1.
12
(0
.9
3-
1.
35
)
0.
24
LD
H
≤U
LN
1.
00
Re
fe
re
nc
e
Lo
ca
lis
at
io
n
H
ea
d/
N
ec
k
1.
00
Re
fe
re
nc
e
≤2
x 
U
LN
1.
43
(1
.2
4-
1.
64
)
<0
.0
01
Tr
un
k
0.
96
(0
.7
9-
1.
16
)
0.
67
> 
2x
 U
LN
2.
98
(2
.2
1-
4.
02
)
<0
.0
01
U
pp
er
 e
xt
re
m
ity
0.
84
(0
.6
6-
1.
06
)
0.
14
Ba
se
lin
e 
su
m
 o
f d
ia
m
et
er
s
1-
50
 m
m
1.
00
Re
fe
re
nc
e
Lo
w
er
 e
xt
re
m
ity
0.
75
(0
.6
1-
0.
92
)
<0
.0
1
51
-1
00
 m
m
1.
02
(0
.8
6-
1.
20
)
0.
83
U
nk
no
w
n
0.
65
(0
.4
7-
0.
89
)
<0
.0
1
> 
10
0 
m
m
1.
27
(1
.0
3-
1.
57
)
0.
02
N
r o
f l
ym
ph
 n
od
es
1
1.
00
Re
fe
re
nc
e
U
nk
no
w
n
0.
79
(0
.5
7-
1.
11
)
0.
18
2-
3
1.
35
(1
.1
9-
1.
54
)
<0
.0
01
N
r o
f i
nv
ol
ve
d 
si
te
s
Co
nt
in
uo
us
1.
17
(1
.0
9-
1.
25
)
<0
.0
01
4 
or
 m
or
e
2.
16
(1
.8
9-
2.
48
)
<0
.0
01
N
r o
f t
ar
ge
t l
es
io
ns
Co
nt
in
uo
us
1.
03
(0
.9
9-
1.
08
)
0.
18
M
et
as
ta
tic
 b
ur
de
n
m
ic
ro
m
et
as
ta
se
s
1.
00
Re
fe
re
nc
e
m
ac
ro
m
et
as
ta
si
s
1.
67
(1
.4
7-
1.
91
)
<0
.0
01
A
bb
re
vi
at
io
ns
: D
SS
, d
is
ea
se
-s
pe
ci
fic
 s
ur
vi
va
l; 
D
TI
C,
 d
ac
ar
ba
zi
ne
; E
CO
G
, E
as
te
rn
 C
oo
pe
ra
tiv
e 
O
nc
ol
og
y 
G
ro
up
; H
R,
 h
az
ar
d 
ra
tio
; I
L-
2,
 in
te
rle
uk
in
-2
; L
D
H
, l
ac
ta
te
 d
eh
yd
ro
ge
na
se
; U
LN
, u
pp
er
 li
m
it 
of
 n
or
m
al
.
70
Chapter 2.3
across different end points concerning disease progression and survival4. This study 
confirms that this female advantage persists in patients with advanced stage III and IV 
melanoma. As in localized melanoma, the advantage is consistent across end points (OS, 
DSS, and PFS). However, the relative female advantage declined from a 30% advantage 
in stage I and II melanoma4 to the 15% to 20% advantage in stage III and IV melanoma in 
this study. Furthermore, we observed that sex HRs shifted even further toward 1 in those 
patient groups with most advanced disease (ie, high tumor burden in stage IV; Fig 2B), 
although this shift was nonsignificant. Still, it seems that the female advantage gradually 
declines as the disease advances.
Few large studies have investigated the effect of sex in advanced melanoma. We have 
listed the published studies with more than 1,000 patients in Table 4. In stage III, the 
majority of studies reported an HR similar to the HR of approximately 0.80 observed in 
this study15-18. The only exceptions are the 2001 AJCC study (HR 0.99)13 and another AJCC 
study that found no sex difference in patients with LN macrometastases (HR 1.07) as 
opposed to patients with LN micrometastases (HR 0.80)15. When they added mitotic rate 
to the model and therewith reduced the study population, remarkably, the HR for mac-
rometastatic patients shifted to 0.79 (Table 4), again comparable to our results (Table 3). 
Thus, the overall picture in the literature is of a consistent relative female advantage of 
approximately 20% in stage III melanoma when compared with males. 
To the best of our knowledge, for stage IV, only four studies of more than 1,000 patients 
reported an adjusted survival HR for sex. Three population-based studies, one from Ger-
Table 5: HRs for females compared to males stratified for menopausal age categories
Premenopausal
(≤45 yr)
Menopausal
(46-59 yr)
Postmenopausal
(≥60 yr)
 
Events 
males
Events 
females HR (95%CI)
Events 
males
Events 
females HR (95%CI)
Events 
males
Events 
females HR (95%CI)
Stage IIIa
(n) (584) (496) (581) (426) (407) (240)
OS 302 219 0.88 (0.73-1.05) 321 186 0.84 (0.69-1.02) 248 121 0.71 (0.56-0.89)
DSS 296 217 0.89 (0.74-1.06) 304 183 0.88 (0.72-1.06) 222 117 0.77 (0.61-0.99)
RFS 367 274 0.88 (0.75-1.03) 381 239 0.88 (0.74-1.05) 285 159 0.83 (0.67-1.03)
TTDM 336 254 0.90 (0.76-1.07) 346 216 0.90 (0.75-1.08) 255 137 0.80 (0.63-1.01)
Stage IVb
(n) (188) (150) (251) (188) (326) (203)
OS 163 122 0.93 (0.72-1.18) 206 137 0.82 (0.65-1.03) 261 168 0.82 (0.67-1.00)
DSS 157 118 0.94 (0.73-1.20) 198 131 0.81 (0.64-1.02) 242 153 0.80 (0.65-0.99)
PFS 184 139 0.88 (0.70-1.11) 241 170 0.76 (0.62-0.93) 311 190 0.77 (0.64-0.92)
a HR’s for gender adjusted for nr. of positive LNs, Size of LN metastasis, Breslow thickness, Body site of primary melanoma, 
ulceration, treatment.
b HR’s for gender adjusted for LDH level, nr. of involved sites, baseline sum of target lesion diameter, ECOG score, nr. of TLs, 
M-stage site categories. 
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many 16 and two from the SEER database14,20, reported fairly consistent HRs ranging from 
0.89 to 0.93 (Table 6), which represent a smaller female advantage compared with our 
current findings (HRs of approximately 0.80; Table 3). However, one trial-based study19 
reported HRs for OS and PFS similar to our results (HR, 0.78 and 0.88, respectively). This 
might be explained by our observation that the female advantage seems to disappear in 
patients with a high metastatic burden: trials use inclusion criteria (e.g. ECOG PS of 0 or 
1) resulting in an over-representation of stage IV patients with lower metastatic burden. 
Because population-based studies use all patients, they should include relatively more 
patients with high metastatic burden, resulting in a smaller female advantage. Notably, 
another smaller trial-based study (n = 813) found an HR of 0.90 (95% CI 0.76 to 1.05) and 
included a literature review identifying five of nine small studies with sex as an indepen-
dent prognostic indicator. 21 In summary, only a few reports found sex survival HRs of 
0.8 to 0.9, indicative of a relative advantage of 10% to 20%, although these estimates 
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0.01-1.00 mm
1.01-2.00 mm
2.01-4.00 mm
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Figure 2. Forest plots: gender Hazard Ratio’s for disease specific survival.
DTIC, dacarbazine; ECOG, Eastern Cooperative Oncology Group performance status; IFN, interferon; IL-2, interleukin-2; 
LDH, lactate dehydrogenase; LN, lymph node; TL, target lesion; ULN, upper limit of normal.
Subgroup analyses presented by using sex hazard ratios (HRs) with their 95% CIs and forest plots for stage III (A) and IV (B) 
for disease-specific survival. P values represent the statistical significance of the interaction term of the presented prog-
nostic indicator and sex in a Cox proportional hazard model. When applicable, the category “unknown” was excluded for 
the interaction term analyses. 
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do not always reach significance and may apply to only to low tumor burden stage IV 
disease.
Explanations for the observed sex difference in survival fall into two categories: it may 
be related to (1) behavioral differences across sex (e.g. delay in diagnosis) or to (2) bio-
logic sex differences affecting melanoma. In localized melanoma, the persistence of sex 
as an independent prognostic factor after adjustment for factors presumably related to 
diagnostic delay (e.g. body site and Breslow thickness)16,22,23 seems to refute the behav-
ioral hypothesis and favor the biologic hypothesis4. In advanced melanoma, especially 
in stage IV, the effects of diagnostic delays and health care consumption are probably 
smaller compared with localized melanoma but they might still exist. To adjust for these 
possible delays, we included multiple confounders that are likely to be associated with 
delayed diagnosis, for example, nodal tumor volume, number of positive LNs in stage III, 
and multiple indicators of metastatic tumor load in stage IV. Furthermore, trial follow-
up protocols should have eliminated sex differences in health care consumption after 
randomization. Therefore, our observation that sex remains an independent prognostic 
factor for all end points in metastatic melanoma confirms that behavioral aspects can-
not fully explain the female advantage in melanoma survival. The consistent female 
advantage in different prognostic subgroups, probably related to diagnostic delays, 
seems to confirm this independence of the sex effect from behavioral aspects (Fig 2). 
It is also important to point out that males had a survival disadvantage whether their 
LN metastases were diagnosed synchronously or nonsynchronously with their primary 
melanoma (Fig 2A), which is another indication that diagnostic delays cannot explain 
the female survival advantage.
It seems that a biologic trait that differs across sex affects melanoma in a profound 
way. This trait results in sex differences in survival and progression across the whole 
spectrum of the disease, from early to late stages. To the best of our knowledge, only 
two hypotheses regarding biologic sex differences have been elaborately described: dif-
ference in the capacity to neutralize oxidative stress24 and the effect of estrogen recep-
tor beta (ER-β) expression25. However ER-β expression declines after menopause25 and 
therefore the ER-βhypothesis dictates that in postmenopausal women, the advantage 
over menshould decline or even disappear. Our findings of an equal advantage for older 
and younger women compared with men of the same age in both advanced (Table 4) 
and localized disease4 seem to contradict this hypothesis. Other possible explanations 
for the female advantage found in the literature that are less elaborately explored in-
clude differences in immune homeostasis26,27 and vitamin D metabolism28,29. Androgens 
could also play a role, and interestingly, one small study found androgen receptors to 
be highly expressed in melanoma metastases30. Further research is needed to confirm or 
exclude any of these hypothetical biologic explanations.
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Table 6. Large (> 1,000 patients) Studies Reporting Adjusted Sex HRs in Advanced Melanoma 
Country Data-
base
Additional 
information
n end-
point
HRa (95%CI) Adjusted for Refer-
ence
Stage III
Interna-
tional
AJCC 1151 DSS 0.99 (0.82-1.20) Age, thickness, site, ulceration, 
Clark level, LN tumor burden, nr 
of positive LNs 
13
USA SEER 1963 DSS 0.81 (0.70-0.93)b Age, race, marital status, histol-
ogy, body site
14
Interna-
tional
AJCC LN micro- 
metastasis
1872 DSS 0.80 (p=0.03) Age, nr of positive LNs, thickness, 
ulceration, Clark level, body site
15
LN macro- 
metastasis
441 DSS 1.07 (p=0.66) Age, nr of positive LNs, thickness, 
ulceration, Clark level, body site
15
Interna-
tional
AJCC LN micro- 
metastasis
1070 DSS 0.86 (p=0.30) Age, nr of positive LNs, thickness, 
ulceration, Clark level, body site, 
Mitotic rate
15
LN macro- 
metastasis
268 DSS 0.79 (p=0.34) Age, nr of positive LNs, thickness, 
ulceration, Clark level, body site, 
Mitotic rate
15
Germany MCR 1321 DSS 0.80 (0.66-0.96) Age, year of diagnosis, primary 
tumor Breslow, histology, site.
16
Europe Nine 
EORTC 
centers
Micro- 
metastasis 
(SLN positive 
patients)
1080 DSS 0.76 (0.61-0.96)b Age, Center, histology, body site, 
clark level Breslow,  Ulceration, 
Rotterdam criteria
17
USA SEER 6868 OS 0.79 (0.73-0.86) Age, Breslow, Ulceration, nr of LN 
meta’s, surgery, Era.
18
DSS 0.80 (0.73-0.88) Age, Breslow, Ulceration, nr of LN 
meta’s, surgery, Era.
18
Stage IV
USA 42 
Phase 
II trials
1278 OS 0.78 (p<0.0001)b ECOG, Visceral metastases, Brain 
metastases, Year of trial (OS) or 
Age (PFS)
19
PFS 0.88 (p=0.026)b ECOG, Visceral metastases, Brain 
metastases, Year of trial (OS) or 
Age (PFS)
19
USA SEER 1038 DSS 0.93 (0.79-1.09)b Age, race, marital status, histol-
ogy, body site
14
Germany MCR 1602 OS 0.89 (0.78-1.03) Age, year of diagnosis, site of me-
tastasis, primary tumor Breslow, 
histology, site.
16
USA SEER 4201 OS 0.91 (0.85-0.98) Age, Time period, M-stage, 
metastectomy
20
Abbreviations: AJCC, American Joint Committee on Cancer; DSS, disease-specific survival; ECOG, Eastern Cooperative 
Oncology Group; EORTC, European
Organisation for Research and Treatment of Cancer; Era, 1988-1999 v 2000-2006; HR, hazard ratio; LN, lymph node; MCR, 
Molecular Cancer Research; OS, overall
survival; PFS, progression-free survival; PS, performance status; SLN, sentinel lymph node;
a HR for females compared with males.
b HR was originally reported for males compared with females; therefore, the HR and 95% CI were inverted to enable 
comparison.
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Major strengths of this study include the large sample size compared with those of 
previous studies (Table 6), a more meticulous standardized follow-up of trial patients 
compared with population-based studies, and complete information on important 
confounders for both stage III and IV. Especially in stage IV, multiple variables were 
available describing metastatic tumor burden that enabled the adjustment of the sex 
HRs for the extent of disease that reduced the influence of unknown diagnostic delays.
This is an important strength of our study compared with the other population-based 
studies mentioned in Table 6 that adjusted for limited sets of confounders. However, 
some of the confounders we used in stage IV analyses were related to target lesions, 
which are chosen by local physicians and may differ across study centers. However, it 
is unlikely that this influenced our results because this possible physician-related sub-
jectivity should not depend on the patients’ sex. Another weakness of our study is that 
trial populations are selected by inclusion criteria, so results cannot be extrapolated to 
the whole advanced melanoma population, especially to patients with a higher tumor 
burden, with brain metastases, and with lower ECOG PS who were excluded from these 
trials. Therefore, to investigate the possible effect of this patient selection bias, the study 
results were compared in detail with those of population-based studies (Table 6).
In conclusion, overall, the female advantage was consistent across end points, 
independent of other prognostic factors, and it persisted in all stages of melanoma 
progression. This contradicts theories about behavioral sex disparities explaining these 
survival differences and strongly suggests a biologic underlying factor. Both clinical and 
laboratory melanoma investigators should take sex into consideration in their research, 
for example by stratifying by sex, to help identify the underlying explanation for this 
phenomenon.
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ABSTRACT
Background and aim: Based on prior studies, we concluded that the female ad-
vantage in melanoma survival is caused by biological factors and not by differences 
in behavior. In this study, we investigated whether this biological advantage was 
caused by a more aggressive tumor in males, as measured by mitotic rate (MR). 
Methods: Data of patients with complete information on MR, Breslow thickness, 
ulceration and primary tumor location were extracted from the database of the 
Melanoma Institute Australia in Sydney. A negative binomial regression model was 
used to assess the independent predictive value of sex for MR. Furthermore, the im-
pact of MR on the sex survival advantage was investigated using Cox proportional 
hazards models modeling disease specific survival. 
Results: 9,306 patients were included in the analysis. Although males had a slightly 
higher MR at diagnosis, sex was no independent predictor of MR after adjustment 
for all other prognostic factors: Incidence Rate Ratio 0.98, 95% Confidence Interval 
(CI) 0.93-1.02. After adjustment for all prognostic factors, females had a significant 
survival advantage of 36%: Hazard Ratio 0.65, 96%CI 0.55-0.75. When added as a 
confounder, MR did not influence this sex hazard ratio. 
Conclusions: Sex does not independently predict the aggressiveness of the 
primary tumor. Furthermore, MR did not influence the known female survival ad-
vantage in melanoma. Based on these results, the biological trait underlying sex 
survival differences in melanoma seems not to be tumor-related, and is therefore 
more likely to be caused by the host factors.
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INTRODUCTION
Sex is an independent prognostic factor for cutaneous melanoma survival and progres-
sion, with females having a substantially better prognosis than males. However, the 
mechanisms behind this phenomenon are still unknown. In previous studies, we argued 
that behavioral aspects such as differences in sun exposure, lower skin cancer awareness 
and lower health care consumption among males could not fully explain the survival dif-
ferences across sex1-3. The main arguments for rejecting these explanations were the per-
sistence of the female advantage after adjustment for prognostic indicators presumably 
related to behavioral aspects (e.g. Breslow thickness and primary tumor localization)1,2,4-6 
and the persistence of the female advantage in melanoma metastasized to the lymph 
nodes and distant organs2,3. Therefore, it is more likely that female survival advantage is 
caused by some biological difference, which might be either tumor-related, i.e. males 
have more aggressive melanomas, or host-related, i.e. females are better ‘equipped’ 
to resist progression and metastasis. To test a possible tumor-related explanation, an 
analysis of sex differences in survival including mitotic rate (MR) of the primary tumor 
is useful. MR, the number of mitotic figures / mm2, has been described as a ‘quantita-
tive measure of melanoma proliferation’ or a reflection of ‘cellular proliferation within 
the primary tumor’7. Increasing MR reflects a more rapidly dividing and therefore more 
aggressive tumor and is an independent predictor of worse survival in melanoma8. We 
hypothesize that the independent prognostic value of sex is mediated by more aggres-
sive primary melanomas in males. If this hypothesis is true, males should have a higher 
MR at diagnosis irrespective of other tumor characteristics such as thickness or ulcer-
ation. Furthermore, if more aggressive tumors explain their worse survival compared to 
females, adjusting the sex survival differences for MR should attenuate the effect of sex 
on survival. The aim of this study is to test these hypotheses and investigate whether 
males indeed have more aggressive primary melanoma tumors than females.
METHODS
Patient population
For this retrospective study, data were extracted from the prospectively collected Mela-
noma Institute Australia (MIA) database. We used information of patients with stage I or 
II cutaneous melanoma disease who had a single primary treated at the MIA with MR 
recorded on their pathology report (n=13958). Patients with missing data on sex (n=4), 
Breslow thickness (n=101) and ulceration (n=1279) were excluded from this analysis. 
Previous studies showed a strong association between sex and site2,4-6, so patients with 
an unknown body site of the primary melanoma were excluded (n=1316). Patients with 
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non-cutaneous (n=44) and in situ melanomas (n=20) were also excluded. Finally, patients 
diagnosed before 1983 were excluded since the MIA started routinely registering MR in 
1983 according to the revised Sydney classification of Malignant Melanoma (n=1881)9. 
Finally, n=9,306 patients could be included in the analysis. Pathology details were ex-
tracted giving first preference to a MIA or review report over reports from other centers. 
Pathology details were extracted only for melanomas for which MR was recorded. 
Variable selection
Complete information for all patients was available for Breslow thickness, ulceration, 
body site and MR. Breslow thickness was categorized according to the American Joint 
Cancer Committee (AJCC) staging system7 in 4 groups: 0-1 mm (T1), 1.01-2 mm (T2), 
2.01-4 mm (T3), >4 mm (T4). Ulceration was categorized as absent vs. present and 
body site as head and neck, truncal, lower extremity and upper extremity. Histological 
subtype was included in 4 categories: superficial spreading melanoma (SSM), nodular 
melanoma (NM), other subtypes and unknown types. Clark level was included in four 
levels (II-V) and one unknown category. Year of diagnosis was included to adjust for 
potential changes over time and was categorized into quartiles (1983-1991, 1992-1998, 
1999-2002 and 2003-2008). Age was used as a continuous variable, but was also used 
as a variable categorized in three groups for subgroup analyses based on presumed 
menopausal status: ≤45 years women were presumed to be premenopausal, 46-59 years 
was considered the menopausal group and ≥60 years postmenopausal, in accordance 
with earlier studies1-4. 
At the MIA, MR was defined as number of mitoses per square mm, in accordance with 
the AJCC guidelines10.  On pathology reports from outside of MIA, MR was often reported 
as mitotic figures per high-power field (HPF). This was converted to mitoses/mm2 using 
the formula 1 mitosis/HPF = 5 mitoses/mm2. MR was considered as a continuous vari-
able in all multivariate analyses, although a variable of 5 categories was constructed for 
subgroup analyses: one category of 0 mitotic activity plus the quartiles of the patients 
with ≥ 1 mitotic rate (1 mitosis, 2 mitoses, 2-5 mitoses, ≥6 mitoses).  
Statistical analysis
Chi-square tests were used to compare distribution of subgroups across sex. Sex differ-
ences of MR as a continuous variable were analyzed using the non-parametric Mann- 
Whitney U test due to the highly skewed distribution of MR. A negative binomial model 
was chosen (see supplemental methods) for the multivariate analysis of predictors of 
MR, and Incidence Rate Ratio’s (IRRs) were calculated with 95% Confidence Intervals (CIs) 
and p-values for all covariates. 
Because of this skewed distribution of MR, we were not able to use regular statisti-
cal methods such as a linear regression model to fit MR. Therefore, four models were 
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considered for the multivariate analysis of predictors of MR,: a Poisson model, a negative 
binomial model, a zero-inflated Poisson model and a zero-inflated negative binomial 
regression model. The Poisson model was discarded due to too much dispersion of MR 
according to the deviance goodness of fit measure. The negative binomial, zero-inflated 
Poisson and zero-inflated negative binomial models all seemed to fit the data. To 
choose between these three models, the Vuong test was used to compare these three 
non-nested models11, which showed the negative binomial regression model to be the 
superior model. Using this negative binomial model, Incidence Rate Ratio’s (IRR) were 
calculated with 95% CIs and p-values for all covariates.
For patients with available follow-up data (n=8,186), survival time was calculated from 
date of primary diagnosis until death or last date of follow-up. Disease Specific Survival 
(DSS) was chosen as the endpoint, with death caused by melanoma considered as event. 
Patients who died from other or unknown causes were censored at their date of death; 
patients who were alive were censored at their last follow-up date. Cox proportional 
hazard (PH) models were used to model DSS and calculate Hazard ratio’s (HRs) and 95% 
CIs for independent variables in three steps. First, crude unadjusted Hazard Ratio’s (HRs) 
for sex were estimated. Then, all other variables were entered in a separate bivariate 
model alongside with sex to test to which extent they adjusted the effect of sex on 
survival. Thirdly, a multivariate model was constructed in a forward step manner adding 
the covariates in order of the magnitude of adjustment of the sex HR as observed in the 
bivariate models. In this way, the effect of all available confounders on the sex HR could 
precisely be assessed in the multivariate setting. 
Analyses were done using PASW Statistics 17.0, Version 17.0.2 (IBM, Armonk, NY, USA). 
Kaplan Meier curves were plotted using STATA/SE 11.1 (StataCorp LP, College Station, 
TX). The multivariate modelling of predictors of mitotic rate was performed using R ver-
sion 2.7.1 (R foundation for Statistical Computing, Vienna, Austria).
RESULTS
Descriptive data of the study population (n=9,306) is summarized in table 1. Confirming 
numerous other studies1,2,4-6, males had a worse distribution of all prognostic indicators 
compared to females. Compared to females, males were older at diagnosis, had thicker 
and more often ulcerated tumors, more often had tumors located on the trunk, head 
and neck, were diagnosed with nodular melanomas more often and had higher Clark 
levels. In the overall cohort, MR was significantly higher in males with a median MR of 
2 compared with 1 in females, p=<0.001 (table 2). When stratifying the overall cohort 
by subgroups, the higher MR in males was confirmed for almost all subgroups in age, 
ulceration, body site, histology (except SSM) and year of diagnosis (except 1999-2002). 
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Table 1. Descriptive data
  numbers (percentage of sex)  
  Male Female pa
Total group (n=9308) 5181 (55.7%) 4127 (44.3%)  
Age     <0.001
<46 yr 1410 (27.2%) 1617 (39.2%)  
46-59 yr 1465 (28.3%) 1139 (27.6%)  
>59 yr 2306 (44.5%) 1371 (33.2%)  
Breslow Thickness     <0.001
0-1 mm 2133 (41.2%) 2085 (50.5%)  
1.01-2 mm 1424 (27.5%) 1133 (27.5%)  
2.01-4 mm 1066 (20.6%) 654 (15.8%)  
>4 mm 558 (10.8%) 255 (6.2%)  
Ulceration     <0.001
Absent 4139 (79.9%) 3495 (84.7%)  
Present 1042 (20.1%) 632 (15.3%)  
Body Site     <0.001
Head and Neck 1040 (20.1%) 507 (12.3%)  
Trunk 2192 (42.3%) 889 (21.5%)  
Arm 1116 (21.5%) 1140 (27.6%)  
Leg 833 (16.1%) 1591 (38.6%)  
Histology     <0.001
SSM 1987 (38.4%) 1821 (44.1%)  
NM 1300 (25.1%) 816 (19.8%)  
Other 555 (10.7%) 359 (8.7%)  
Unknown 1339 (25.8%) 1131 (27.4%)  
Clark Level     <0.001
II 831 (16.0%) 1034 (18.9%)  
III 2034 (35.1%) 1764 (37.8%)  
IV 2525 (41.3%) 1957 (37.4%)  
V 352 (5.9%) 194 (4.0%)  
Unknown 187 (1.7%) 147 (1.9%)  
Year of diagnosis     <0.001
1983-1991 1090 (21.0%) 1029 (24.9%)  
1992-1998 1364 (26.3%) 1066 (25.8%)  
1999-2002 1300 (25.1%) 907 (22.0%)  
2003-2008 1427 (27.5%) 1125 (27.3%)  
Follow-up (n=8186)      
Median follow-up: 
4.7 yrs 4.8 yrs 4.6 yrs 0.54
NM: Nodular Melanoma, SSM: Superficial Spreading Melanoma
a Chi-square test
83
2.4
Gender Differences and Mitotic Rate
Ta
bl
e 
2.
 A
ss
oc
ia
ti
on
 o
f M
it
ot
ic
 R
at
e 
an
d 
Se
x 
 
Se
x
M
it
ot
ic
 R
at
e 
Co
nt
in
uo
us
M
it
ot
ic
 ra
te
 0
 a
nd
 4
 q
ua
rt
ile
s
nu
m
be
rs
 (p
er
ce
nt
ag
e 
of
 se
x)
 
 
 
M
ed
ia
n
IQ
R
pa
_0
 m
it
os
es
_
_1
 m
it
os
is
_
_2
 m
it
os
es
_
_3
-5
 m
it
os
es
_
_≥
6 
m
it
os
es
_
pb
To
ta
l g
ro
up
m
al
e
2
(0
-5
)
<0
.0
01
14
40
(2
7.
8%
)
88
8
(1
7.
1%
)
66
5
(1
2.
8%
)
10
77
(2
0.
8%
)
11
11
(2
1.
4%
)
<0
.0
01
 
fe
m
al
e
1
(0
-4
)
12
83
(3
1.
1%
)
83
0
(2
0.
1%
)
60
0
(1
4.
5%
)
80
0
(1
9.
4%
)
61
4
(1
4.
9%
)
 
A
ge
 
 
 
 
 
 
 
 
 
 
 
 
<4
6 
yr
m
al
e
1
(0
-3
)
0.
05
49
4
(3
5.
0%
)
28
2
(2
0.
0%
)
19
4
(1
3.
8%
)
27
1
(1
9.
2%
)
16
9
(1
2.
0%
)
0.
03
 
fe
m
al
e
1
(0
-3
)
57
6
(3
5.
6%
)
37
9
(2
3.
4%
)
23
5
(1
4.
5%
)
26
4
(1
6.
3%
)
16
3
(1
0.
1%
)
 
46
-5
9 
yr
m
al
e
2
(0
-4
.5
)
<0
.0
01
42
3
(2
8.
9%
)
26
8
(1
8.
3%
)
19
4
(1
3.
2%
)
29
2
(1
9.
9%
)
28
8
(1
9.
7%
)
<0
.0
01
 
fe
m
al
e
1
(0
-3
)
38
5
(3
3.
8%
)
22
7
(1
9.
9%
)
17
5
(1
5.
4%
)
21
3
(1
8.
7%
)
13
9
(1
2.
2%
)
 
>5
9 
yr
m
al
e
3
(1
-6
)
0.
01
52
3
(2
2.
7%
)
33
8
(1
4.
7%
)
27
7
(1
2.
0%
)
51
4
(2
2.
3%
)
65
4
(2
8.
4%
)
0.
01
 
fe
m
al
e
2
(1
-5
)
32
2
(2
3.
5%
)
22
4
(1
6.
3%
)
19
0
(1
3.
9%
)
32
3
(2
3.
6%
)
31
2
(2
2.
8%
)
 
Br
es
lo
w
 T
hi
ck
ne
ss
 
 
 
 
 
 
 
 
 
 
 
0-
1 
m
m
m
al
e
0
(0
-1
)
0.
08
12
02
(5
6.
4%
)
49
5
(2
3.
2%
)
21
1
(9
.9
%
)
18
8
(8
.8
%
)
37
(1
.7
%
)
0.
12
 
fe
m
al
e
0
(0
-1
)
11
14
(5
3.
4%
)
50
9
(2
4.
4%
)
25
3
(1
2.
1%
)
17
4
(8
.3
%
)
35
(1
.7
%
)
 
1.
01
-2
 m
m
m
al
e
2
(1
-5
)
0.
21
18
0
(1
2.
6%
)
26
7
(1
8.
8%
)
29
5
(2
0.
7%
)
41
8
(2
9.
4%
)
26
4
(1
8.
5%
)
0.
19
 
fe
m
al
e
2
(1
-4
)
13
2
(1
1.
7%
)
24
0
(2
1.
2%
)
23
6
(2
0.
8%
)
34
9
(3
0.
8%
)
17
6
(1
5.
5%
)
 
2.
01
-4
 m
m
m
al
e
5
(3
-9
)
0.
01
38
(3
.6
%
)
98
(9
.2
%
)
11
8
(1
1.
1%
)
33
7
(3
1.
6%
)
47
5
(4
4.
6%
)
0.
05
 
fe
m
al
e
4
(2
-8
)
30
(4
.6
%
)
71
(1
0.
9%
)
93
(1
4.
2%
)
21
0
(3
2.
1%
)
25
0
(3
8.
2%
)
 
>4
 m
m
m
al
e
7
(4
-1
2)
0.
37
20
(3
.6
%
)
28
(5
.0
%
)
41
(7
.3
%
)
13
4
(2
4.
0%
)
33
5
(6
0.
0%
)
0.
89
 
fe
m
al
e
7
(4
-1
3)
7
(2
.7
%
)
10
(3
.9
%
)
18
(7
.1
%
)
67
(2
6.
3%
)
15
3
(6
0.
0%
)
 
U
lc
er
at
io
n
 
 
 
 
 
 
 
 
 
 
 
 
A
bs
en
t
m
al
e
1
(0
-3
)
<0
.0
01
14
08
(3
4.
0%
)
81
3
(1
9.
6%
)
55
7
(1
3.
5%
)
80
4
(1
9.
4%
)
55
7
(1
3.
5%
)
<0
.0
01
 
fe
m
al
e
1
(0
-3
)
12
48
(3
5.
7%
)
77
5
(2
2.
2%
)
52
1
(1
4.
9%
)
61
2
(1
7.
5%
)
33
9
(9
.7
%
)
 
Pr
es
en
t
m
al
e
6
(3
-1
2)
<0
.0
01
32
(3
.1
%
)
75
(7
.2
%
)
10
8
(1
0.
4%
)
27
3
(2
6.
2%
)
55
4
(5
3.
2%
)
<0
.0
1
84
Chapter 2.4
Ta
bl
e 
2.
  (
Co
nt
in
ue
d)
 
Se
x
M
it
ot
ic
 R
at
e 
Co
nt
in
uo
us
M
it
ot
ic
 ra
te
 0
 a
nd
 4
 q
ua
rt
ile
s
nu
m
be
rs
 (p
er
ce
nt
ag
e 
of
 se
x)
 
 
 
M
ed
ia
n
IQ
R
pa
_0
 m
it
os
es
_
_1
 m
it
os
is
_
_2
 m
it
os
es
_
_3
-5
 m
it
os
es
_
_≥
6 
m
it
os
es
_
pb
 
fe
m
al
e
5
(2
-1
0)
75
(5
.5
%
)
55
(8
.7
%
)
79
(1
2.
5%
)
18
8
(2
9.
7%
)
27
5
(4
3.
5%
)
 
Bo
dy
 S
it
e
 
 
 
 
 
 
 
 
 
 
 
 
H
ea
d 
an
d 
N
ec
k
m
al
e
3
(1
-7
)
<0
.0
01
20
9
(2
0.
1%
)
14
8
(1
4.
2%
)
12
7
(1
2.
2%
)
24
2
(2
3.
3%
)
31
4
(3
0.
2%
)
<0
.0
01
 
fe
m
al
e
2
(0
-5
)
14
2
(2
8.
0%
)
75
(1
4.
8%
)
75
(1
4.
8%
)
10
7
(2
1.
1%
)
10
8
(2
1.
3%
)
 
Tr
un
k
m
al
e
1
(0
-4
)
0.
01
74
8
(3
4.
1%
)
39
7
(1
8.
1%
)
25
9
(1
1.
8%
)
40
4
(1
8.
4%
)
38
4
(1
7.
5%
)
<0
.0
01
 
fe
m
al
e
1
(0
-3
)
30
6
(3
4.
4%
)
21
5
(2
4.
2%
)
10
7
(1
2.
0%
)
15
5
(1
7.
4%
)
10
6
(1
1.
9%
)
 
A
rm
m
al
e
2
(0
-5
)
<0
.0
01
29
9
(2
6.
8%
)
18
0
(1
6.
1%
)
14
9
(1
3.
4%
)
24
5
(2
2.
0%
)
24
3
(2
1.
8%
)
<0
.0
01
 
fe
m
al
e
2
(0
-4
)
33
5
(2
9.
4%
)
23
6
(2
0.
7%
)
16
8
(1
4.
7%
)
23
3
(2
0.
4%
)
16
8
(1
4.
7%
)
 
Le
g
m
al
e
2
(1
-5
)
<0
.0
01
18
4
(2
2.
1%
)
16
3
(1
9.
6%
)
13
0
(1
5.
6%
)
47
8
(2
1.
2%
)
17
0
(2
0.
4%
)
<0
.0
01
 
fe
m
al
e
2
(0
-4
)
50
0
(3
1.
4%
)
30
4
(1
9.
1%
)
25
0
(1
5.
7%
)
18
6
(2
2.
3%
)
23
2
(1
4.
6%
)
 
H
is
to
lo
gy
 
 
 
 
 
 
 
 
 
 
 
 
SS
M
m
al
e
1
(0
-2
)
0.
37
81
9
(4
1.
2%
45
5
(2
2.
9%
)
24
8
(1
2.
5%
)
28
7
(1
4.
4%
)
17
8
(9
.0
%
)
0.
12
 
fe
m
al
e
1
(0
-2
)
75
6
(4
1.
5%
)
42
8
(2
3.
5%
)
26
4
(1
4.
5%
)
24
0
(1
3.
2%
)
13
3
(7
.3
%
)
 
N
M
m
al
e
5
(3
-1
0)
<0
.0
01
34
(2
.6
%
)
11
4
(8
.8
%
)
16
2
(1
2.
5%
)
37
0
(2
8.
5%
)
62
0
(4
7.
7%
)
<0
.0
01
 
fe
m
al
e
4
(2
-8
)
41
(5
.0
%
)
89
(1
0.
9%
)
10
7
(1
3.
1%
)
25
8
(3
1.
6%
)
32
1
(3
9.
3%
)
 
O
th
er
m
al
e
2
(0
-5
)
0.
02
14
1
(2
5.
4%
)
10
3
(1
8.
6%
)
70
(1
2.
6%
)
11
9
(2
1.
4%
)
12
2
(2
2.
0%
)
0.
05
 
fe
m
al
e
2
(0
-4
)
10
1
(2
8.
1%
)
75
(2
0.
9%
)
54
(1
5.
0%
)
79
(2
2.
0%
)
50
(1
3.
9%
)
 
U
nk
no
w
n
m
al
e
2
(0
-4
)
<0
.0
1
44
6
(3
3.
3%
)
21
6
(1
6.
1%
)
18
5
(1
3.
8%
)
30
1
(2
2.
5%
)
19
1
(1
4.
3%
)
<0
.0
01
 
fe
m
al
e
1
(0
-3
)
38
5
(3
4.
0%
)
23
8
(2
1.
0%
)
17
5
(1
5.
5%
)
22
3
(1
9.
7%
)
11
0
(9
.7
%
)
 
Cl
ar
k 
Le
ve
l
 
 
 
 
 
 
 
 
 
 
 
 
II
m
al
e
0
(0
-0
)
0.
15
64
6
(7
7.
7%
)
12
3
(1
4.
8%
)
29
(3
.5
%
)
27
(3
.2
%
)
6
(0
.7
%
)
0.
08
 
fe
m
al
e
0
(0
-1
)
57
9
(7
4.
2%
)
14
4
(1
8.
5%
)
37
(4
.7
%
)
15
(1
.9
%
)
5
(0
.6
%
)
 
85
2.4
Gender Differences and Mitotic Rate
Ta
bl
e 
2.
  (
Co
nt
in
ue
d)
 
Se
x
M
it
ot
ic
 R
at
e 
Co
nt
in
uo
us
M
it
ot
ic
 ra
te
 0
 a
nd
 4
 q
ua
rt
ile
s
nu
m
be
rs
 (p
er
ce
nt
ag
e 
of
 se
x)
 
 
 
M
ed
ia
n
IQ
R
pa
_0
 m
it
os
es
_
_1
 m
it
os
is
_
_2
 m
it
os
es
_
_3
-5
 m
it
os
es
_
_≥
6 
m
it
os
es
_
pb
III
m
al
e
1
(0
-4
)
<0
.0
1
53
1
(2
9.
2%
)
39
1
(2
1.
5%
)
25
6
(1
4.
1%
)
34
7
((1
9.
1%
)
29
1
(1
6.
0%
)
<0
.0
01
 
fe
m
al
e
1
(0
-3
)
47
3
(3
0.
4%
)
37
7
(2
4.
2%
)
26
1
(1
6.
8%
)
27
9
(1
7.
9%
)
16
8
(1
0.
8%
)
 
IV
m
al
e
3
(1
-6
)
<0
.0
01
22
4
(1
0.
5%
)
34
0
(1
5.
9%
)
33
9
(1
5.
8%
)
60
1
(2
8.
1%
)
63
7
(2
9.
8%
)
<0
.0
01
 
fe
m
al
e
3
(1
-5
)
19
7
(1
2.
8%
)
27
9
(1
8.
1%
)
27
9
(1
8.
1%
)
44
4
(2
8.
8%
)
34
4
(2
2.
3%
)
 
V
m
al
e
6
(3
-1
1)
0.
40
20
(6
.5
%
)
19
(6
.2
%
)
27
(8
.8
%
)
83
(2
7.
0%
)
15
8
(5
1.
5%
)
0.
59
 
fe
m
al
e
5
(2
.7
5-
10
)
13
(7
.8
%
)
16
(9
.6
%
)
12
(7
.2
%
)
47
(2
8.
3%
)
78
(4
7.
0%
)
 
U
nk
no
w
n
m
al
e
2
(1
-5
)
0.
80
19
(2
2.
1%
)
15
(1
7.
4%
)
14
(1
6.
3%
)
19
(2
2.
1%
)
19
(2
2.
1%
)
0.
95
 
fe
m
al
e
2
(0
-5
)
21
(2
6.
3%
)
14
(1
7.
%
)
11
(1
3.
8%
)
15
(1
8.
8%
)
19
(2
3.
8%
)
 
Ye
ar
 o
f d
ia
gn
os
is
 
 
 
 
 
 
 
 
 
 
 
19
83
-1
99
1
m
al
e
2
(1
-5
)
<0
.0
01
24
5
(2
2.
5%
)
24
2
(2
2.
2%
)
14
2
(1
3.
0%
)
25
5
(2
3.
4%
)
20
6
(1
8.
9%
)
<0
.0
01
 
fe
m
al
e
1
(0
-4
)
27
5
(2
6.
7%
)
25
3
(2
4.
^%
)
16
8
(1
6.
3%
)
20
9
(2
0.
3%
)
12
4
(1
2.
1%
)
 
19
92
-1
99
8
m
al
e
2
(0
-5
)
<0
.0
1
38
5
(2
8.
2%
)
21
6
(1
5.
8%
)
17
4
(1
2.
8%
)
28
7
(2
1.
0%
)
30
2
(2
2.
1%
)
0.
02
 
fe
m
al
e
2
(0
-4
)
34
1
(3
2.
0%
)
17
8
(1
6.
7%
)
14
8
(1
3.
9%
)
21
6
(2
0.
3%
)
18
3
(1
7.
2%
)
 
19
99
-2
00
2
m
al
e
2
(0
-4
)
0.
08
42
8
(3
2.
9%
)
20
2
(1
5.
5%
)
17
4
(1
3.
4%
)
23
4
(1
8.
0%
)
26
2
(2
0.
2%
)
0.
01
 
fe
m
al
e
1
(0
-4
)
29
7
(3
2.
7%
)
17
9
(1
9.
7%
)
12
9
(1
4.
2%
)
16
5
(1
8.
0%
)
13
7
(1
5.
1%
)
 
20
03
-2
00
8
m
al
e
2
(0
-5
)
<0
.0
01
38
2
(2
6.
8%
)
22
8
(1
6.
0%
)
17
5
(1
2.
3%
)
30
1
(2
1.
1%
)
34
1
(2
3.
9%
)
<0
.0
01
 
fe
m
al
e
1
(0
-4
)
37
0
(3
2.
9%
)
22
0
(1
9.
6%
)
15
5
(1
3.
8%
)
21
0
(1
8.
7%
)
17
0
(1
5.
1%
)
 
N
M
: N
od
ul
ar
 M
el
an
om
a,
 S
SM
: S
up
er
fic
ia
l S
pr
ea
di
ng
 M
el
an
om
a.
a  M
an
n-
W
hi
tn
ey
 U
 te
st
b  C
hi
-s
qu
ar
e 
te
st
. 
86
Chapter 2.4
Although statistically significant, the actual differences in MR were small with equal me-
dian values across sex in the majority of subgroups (table 2). When stratifying for tumor 
thickness however, MR differed across sex only for the T3 subgroup (2.01-4mm Breslow 
thickness). In the Clark level subgroups, only Clark level III and IV showed a significant sex 
difference in MR. When assessed as a categorical variable, MR did not differ across sex for 
any subgroup of Breslow thickness, nor for SSM and Clark levels II, V and unknown (table 
2). In all other subgroups, the sex distribution differed significantly, with a consistently 
higher proportion of males in the highest MR category (≥6 mitoses, table 2).
When adjusting for all covariates in the negative binomial regression model, sex was 
not predictive of MR (HR 0.98, 95% CI 0.93-1.02, p=0.32). With the exception of year of 
diagnosis, all other covariates - Breslow thickness, ulceration, site of primary, histological 
subtype, Clark level and age - were significantly and independently predictive of MR 
(Table 3). 
Median follow-up of the survival data (n=8,186, survival data was missing in n=1122 
patients) was 4.7 years and did not differ across sex (table 1). The female survival advan-
tage was independent of MR as shown in the Kaplan-Meier curves: whether tumors had 
a high or low MR, females had superior survival to males (figure 1). In the category of a 
MR of 0, this was insignificant due to small numbers of events, although the HR (0.62) 
was comparable to other categories (figure 1). 
When constructing the forward step multivariate model, Breslow thickness and body 
site of the primary were the only two variables which changed the sex HR considerably: 
Breslow thickness changed the sex HR from 0.50 to 0.59, body site of primary shifted the 
multivariately adjusted sex HR from 0.60 to 0.65. All other covariates –including mitotic 
rate– caused virtually no shift in the sex HR (0.01 or less, table 4). In the final complete 
multivariately adjusted Cox PH model, sex, age, Clark level, ulceration, site of primary, 
thickness and MR were significant predictors of melanoma-specific survival. Histological 
subtype and year of diagnosis were not significantly associated with survival (table 5). 
Stratifying the study population in three groups for menopausal age showed that sex 
was a significant prognostic factor in all age groups. Although there was an apparent 
trend for a slightly lower female advantage in older age groups, this was non-significant 
(p for interaction 0.11, table 6). 
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Table 3. Multivariate prediction model of Mitotic Rate
Negative Binomial Regression Model
Variable category IRR (95% CI) p 
Sex male ref
female 0.98 (0.93-1.02) 0.32
Age (Continuous) 1.00 (1.00-1.00) 0.02
Clark Level II ref
III 3.00 (2.72-3.31) <0.001
IV 3.06 (2.76-3.39) <0.001
V 3.25 (2.83-3.73) <0.001
unknown 3.08 (2.58-3.68) <0.001
Ulceration Absent ref  
  present 1.53 (1.45-1.62) <0.001
Site of Primary Head and Neck ref
Trunk 0.82 (0.77-0.87) <0.001
Arm 0.91 (0.85-0.98) <0.01
Leg 0.90 (0.84-0.96) <0.01
Histological subtype SSM ref  
  NM 1.47 (1.38-1.56) <0.001
  Other 0.83 (0.76-0.90) <0.001
  Unknown 1.04 (0.98-1.11) 0.18
Thickness 0-1 mm ref
1.01-2mm 2.47 (2.32-2.63) <0.001
2.01-4 mm 3.83 (3.55-4.13) <0.001
>4 mm 4.67 (4.23-5.15) <0.001
Year of diagnosis 1983-1991 ref  
  1992-1998 0.99 (0.93-1.05) 0.66
  1999-2002 0.95 (0.89-1.02) 0.14
  2003-2008 1.01 (0.95-1.08) 0.65
CI: Confidence Interval, IRR: Incidence Rate Ratio, NM: Nodular Melanoma, ref: reference category, SSM: Superficial 
Spreading Melanoma
Table 4. Forward Step Multivariate Adjustment of the Sex in a Cox PH model of DSS
Model Adjustment Sex HR (95% CI)
Model A Crude 0.50 (0.43-0.58)
Model B Model A + Breslow thickness 0.59 (0.51-0.68)
model C Model B + Age 0.60 (0.51-0.69)
Model D Model C + Ulceration 0.60 (0.52-0.70)
Model E Model D + Site of Primary 0.65 (0.56-0.76)
Model F Model E + Histological Subtype 0.65 (0.56-0.76)
Model G Model F + Mitotic Rate (continuous) 0.65 (0.56-0.76)
Model H Model G + Clark level 0.65 (0.56-0.76)
Model I Model H + Year of diagnosisa 0.65 (0.56-0. 76)
Variables were added in the order of their effect on the sex HR in the bivariate analyses (Table 4)
a See table 5 for the complete multivariate Cox Proportional Hazard model.
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Table 5. Multivariate Cox proportional Hazard Model for Disease Specific survival
Variable category HR (95% CI) p 
Sex male ref
female 0.65 (0.56-0.76) <0.001
Age (Continuous) 1.01 (1.00-1.01) 0.001
Clark Level II Ref
III 3.20 (1.86-5.51) <0.001
IV 3.59 (2.07-6.24) <0.001
V 4.30 (2.37-7.79) <0.001
unknown 2.54 (1.25-5.14) 0.010
Ulceration Absent ref  
  present 1.52 (1.31-1.78) <0.001
Site of Primary Head and Neck Ref
Trunk 1.00 (0.83-1.20) 0.97
Arm 0.60 (0.48-0.75) <0.001
Leg 0.79 (0.64-0.97) 0.001
Histological subtype SSM ref  
  NM 0.97 (0.80-1.19) 0.79
  Other 0.86 (0.66-1.12) 0.26
  Unknown 0.94 (0.77-1.15) 0.56
Thickness 0-1 mm ref
1.01-2mm 1.51 (1.18-1.94) 0.001
2.01-4 mm 2.63 (2.01-3.45) <0.001
>4 mm 3.77 (2.75-5.17) <0.001
Mitotic Rate (Continuous) 1.02 (1.01-1.03) 0.001
Year of diagnosis 1983-1991 ref  
  1992-1998 0.93 (0.79-1.09) 0.37
  1999-2002 0.97 (0.80-1.18) 0.78
  2003-2008 0.84 (0.66-1.08) 0.17
This multivariate Cox proportional hazards model corresponds to ‘model I’ in table 4.
CI: Confidence Interval, HR: Hazard Ratio, NM: Nodular Melanoma, ref: reference category,
SSM: Superficial Spreading Melanomaw
Table 6. Effect of sex on DSS across different age groups
Sex HR (95% CI) p
Premenopausal age (≤45 yrs) 0.57 (0.42-0.78) <0.001
Menopausal (46-59 yr) 0.60 (0.44-0.80) 0.001
Postmenopausal (≥60 yrs) 0.72 (0.57-0.91) 0.01
P for interaction: 0.11
CI: Confidence Interval, DSS: Disease Specific Survival, HR: Hazard Ratio.
HR’s for sex (female vs. male) adjusted for Breslow thickness, body site, ulceration, MR, Clark level, histologic subtype and 
year of diagnosis
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DISCUSSION
To our knowledge, this study is the first study investigating sex differences in melanoma 
in relation to MR. First, we demonstrated that sex is the only included variable which did 
not predict MR independently of other clinical and tumor characteristics: in the negative 
binomial regression, the IRR was close to 1 (IRR 0.98, 95% CI 0.93-1.02; table 3) indicating 
no effect. This is remarkable since males do have a higher MR at diagnosis (table 2). 
However, this seems to be explained merely by their thicker tumors at diagnosis –as il-
lustrated by the equal MR across sex within categories of thickness (table 2)– and not by 
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Figure 1. Kaplan Meier curves for the total study population and five categories of Mitotic Rate.
CI: confidence interval, HR: Hazard Ratio
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more aggressive tumors in males. Secondly, considering this lack of a sex effect on MR, 
it is not surprising that MR does not explain the female melanoma survival advantage: 
when adding MR to the Cox PH model in the multivariate setting, MR had no additional 
adjusting effect on the sex HR next to Breslow thickness and body site (table 4). This is 
also illustrated by the consistent female advantage in the Kaplan Meier curves of five 
different MR categories (figure 1). Summarizing our findings, there is a minor sex dif-
ference in MR at diagnosis; however this disappears after adjustment for other tumor 
characteristics and has no influence on the female survival advantage after diagnosis. 
As mitotic rate is a measure of proliferation of the primary tumor7, it can be considered 
a marker of tumor aggressiveness. Our results show that males do not have a more ag-
gressive primary tumor at diagnosis in terms of cellular proliferation if other important 
tumor characteristics are taken into account. This finding is supported by observations 
that the genetic makeup of melanoma does not differ across sex: multiple studies dem-
onstrated equal mutation rates of important melanoma genes for males and females: 
e.g. BRAF12-16, NRAS15,16 and KIT17. Apparently, the primary tumor does not truly differ 
across sex, both in genetics and in mitotic activity.
According to these observations, we conclude that the sex difference in melanoma 
survival is not explained by a more aggressive tumor at diagnosis. Thus, it is more likely 
that host-related differences are causing the female survival advantage: possibly some 
sex-specific trait is protecting females against progression, metastases and therefore 
death from their melanoma, regardless of e.g. the tumor’s thickness, MR or ulceration. 
An example of such a host-related factor influencing melanoma progression is a differ-
ence in the handling across sex of oxidative stress, as we proposed before18.
Breslow thickness and site of the primary were the only two variables which consider-
ably confounded the sex HR in the multivariate survival model (table 4). Other variables 
had virtually no impact on the sex HR, although these variables, e.g. MR and ulceration, 
do have important prognostic value and differ significantly across sex (table 1). This 
finding is similar to the one from our previous population-based study in the German 
region of Bavaria2, in which we also observed Breslow thickness and body site to be 
the only variables which consistently altered the sex HR upon adjustment in multivari-
ate models. Behavioral differences -e.g. males delaying health care visits or differences 
in sun exposure habits- have long been thought to explain the female advantage in 
melanoma survival. Breslow thickness and body site are probably at least partly related 
to behavior: diagnostic delays lead to thicker tumors and different sun exposure habits 
to differences in the site of the primary melanoma. Therefore, we hypothesize that the 
adjustment of the crude DSS sex HR of 0.50 to 0.65 (table 4) by these two variables rep-
resents the effect of sex differences in behavior, leaving an unexplained ~35% relative 
female advantage due to biological host-related differences. This 35% relative female 
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advantage is similar to the 30% female advantage found in our European trial-based 
study and other published literature1. 
We would like to emphasize that although MR did not affect the gender HR, it was 
significantly associated with survival in our final multivariate model (table 5), as has 
been shown before7,8. Other well known prognostic markers in melanoma, such as age, 
Breslow thickness, ulceration, site of the primary and Clark level were also significantly 
associated with disease-specific survival, however, histological subtype and year of 
diagnosis were not (table 5).
When compared to males of the same age, females had a survival advantage in pre-, 
menopausal and postmenopausal age groups. Although this female advantage ap-
peared to decrease in the older age groups, this was not significant (p for interaction 
0.11, table 6). Some previously published studies observed the female advantage to 
disappear at older, postmenopausal ages5,6,19,20. However, the majority of studies found 
that the female advantage persisted in these older groups1,2,4,21-24, even among more 
advanced stage III and IV melanoma3,25,26. Therefore, combining our results and these 
previous studies, we conclude that the females have a survival advantage in both pre- 
and postmenopausal age.  
A major strength of this study compared to previous studies concerning sex differ-
ences in melanoma is the inclusion of MR as a confounder, which was the second most 
important prognostic factor in local melanoma in a recent large AJCC study8. Further-
more, this study has a large study population (n=9,306 for the predictive study, n=8,186 
for the survival study) and a long follow-up time (median follow-up 4.7 years).
In comparison with our previous studies1-3, a weakness of this study is the lack of 
information on progression of melanoma such as occurrence of lymph node or distant 
metastases, which could have shed more light on the aggressiveness of the disease. 
Furthermore, this study was performed in a single-institution representing a specialized 
tertiary referral centre and might therefore not be representative of the whole mela-
noma patient population. However, the magnitude of the independent female survival 
advantage (table 5) was highly comparable to population-based studies1,2. Finally, as 
this study used data from a 1983 to 2008, MR was probably defined and registered in 
different ways during the study period, as different methods have been used since 
19839,10. However, as these changes in MR definition should not differ across sex (i.e., 
non-differential misclassification bias), it is likely this bias has not heavily impacted our 
results. 
92
Chapter 2.4
CONCLUSION
We previously demonstrated the highly consistent and independent sex difference in 
melanoma prognosis in both localized1,2,4 and advanced melanoma2,3 which led to the 
conclusion that an unknown biological explanation underlies this phenomenon. In 
this study, we present further epidemiological evidence that this explanation seems 
not to be related to a more aggressive primary tumor at diagnosis as defined by MR. 
Therefore, we hypothesize that the female advantage is related to biological traits of 
the host allowing more aggressive tumor behavior in males, irrespective of the type and 
proliferation rate of the actual tumor itself. 
93
2.4
Gender Differences and Mitotic Rate
REFERENCES 
 1. Joosse A, Collette S, Suciu S, et al: Superior Outcome of Women With Stage I/II Cutaneous 
Melanoma: Pooled Analysis of Four European Organisation for Research and Treatment of Cancer 
Phase III Trials. J Clin Oncol 30:2240-7, 2012
 2. Joosse A, de Vries E, Eckel R, et al: Gender differences in melanoma survival: female patients have 
a decreased risk of metastasis. J Invest Dermatol 131:719-26, 2011
 3. Joosse A, Collette S, Suciu S, et al: Sex Is an Independent Prognostic Indicator for Survival and 
Relapse/Progression-Free Survival in Metastasized Stage III to IV Melanoma: A Pooled Analysis of 
Five European Organisation for Research and Treatment of Cancer Randomized Controlled Trials. 
J Clin Oncol, 2013
 4. de Vries E, Nijsten TE, Visser O, et al: Superior survival of females among 10,538 Dutch melanoma 
patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 19:583-9, 
2008
 5. Mervic L, Leiter U, Meier F, et al: Sex differences in survival of cutaneous melanoma are age 
dependent: an analysis of 7338 patients. Melanoma Res 21:244-52, 2011
 6. Lasithiotakis K, Leiter U, Meier F, et al: Age and gender are significant independent predictors of 
survival in primary cutaneous melanoma. Cancer 112:1795-804, 2008
 7. Balch CM, Gershenwald JE, Soong SJ, et al: Update on the melanoma staging system: the impor-
tance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol 104:379-85, 2011
 8. Thompson JF, Soong SJ, Balch CM, et al: Prognostic significance of mitotic rate in localized primary 
cutaneous melanoma: an analysis of patients in the multi-institutional american joint committee 
on cancer melanoma staging database. J Clin Oncol 29:2199-205, 2011
 9. McGovern VJ, Cochran AJ, Van der Esch EP, et al: The classification of malignant melanoma, its 
histological reporting and registration: a revision of the 1972 Sydney classification. Pathology 
18:12-21, 1986
 10. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and 
classification. J Clin Oncol 27:6199-206, 2009
 11. Vuong QH: Likelihood Ratio Tests for Model Selection and Non-Nested Hypotheses. Econometrica 
57:307-333, 1989
 12. Long GV, Menzies AM, Nagrial AM, et al: Prognostic and Clinicopathologic Associations of Onco-
genic BRAF in Metastatic Melanoma. J Clin Oncol, 2011
 13. Bauer J, Buttner P, Murali R, et al: BRAF mutations in cutaneous melanoma are independently 
associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the 
primary tumor site. Pigment Cell Melanoma Res 24:345-51, 2011
 14. Qi RQ, He L, Zheng S, et al: BRAF exon 15 T1799A mutation is common in melanocytic nevi, but 
less prevalent in cutaneous malignant melanoma, in Chinese Han. J Invest Dermatol 131:1129-38, 
2011
 15. Devitt B, Liu W, Salemi R, et al: Clinical outcome and pathological features associated with NRAS 
mutation in cutaneous melanoma. Pigment Cell Melanoma Res, 2011
 16. Si L, Kong Y, Xu X, et al: Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large 
scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer, 2011
 17. Kong Y, Si L, Zhu Y, et al: Large-scale analysis of KIT aberrations in Chinese patients with mela-
noma. Clin Cancer Res 17:1684-91, 2011
 18. Joosse A, De Vries E, van Eijck CH, et al: Reactive oxygen species and melanoma: an explanation 
for gender differences in survival? Pigment Cell Melanoma Res 23:352-64, 2010
94
Chapter 2.4
 19. Kemeny MM, Busch E, Stewart AK, et al: Superior survival of young women with malignant mela-
noma. Am J Surg 175:437-44; discussion 444-5, 1998
 20. Shaw HM, McGovern VJ, Milton GW, et al: Malignant melanoma: influence of site of lesion and age 
of patient in the female superiority in survival. Cancer 46:2731-5, 1980
 21. Stidham KR, Johnson JL, Seigler HF: Survival superiority of females with melanoma. A multivariate 
analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg 
129:316-24, 1994
 22. Masback A, Olsson H, Westerdahl J, et al: Prognostic factors in invasive cutaneous malignant 
melanoma: a population-based study and review. Melanoma Res 11:435-45, 2001
 23. Micheli A, Ciampichini R, Oberaigner W, et al: The advantage of women in cancer survival: an 
analysis of EUROCARE-4 data. Eur J Cancer 45:1017-27, 2009
 24. Chirlaque MD, Salmeron D, Ardanaz E, et al: Cancer survival in Spain: estimate for nine major 
cancers. Ann Oncol 21 Suppl 3:iii21-29, 2010
 25. Rutkowski P, Nowecki ZI, Zdzienicki M, et al: Cutaneous melanoma with nodal metastases in 
elderly people. Int J Dermatol 49:907-13, 2010
 26. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metas-
tases. J Am Coll Surg 181:193-201, 1995
Chapter 3
Possible Explanations: 
Literature studies

Chapter 3.1
Reactive oxygen species and melanoma: an 
explanation for gender differences in survival?
Arjen Joosse, Esther De Vries, Casper H. van Eijck, Alexander M. M. 
Eggermont, Tamar Nijsten and Jan Willem W. Coebergh
Pigment Cell and Melanoma Research 2010 June; 23(3): 352-64
98
Chapter 3.1
ABSTRACT
Epidemiological research consistently shows a female advantage in melanoma 
survival. So far, no definite candidate for the explanation of this phenomenon has 
emerged. We propose that gender differences in oxidative stress caused by radical 
oxygen species (ROS) underlie these survival differences. It is known that males 
express lower amounts of anti-oxidant enzymes, resulting in more oxidative stress 
than females. The primary melanoma environment is characterized by high ROS 
levels, from exogenous sources as well as ROS production within melanoma cells 
themselves. ROS are known to be able to promote metastasis through a wide vari-
ety of mechanisms. We hypothesize that the higher levels of ROS in men enhance 
selection of ROS-resistance in melanoma cells. Subsequently, ROS can stimulate the 
metastatic potential of melanoma cells. In addition, due to the lower anti-oxidant 
defenses in men, ROS produced by melanoma cells cause more damage to healthy 
tissues surrounding the tumor, further stimulating metastasis. Therefore, ROS may 
explain the observed differences between males and females in melanoma survival.
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INTRODUCTION
Female gender has been observed to be an independent positive prognostic factor in 
melanoma survival. So far, there are no definite hypotheses to explain this phenomenon. 
Based on a literature review, we propose gender differences in oxidative stress caused 
by reactive oxygen species (ROS) as a possible biological mechanism underlying the 
melanoma survival advantage in females. Four well-established observations in current 
literature will be linked as the basis for our hypothesis (Figure 1). First, we will discuss 
these four observations: (i) known gender differences in melanoma survival; (ii) ROS in 
the melanoma environment; (iii) the influence of ROS on melanoma invasion and me-
tastasis; and (iv) known gender differences in the oxidative balance. Subsequently, the 
hypothesis will be summarized and finally potential links with other issues in melanoma 
research will be discussed. 
Hypothesis:
Oxidative stress differences 
causes gender differences in 
melanoma Survival
(Subheading 6)
MM environment: high 
levels of intra- and 
extracellular oxidative 
stress
(Subheading 2)
Known gender 
differences in melanoma 
survival
(Subheading 1)
Known gender 
differences in anti-
oxidant expression and 
oxidative stress
(Subheading 5)
Oxidative stress 
stimulates invasion and 
metastasis
(Subheading 4)
Figure 1. Basic Elements of the Hypothesis
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(1) THE FEMALE ADVANTAGE IN MELANOMA SURVIVAL
Both the incidence and survival of malignant melanoma (MM) differ substantially across 
gender. Since incidence is determined markedly by risk behavior which differs across 
gender, we will focus here on survival differences only. Clark et al. already stated in 1969 
that as has been noted by several workers, the disease is somewhat less malignant in the 
female when compared with the male1. Since then, many studies have shown gender to 
be an independent prognostic factor of melanoma survival, since it remains significant 
after adjusting for virtually all known prognostic indicators including age, Breslow thick-
ness, Clark level of invasion, body site, histological subtype and even newly emerged 
prognostic factors, such as ulceration, sentinel node status, and mitotic rate2-9.
Male primary melanomas seem to grow faster than those in females10, men present 
more often with nodal and visceral metastases3, and male patients progress more rapidly 
to stage III11 and maybe even to stage IV melanoma6, e.g. are more likely to develop brain 
metastases12. This is confirmed by our recent  observation of a higher risk of metastasis 
in males13. After injection of metastatic melanoma cells, male mice developed more 
liver metastases14. All these observations suggest that melanoma spreads more easily 
throughout the body in males than in females.
Estrogens have been studied extensively as the cause of this phenomenon. However, 
neither pregnancy, nor oral contraceptives and hormone replacement seem to influence 
melanoma survival15. Some researchers observed that the female advantage disappears 
after menopause4,6. However, others found that the longer survival of females persists 
after menopause3,16,17. Finally, others reported that the survival difference between 
the sexes decreased from a premenopausal hazard ratio (HR) of 0.42 [95% confidence 
interval (CI): 0.39–0.45] to a post-menopausal HR of 0.56 [95% CI 0.53–0.60]18. This might 
explain the conflicting results in literature: if the female advantage indeed decreases 
after menopause, some researchers might find non-significant differences after meno-
pause, while others observe that the advantage persists. Overall, estrogens do not seem 
to fully explain the female survival advantage in melanoma.
(2) OXIDATIVE STRESS IN MELANOMA CARCINOGENESIS
Oxidative stress caused by high levels of ROS, such as superoxide anion and hydrogen 
peroxide, is suggested increasingly to be involved in melanoma carcinogenesis19-22. 
ROS are highly reactive and capable of damaging a wide range of molecules through 
radical-type reactions23. Melanoma cells generate large amounts of ROS compared with 
surrounding tissues or melanocytes24 and excrete ROS into the extracellular space25,26. 
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Furthermore, intracellular levels of ROS are elevated in MM cells27. This upgraded ROS 
production has also been observed in dysplastic nevi28. 
Other solid tumors also generate ROS29-31. However, several observations suggest that 
MM cells have unique ROS properties compared with other solid cancers.
•	 MM	cells	exhibit	significantly	higher	oxidative	stress	and	produce	larger	amounts	of	
ROS compared with squamous cell carcinoma (SCC) and basal cell carcinoma (BCC)24, 
as well as colon, pancreatic, and breast cancer cells26.
•	 Compared	with	other	cell	 types,	 the	precursor	of	 the	melanoma	cell,	 the	melano-
cyte, has unique oxidative properties. During physiological melanin synthesis, ROS 
emerge as byproducts and are efficiently scavenged within the melanosomes by 
melanin, which acts as an anti-oxidant32. However, in MM cells, melanosomes ac-
tively produce excessive amounts of ROS33. Somehow, the function of melanosomes 
changes from ROS scavengers in melanocytes to ROS producers in melanomas. This 
could be caused by heavy oxidization of melanin, changing melanin from an antioxi-
dant to a pro-oxidant20. Since melanosomes are unique to melanocytes, this seems 
to be of importance in melanoma development. Indeed, research suggests a link 
between melanosomes within melanomas and oxidative stress: First, melanosomes 
in MM cells exhibit structural aberrations21. Secondly, increased melanogenesis is 
associated with increased oxidative stress in dysplastic nevus (DN) cells34. Thirdly, 
DN and MM cells produce – compared with normal melanocytes – relatively less 
‘regular’ eumelanin and more pheomelanin, which is associated with more oxidative 
stress22,28,35.
In view of these unique melanoma properties, elevated production of ROS seems to 
be a melanoma-specific defect21. Finally, other factors may contribute to even higher 
ROS levels around the primary tumor: the skin is a hypoxic tissue, leading to ROS produc-
tion22,36 and exogenous attacks (e.g. UV-radiation) further increase oxidative stress37. In 
addition, tumor-associated immune cells also excrete ROS22,38. In summary, the primary 
melanoma tumor environment is characterized by high levels of ROS.
The primary melanoma: Selection for ROS-resistance
Reactive oxygen species can have both stimulating and lethal effects on a cell. High 
levels of ROS may lead to apoptosis, intermediate levels to cycle halting and early cell 
senescence34 and low levels to apoptosis-resistance and cell proliferation30,39. These 
bivalent effects at different ROS levels have indeed been observed in prostate cancer 
cells40 and require human cells to sustain a delicate ‘ROS-balance’41. This balance is prob-
ably altered in MM cells: high ROS levels stimulate proliferation of the cancer cell, but 
simultaneously force the cancer cells to develop pathways to prevent apoptosis. Indeed 
multiple MM cell lines in vitro exhibit high resistance to ROS-induced apoptosis42,43. MM 
cells may achieve this ‘ROS-resistance’ through various pathways:
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•	 By	 increasing	 the	 expression	 of	 anti-oxidant	 enzymes,	 as	 some	 MM	 cells	 do22,24, 
especially the anti-oxidant Glutathione (GSH) seems to be associated with ROS re-
sistance22,44,45. However, decreased expression of anti-oxidant enzymes has also been 
observed in melanoma cells46,47, suggesting differences in anti-oxidant regulation 
between MM cells. 
•	 Another	way	to	achieve	ROS	resistance	could	be	to	block	ROS-induced	apoptosis,	e.g.	
through activating the mitogen-activated protein kinase (MAPK) pathway inducing 
cell proliferation and apoptosis suppression48,49. First of all, ROS may directly activate 
this pathway leading to aberrant activation of NF-κB, blocking apoptosis48,50. Sec-
ondly, ROS are mutagenic molecules51,52 and may therefore cause genetic alterations 
of genes important in apoptosis. An example of a gene observed to be frequently 
mutated in melanoma is BRAF53, which activates the MAPK pathway and thus sup-
presses apoptosis22. p53, another important regulator of apoptosis, is not frequently 
mutated, but is commonly inactivated in melanoma54. Interestingly, low levels of 
ROS activate p53 and thus apoptosis, but high ROS levels cause inactivation of p53, 
inhibiting apoptosis30. Other apoptosis regulators known to be potentially mutated 
or functionally altered by ROS include RAS, MEK, and ERK within the MAPK pathway, 
and PTEN, Rb and AKT21,22,55. 
•	 Another	pathway	involves	microphtalmia-associated	transcription	factor	(MiTF)	and	
apurinic⁄apyrimidinic endonuclease (APE-1). APE-1 is a key protein for redox sensing 
and DNA damage repair, and is therefore important for cell survival. It was shown 
that under oxidative stress, MiTF upgrades APE-1 levels, preventing apoptosis. MM 
cells positive for MiTF indeed exhibited elevated ROS-resistance56.
Since none of the therapies aimed at specific targets within these pathways have 
yielded positive results so far, MM cells are hypothesized to have a redundancy of 
apoptosis-suppression pathways21.
Reactive oxygen species derived from immune cells have been proposed to exert a 
‘selective pressure’ on MM cells to develop ROS-resistance22. Following this hypothesis, 
the entire ‘ROS-infested environment’ in and around the primary tumor may exert a 
selective pressure on MM cells, causing ‘natural selection’ of those with the highest ROS 
resistance, whereas unfit cells die of ROS-induced apoptosis. A similar mechanism, i.e. 
ROS-induced selection of tumor cells with p53 mutation, has also been proposed in 
breast cancer36.
Interestingly, chemotherapy, radiotherapy, and immunotherapy, although via differ-
ent pathways, ultimately aim to induce ROS-mediated apoptosis. Therefore, selection 
within the primary tumor for ROS-resistance may partly explain the therapy resistance 
of melanoma21,22.
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(3) ROS STIMULATES MELANOMA METASTASIS
Both endothelial and immune cells excrete ROS to attack and kill most metastatic MM 
cells22,38. Therefore, some level of ROS resistance is an essential requirement for a cell to 
merely survive the metastatic process57. Indeed, high GSH levels associated with ROS 
resistance increased MM metastasis in a mouse model58. After acquiring ROS resistance 
to block apoptosis, MM cells can also use high ROS levels to further stimulate their 
metastatic potential41 through an impressive variety of pathways:
•	 Inducing DNA changes. Melanoma metastasis is associated with a large number of 
genes59. ROS cause DNA mutations51,52, which can increase MM potential if the ‘right’ 
genes are hit. Indeed, ROS induce DNA damage in dysplastic nevi34 and may cause 
mitochondrial DNA damage in MM, which is associated with metastatic disease 
progression60. Furthermore, ROS can induce epigenetic changes, i.e. DNA-methyla-
tion61, leading to differences in gene expression. In vitro, DNA-methylation increased 
the migratory and invasive ability of MM cells62, e.g. by inducing anoikisa  resistance61, 
a cell property that increases metastatic potential in MM63.
•	 Activating cell proliferation. In addition to apoptosis resistance, the activation of 
redox-sensitive transcription factors (e.g. NF-ΚB, AP-1, c-myc) also leads to enhanced 
cell cycle progression and sustained proliferation48, for example, through activating 
the MAPK or the Hypoxic inducible factor 1α (HIF1 α) pathways64. Indeed, high ROS 
levels stimulated cell cycle progression and melanoma tumor growth65. In mouse 
fibroblasts, ROS stimulated proliferation and increased tumorigenicity66. In summary, 
ROS are able to boost and sustain the growth of a tumor.
•	 Destruction of surrounding tissue. MM cells secrete ROS into the extracellular space 
which may directly stimulate metastasis through destruction of surrounding tis-
sues24,25. For example, in vitro MM cells produce ROS which damage endothelial cells. 
This may mediate extravasation of metastatic MM cells, which subsequently form 
metastatic colonies67,68.
•	 Escaping immune surveillance. ROS produced by MM cells may also block detection 
by the immune system by inducing apoptosis in nearby dendritic cells, inhibiting 
tumor antigen presentation69. Such an ‘immune-escape’ would protect metastasiz-
ing cells, since they do not encounter tumor-specific T-lymphocytes when traveling 
through the body.
•	 Adhesion of circulating tumor cells (CTCs) .To metastasize, CTCs must adhere to 
vessel walls, extravasate, and enter a distant site. CTCs have been demonstrated in 
MM patients and are associated with disease progression and survival70. In colon and 
a.  Anoikis (greek word for: “homelessness”): type of apoptosis caused by the loss of cell adhesion of an epithelial 
cell to the extracellular matrix of its host tissue (“to attach or die”).
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pancreatic cancer, ROS have been shown to induce various adhesion molecules on 
endothelial, peritoneal, and tumor cells, significantly increasing tumor cell adhe-
sion71,72. In melanoma, ROS also induce these adhesion molecules (Table 1), which 
may promote metastasis by guiding tumor cells to metastatic target tissues.
•	 Activating pro-metastatic cellular processes. In addition, ROS are able to upregu-
late a variety of key molecules important in stimulating proliferation and metastasis 
(Table 1).
In summary, ROS act as pro-metastatic agents through a wide range of pathways, il-
lustrated in Figure 2. In addition to endogenously produced ROS, MM cells may also use 
exogenous sources of ROS encountered during metastasis to stimulate their metastatic 
growth, e.g. ROS induced by ischemia when CTC’s cause embolization of a capillary38 or 
ROS generated by the respiratory burst following surgical removal of the primary tumor. 
Surgical removal indeed stimulated metastatic tumor growth in mice73. 
It is interesting to compare ROS and metastatic ability in melanoma with other skin 
cancer types. In terms of oxidative stress, melanoma ranks highest, followed by SCC and 
BCC, respectively24. Interestingly, the metastatic ability of these skin-cancers follow the 
same order: melanoma metastasizes regularly, SCC rarely, and BCC virtually never.
Anti-oxidants and melanoma metastasis
It has been suggested that ROS stimulate metastasis, and increased activity of the anti-
oxidant superoxide dismutase (SOD) was associated with lower MM cell line metastatic 
ability46. This triggered further research into the effect of administering antioxidants in 
MM mouse models. The majority of evidence indeed indicates a metastasis-inhibiting 
effect of antioxidants (Table 2), although a small number of studies found that anti-
oxidants actually stimulate MM metastasis (shaded fields in Table 2). This illustrates the 
complex ‘ROS-balance’ in MM cells. Effects of anti-oxidants may be according to the 
type of anti-oxidant: again, GSH in particular seems to increase metastasis, but catalase, 
SOD and N-acetylcysteine seem to be able to prevent metastasis. Importantly, SOD and 
catalase differ in biological function41. Timing of administration (early or late in carcino-
genesis) and type of administration, such as targeted delivery41, may also influence the 
anti-metastatic effect.
In summary, the high levels of ROS in MM possibly promote melanoma metastasis 
through many different pathways. Evidence suggests that anti-oxidants may suppress 
metastasis.
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(4) NATURE’S RANDOMIZED TRIAL: THE ROLE OF GENDER
Inevitably, the following question comes to mind: Can anti-oxidants suppress MM metas-
Table 1: examples of ROS-mediated pro-metastatic pathways in malignant melanoma
Target ROS action 
on target 
molecule
Effect of target on 
metastasis
Main 
Reference(s)
Supportive evidence 
(Same reference as under “Main Ref.” 
unless otherwise indicated)
(MT-) 
MMPs 
Activation 
(through AP-1 
activation) 
Associated with 
metastasis, possibly 
through proteolytic 
degradation of ECM, thus 
promoting tissue invasion.
77 Peritoneal MM cells in mice produced 
large amounts of MMPs78
MMP inhibition by antioxidant reduced 
MM invasive ability
uPAR Upregulation 
through AP-1
Activates plasminogen, 
which is associated with 
cancer invasion and 
metastasis
79 Expression associated with advanced 
primary / metastatic melanoma lesions80
CXCR4 Upregulation 
of expression81
Essential during early 
migration (homing MM 
cells to target organs)
82 Combination of CXCR4 and MT1-MMP1 
overexpression induced growth, 
invasion, lung metastasis and mortality 
in mice. 
IL-8 Increasing 
synthesis83
Stimulates angiogenesis, 
tumor growth, cell 
migration and metastasis 
84 Serum IL-8 serum levels correlates with 
advanced disease and poor survival, 
MM cell IL-8 expression correlates with 
spontaneous metastasis 
EGFR  upregulation Important in invasion, 
proliferation and 
metastasis of MM
73 ROS-induced EGFR upregulation 
resulted in higher proliferation and 
mortality in MM mouse model 
VEGF Increasing  
levels 
(through NF-
κB activation) 
Angiogenesis, essential for 
metastasis 
85, 86 VEGF serum levels associated with MM 
progression85
Adhesion molecules
ICAM-1 Upregulation 
in target 
tissue for 
metastasis
Promoting tumor call 
adhesion at metastatic 
site and thus survival
78 ROS induced ICAM-1 expression in mice 
resulted in higher tumor cell survival 
VCAM-1 Upregulation 
on endothelial 
cells
Stimulating tumor 
adhesion at vessel wall 
and thus extravasation 
87 ROS-induced upregulated VCAM 
expression resulted in more hepatic 
metastases in mice
VLA-4 Upregulation 
on MM cells
VLA-4 binds to VCAM-
1 on endothelial cells, 
strengthening cell 
adhesion and thus 
extravasation
57
Abbreviations: CXCR4: CXC chemokine receptor 4, ECM: extracellular matrix, EGFR: epidermal growth factor receptor, ICAM-
1: intercellular adhesion molecule-1, IL-8: Interleukine-8, MM: malignant melanoma, (MT-)MMPs: (membrane-type) matrix 
metalloproteinases, ROS: Reactive Oxygen Species, uPAR: urokinase plasminogen activator receptor, VCAM-1: vascular cell 
adhesion molecule-1, VEGF: vascular endothelial growth factor 
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tasis in humans? So far, the effect of antioxidant suppletion on melanoma incidence has 
been investigated, but trials were limited by the small numbers of events, and no signifi-
cant effect74 or even a detrimental effect was found75. More importantly, in all of these 
ROS-
Balance
Upregulation 
of ROS in 
MM cell
Apoptosis
Survival 
Through ROS-
resistance
Body anti-
oxidant defenses
+
-
Female 
Gender
Activating 
transcrip-
tional factors
Destruction 
of 
surrounding 
tissues
Upregulating 
adhesion 
molecules in 
metastasis 
target tissues
Activating 
MMPs
DNA 
Changes
Upregulating  
EGFR & 
VEGF 
(angio-
genesis)
Escaping 
Immune 
surveillance
Stimulating 
cell division
Proliferation 
(growth primary 
tumor)
Increased 
mitotic 
rate
+
+
Distant
Metastasis
Death
+
Increased 
Anoikis 
resistance
+
High levels of 
ROS around 
primary MM
+
Figure 2. From oxidative stress to metastasis of melanoma: possible pathways and interaction with 
gender.
As ROS is upregulated in and around MM cells, this challenges the ‘ROS-balance’ of the cell. This cell must ‘adapt or die’, and 
thus will either commit apoptosis or survive by developing ROS resistance. Subsequently, ROS levels remain high around 
the surviving tumor cells and promote proliferation and metastasis through a wide variety of pathways (dark gray blocks) 
ultimately leading to death of the patient. The role of gender is illustrated by the positive relationship of female gender 
with body anti-oxidant defense systems, influencing ROS levels in the primary MM environment. 
EGFR, epidermal growth factor receptor; MM, malignant melanoma; MMPs, matrix metalloproteinases; ROS, reactive oxy-
gen species; VEGF, vascular endothelial growth factor.
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studies the effect of anti-oxidants depended on gender, both in melanoma incidence75 
and overall cancer incidence74,76. This strongly suggests gender to be of importance in 
the association between MM and ROS. Unfortunately, no trials investigated the effect 
of anti-oxidants on melanoma metastasis or survival. We propose, however, that nature 
itself provides us with such a trial, executed on a universal scale: males versus females.
Gender and oxidative damage
Gender affects a wide variety of mechanisms involved in the redox features of cells23. Com-
pared with females, males express lower levels of anti-oxidants, such as GSH, catalase, and 
SOD88-90 and consequently exhibit a higher rate of oxidative damage88,89,91,92. This is confirmed 
by a 29% higher level of urinary waste products of oxidative damage in healthy males after 
adjustment for smoking and body mass index93. This is hypothesized to explain the overall 
prolonged life expectancy of females, since oxidative damage may cause, for example, car-
diovascular disease and cancer51,88,94. The genetic overexpression of antioxidant enzymes in 
females is possibly induced by estrogen receptor activation95. Indeed, menopause induced 
in mice by ovariectomy increased vulnerability to oxidative damage96. However, estrogen 
levels do not fully explain these differences in anti-oxidant defense: androgens such as 
testosterone actually seem to diminish these same defense systems96. 
As a confirmation of these gender differences in antioxidant defense mechanisms 
within cells, healthy male murine vascular smooth muscle cells exposed to ROS under-
went apoptosis more easily compared with female cells90. This also applies to the skin: 
female mice exhibit an increased anti-oxidant capacity and lower levels of oxidative 
damage in the skin compared with males97. In summary, men exhibit higher levels of 
oxidative damage compared with females.
(5) A HYPOTHESIS FOR GENDER DIFFERENCES
In view of the literature above, we hypothesize that the known male disadvantage in 
survival of melanoma is caused by their reduced ability to neutralize oxidative stress. 
Our hypothesis comprises the following: the primary melanoma environment is charac-
terized by high
ROS levels (Section 2). This leads to selection of ROS resistance. Subsequently, MM 
cells that are resistant to ROS-induced apoptosis can ‘use’ ROS to stimulate metastasis 
through a great variety of pathways (Figure 2, Table 1, Section 3). Men exhibit lower levels 
of anti-oxidant defense systems compared with females (Section 4). This subsequently 
leads to: (i) higher ROS resistance in male MM cells as the selective pressure of ROS is 
stronger forcing male MM cells to develop higher levels of ROS resistance to survive; (ii) 
higher levels of ROS stimulating MM metastasis; and (iii) more tumor-inflicted damage 
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Table 2. Iatrogenic Anti-oxidant administration & Melanoma Metastasis: literature overview
Anti-oxidant 
(Administration)
Model 
(MM cell line)
Effect on MM / metastasis / survival Reference(s)
SOD 
Catalase 
(added to cell 
culture)
In vitro: tumor spheroids 
(multiple MM cells) 
interacting with a co-
cultured monolayer of 
endothelial cells
(ST-ML-11/12/14, SK-
MEL-28)
ST-ML-12: SOD protected endothelial cells from 
damage by ROS produced by MM-cells 
ST-ML-11/14, SK-MEL-28: Catalase protected 
endothelial cells 
(Hypothesized:) inhibition of extravasation in 
the metastatic process
67,68
MnSOD 
(transfection of 
DNA in MM cells)
In vitro: soft agar model
In vivo: nude mice 
model
(UACC 903)
-MM cell with transfected DNA lose ability to 
form colonies in soft agar / to form tumors at 
injection sites in nude mice 
-(Hypothesized:) reduced capacity to form 
metastatic colonies
98
N-Acetylcysteine
(Adding in chamber 
assays)
(pretreatment MM 
cells / diet)
In vitro: Boyden chamber 
assays
In vivo: pulmonary me-
tastasis mouse model 
(A2058, K1735, B16F10)
In vitro inhibiting invasiveness  of MM cells
In vivo: decrease in number of lung metastases
99
N-Acetylcysteine
(MM cells pretreat-
ment / diet supple-
tion)
In vivo: pulmonary / 
spontaneous metastasis 
mouse model
(B6F10)
-Prolonged survival of mice
-Inhibition of lungmetastases / spontaneous 
metastases
100
Catalase
(Intrasplenic injec-
tion)
Hepatic Metastasis 
Mouse model
(B16)
Significant reduction of hepatic metastasis 
(number and volume)
57
rHuSOD
(Intrasplenic injec-
tion)
Significant increase of hepatic metastasis
N-Acetylcysteine
(adding to diet)
Spontaneous metastasis 
mouse model 
-Prolonged survival 
-Decreased weight of primary tumor
-Inhibition of lung metastasis
101
Asc2P6Plm
(i.v. injection / MM 
cell pretreatment)
Pulmonary metastasis 
mouse model
-Inhibiting invasion
-Dose dependent anti-metastatic effect
102,103
Asc2P
(repeated addition 
to model / pretreat-
ment of MM cells, 
i.v. injection)
In vitro Matrigel inva-
siveness
In vitro cell migration 
assays
In vivo pulmonary meta-
static mouse model
(B16-BL6)
In vitro Dose-dependent reduction of invasion, 
cell motility and migration. 
In vivo: Significant reduction of number of meta-
static nodules in lung
104
Catalase
(i.v. injected)
Hepatic metastasis 
mouse model
(B16M)
Reduced MM cell adhesion to HSE cells
(Hypothesized:) inhibition of liver metastases
87
EGCG (polyphe-
nol)
(Intraperitoneally 
injected)
Pulmonary metastasis 
mouse model
(B16F3m)
-Inhibiting adhesion and spreading
-Prolonged survival of tumor bearing mice
-Reduction of pulmonary metastases
105
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Table 2.  (Continued)
Anti-oxidant 
(Administration)
Model 
(MM cell line)
Effect on MM / metastasis / survival Reference(s)
PEG-catalase (i.v. 
injection, different 
time schedules) 
Pulmonary metastasis 
mouse model
(B16-BL6)
-Inducing “tumor dormancy”
-prolonged survival of tumor bearing mice
-Reduction of nr of tumor cells / number of 
metastatic nodules in lungs
106
PEG-catalase
(i.v. injected)
Mouse metastasis 
model
(B16-BL6)
-Preventing adhesion & proliferation, inducing 
tumor dormancy
-Prolonged survival of metastasis bearing mice
-Reduced number of tumor cells in lung
107
GPx4
(transfection of 
DNA in MM cells)
Pulmonary metastasis 
mouse model
(B16-BL6)
-Drastic inhibition of lung metastasis 108
PEG-catalase 
PEG-SOD 
(i.v. injected)
Primary tumor removal / 
experimental metastasis 
mouse models
(B16-BL6)
-Prolonged survival after primary tumor 
removal (SOD)
-Significantly suppressed metastatic growth 
(both SOD and catalase) 
73
109
PEG-catalase
(Intraperitoneal 
injection)
Peritoneal dissemina-
tion mouse model
(B16-BL6)
-Prolonged survival of tumor bearing mice
-Reduction in nr. of peritoneal tumor cells
78
ED-catalase
(Intraperitoneal 
injection)
Peritoneal dissemina-
tion mouse model
(B16-BL6)
-Prolonged survival of tumor bearing mice
-Reduction in nr. of peritoneal tumor cells
110
Mixture: 
ascorbic acid, 
NAC, polyphenol, 
Selenium, Copper, 
Manganese
(diet suppletion)
Local MM / metastasis 
mouse models
(B16FO)
-Less splenic tumor growth (=injection site)
-Prolonged survival
-Reduced liver metastases
111
GSH
(pretreatment of 
MM cells)
Hepatic metastasis 
mouse model
(B16M)
-Higher metastatic activity 58
HO-1
(transfection of 
DNA in MM cells)
In vitro: several models
In vivo: primary tumor & 
pulmonary metastasis 
mouse models
In vitro: higher angiogenic potential, higher 
proliferation, more resistance to ROS.
In vivo: more angiogenesis, shortened survival 
of mice
increased number and size of metastatic tumors 
43
Resveratrol / 
Piceatannol 
(Intraperitoneal 
injection)
Pulmonary metastasis 
mouse model
(B16-BL6) 
-Resveratrol: fasting grower tumors at highest 
doses
-Increased numbers of lung metastases
112
Abbreviations: Asc2P: 2-O-phosphorylated L-ascorbic acid, Asc2P6Plm: ascorbic acid -2-O-phosphate-6-O-palmitate, ED: 
ethylenediamine-conjugated, EGCG: Epigallocatechin-3-gallate, GPx4: Glutathione Peroxidase 4, GSH: gluthathione, HO-1: 
heme oxygenase-1, HSE: hepatic sinusoidal endothelium, i.v.: intravenous, MM: malignant melanoma,  MnSOD: manga-
nese superoxide dismutase, NAC: N-acetylcysteine, PEG: polyethylene glycol-conjugated, rHuSOD: Recombinant Human 
superoxide dismutase, ROS: reactive oxygen species, SOD: superoxide dismutase.
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to surrounding cells since healthy tissue has a lower defense against the ROS produced 
by MM cells90. These mechanisms of our hypothesis are illustrated in Figure 3.
It has been suggested that the reduced survival of male MM patients may be 
caused in particular by a higher rate of hematogenous (systemic) metastasis9. Clearly, 
evidence links ROS with all components of the process of hematogenous metastasis: 
ROS potentially stimulate angiogenesis38, intravasation113, adhesion to the vessel wall87, 
and extravasation68 of MM cells. Therefore, higher ROS levels in males may stimulate 
hematogenous metastasis, resulting in lower male survival rates. 
According to this hypothesis, ‘nature’s own randomized trial’ (i.e. higher anti-oxidant 
expression in females) results in the following outcomes, as observed in epidemiological 
studies3:
•	 Reduced	proliferation	 in	 females	 (lower	Breslow	 thickness,	 fewer	nodular	melano-
mas, less ulceration).
•	 Lower	likelihood	of	metastasis	in	females.	
•	 Subsequent	higher	female	survival	rates.	
Melanoma metastasis mouse models support this hypothesis, since administration of 
anti-oxidants frequently resulted in prolonged survival of mice (Table 2). This resembles 
the survival advantage for female melanoma patients3,4 who also exhibit higher levels of 
anti-oxidant enzymes.
(6) THE ROS HYPOTHESIS AND OTHER ISSUES IN MELANOMA RESEARCH
There are numerous other factors that have been associated with melanoma progres-
sion and outcome which might differ across gender. Examples include alcohol con-
sumption114, sun exposure115, body mass index116 or exercising117. Interestingly, all of 
these factors have also been associated with altering the oxidative balance. Therefore, 
gender differences in these lifestyle factors may contribute to the gender differences in 
melanoma survival by altering ROS levels. As mentioned earlier, chemotherapy is also 
ultimately aimed at increasing the oxidative stress within melanoma cells21. Therefore, 
gender differences in compliance to treatment could alter the oxidative balance between 
the sexes and therefore lead to survival differences in stage IV patients. This, however, 
seems unlikely as an explanation of the total female survival advantage, because only 
stage IV patients receive chemotherapy, and an effective regimen is lacking.
A remaining question is whether the female survival advantage persists after 
menopause or not. As outlined in Section 1, the advantage might decrease yet remain 
significant after menopause18. Gender differences in oxidative balance related to sex 
hormones as described in Section 4 might be able to explain this: the post-menopausal 
drop in estrogen levels may cause the female advantage to become smaller. The per-
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sisting small survival disadvantage for elderly males compared with post-menopausal 
older females may be caused by the fact that testosterone still antagonizes anti-oxidant 
enzymes in males.
Reactive oxygen species may also be linked with some other prognostic indicators, 
most obviously age. Men are older at diagnosis3 and older patients have a worse prog-
nosis4. Comparable with male versus female cells, older cells have lower anti-oxidant 
defenses than younger cells. Therefore, they suffer higher levels of oxidative stress118, 
hypothetically leading to a more aggressive melanoma in older patients. Interestingly, 
the most rapid primary tumor growth in MM was observed in elderly males10. ROS also 
stimulate cell division51 and cell cycle progression65, and therefore increase the mitotic 
rate, a recently emerged independent prognostic indicator for MM8 associated with 
rapid tumor growth10. ROS causing a higher mitotic rate may explain the higher average 
Breslow thickness in males. This seems to be supported by the observation that not 
delay in diagnosis119 but aggressive rapid tumor growth causes thick tumors10. The same 
could apply to the higher incidence of nodular melanoma (NM) in men3. Indeed NM 
exhibit more mitochondrial DNA damage, suggesting higher levels of oxidative stress60.
Melanoma is regarded as a highly immunogenic tumor120. Immune homeostasis dif-
fers across gender: females produce more vigorous cellular and humoral immune reac-
tions, are more resistant to infections, and exhibit higher incidence rates of autoimmune 
disease than males121. These gender differences in immune homeostasis were recently 
hypothesized to be caused actually by gender differences in oxidative balance122. There-
fore, the immune reaction to MM may differ across gender due to differences in ROS 
levels. Indeed, oxidative stress and the immune system strongly influence each other: 
inflammatory reactions produce ROS that act as signaling molecules within immune 
cells, oxidative stress modulates the expression of various immune and inflammatory 
molecules, and anti-oxidants regulate lymphocyte and inflammatory cell function122. 
Moreover, cytokines can modulate ROS generation in cells, and immune cells them-
selves generate ROS123. Experimental research has indeed shown that the combination 
of inflammatory conditions and high ROS levels promotes melanoma progression and 
metastasis124 and melanoma cell adhesion, extravasation and liver metastasis87. In sum-
mary, oxidative stress and immune homeostasis are both influenced by gender and are 
closely intertwined. 
Altogether, oxidative stress seems to be associated with many important aspects of mela-
noma biology: lifestyle factors, important prognostic factors (age, mitotic rate, Breslow thick-
ness, nodular melanoma), and immune homeostasis. This further emphasizes the central 
role of ROS in melanoma biology. However, much research must be done to further unravel 
these relationships and to discriminate between cause and consequences. Overall, many 
factors influencing melanoma survival may differ across gender. Oxidative stress seems to be 
associated with many of those factors; however, it may not be the only explanation.
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Figure 3. ROS and gender in melanoma progression.
Yellow stars: oxidative stress caused by high levels of reactive oxygen species (ROS). Thick cell walls: high levels resistance 
to ROS-induced apoptosis (ROS resistance). Thin cell walls: low levels resistance to ROS-induced apoptosis. Hatched cells: 
cell committing apoptosis. 
Panel 1A and B: The primary melanoma environment is characterized by high levels of oxidative stress caused by multiple 
factors: MM cells produce ROS themselves, the skin is a hypoxic tissue and other sources of ROS can be found around the 
tumor (e.g. tumor-associated immune cells). Importantly, oxidative stress differs across gender: the level of oxidative stress 
is higher in male tissue (more yellow stars) and male cells are less well equipped with anti-oxidant defenses (thinner cell 
walls) than females.
Panel 2A and B: High levels of ROS lead to apoptosis (symbolized by hatched cells). Therefore, ROS act as a selective pres-
sure, giving rise to ROS-resistant melanoma cells, which can produce high levels of ROS without succumbing to apoptosis. 
Since their ROS levels are higher, this selective pressure is stronger in males.
Panel 3A and B: Because melanoma cells become ROS-resistant, they can use their produced ROS (and ROS derived from 
their environment) to stimulate their proliferative potential (++++). As male melanoma cells can produce higher levels 
of ROS without dying from apoptosis, they develop more proliferative tumors (i.e. thicker melanomas) than females. 
Furthermore, ROS produced by melanoma cells can induce apoptosis in surrounding tissue, e.g. in endothelial cells, thus 
promoting metastasis. 
Panel 4A and B: Upon entering the blood vessel, the acquired ROS resistance – higher in males – protects melanoma cells 
from ROS-mediated attacks (e.g. by circulating immune cells). This increases survival of metastatic melanoma cells, espe-
cially in males. The produced ROS may further promote metastasis by inducing cell adhesion and by causing subsequent 
endothelial cell apoptosis, providing an entrance for tumor cells into metastatic sites. At these sites, metastatic cells are 
protected by their ROS resistance preventing them from undergoing apoptosis when attacked by ROS. Metastasis is fur-
ther promoted by their ROS-induced proliferative potential and ROS-mediated destruction of surrounding tissue. 
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ABSTRACT
An increasing body of evidence shows that females have a survival advantage in lo-
calized and metastasized melanoma. However, the explanation for this phenomenon 
remains unclear. This narrative review attempts to outline several possible explanations 
for this female advantage in melanoma by proposing multiple candidates derived from 
literature. 
Behavioral differences across gender might lead to differences in diagnostic delays 
and differences in body site distribution across gender, possibly partly explaining the 
gender differences in survival. However, after adjustment for confounders related to 
delays (e.g. Breslow thickness) and body site, the female advantage persists. Therefore, 
behavioral explanations do not seem to fully explain the female survival advantage.
Underlying biological explanations can be divided in differences in the tumor or 
differences in the host. So far, no definite gender differences in the tumor, e.g. tumor 
mitotic rate or tumor mutation rates, have been found. Therefore, the tumor itself does 
not seem to differ across gender. 
Several host factors which differ across gender have been linked to melanoma 
progression and survival and might therefore offer an explanation for the female mela-
noma advantage. These include: estrogen and androgen levels, estrogen Receptor β, 
the immune system,  autophagy, reactive oxygen species, matrix metalloproteinase-2 
(MMP-2), skin physiology, vitamin D and obesity. There is no evidence that therapeutic 
strategies influence these gender differences in survival.
More research is needed to unravel this intriguing phenomenon in melanoma survival. 
Future research in melanoma concerning these and other possible factrs influencing 
progression and survival should take gender into account.
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INTRODUCTION 
Female patients have a better prognosis in many types of cancer. Two large studies 
found that this female advantage was the largest for cutaneous melanoma1,2. In a Euro-
pean study females had a 5% lower relative excess risk for dying of cancer than males, 
while for melanoma alone this was more than 50%1. Therefore, this gender phenom-
enon seems to be small in cancer in general but is an important feature of cutaneous 
melanoma. Indeed, a multitude of studies reported an independent significant female 
advantage in localized melanoma (table 1), as well as in advanced stage III (table 2) and 
IV (table 3) melanoma. Several authors suggested this gender difference to occur at the 
level of metastases3-5 because in addition to  survival,  progression-free or disease-free 
survival also differ significantly across gender6-11 However, gender not only affects the 
risk of metastasis but remains of prognostic value after disease progression, even after 
distant metastasis9,10,12,13. Investigating different metastatic patterns, it was suggested 
that only lymphatic14 or only distant hematogenous metastasis15 was affected by gender. 
However, we recently found that both lymph node and distant metastasis were equally 
affected by gender9,11. Therefore, it seems that for all steps in melanoma progression, 
from diagnosis to death, women do better than men. There is one remarkable exception 
however: there are no gender differences in the likelihood of having positive sentinel 
lymph node biopsies15-24. 
Considering all the evidence and effect size of gender differences in melanoma 
progression and survival, surprisingly little research has been done on possible ex-
planations, leaving this one of the most intriguing mysteries in the field of melanoma 
prognostic factors25. In this narrative literature review, we report possible explanations 
for the female advantage in melanoma survival. 
BEHAVIORAL FACTORS
A possible explanation of the gender differences in melanoma survival are behavioral 
differences between genders, resulting in an advantageous distribution of tumor char-
acteristics at diagnosis (mainly Breslow thickness and body site distribution of the 
primary melanoma) in females. 
Breslow thickness and behavior
Many studies showed a significant higher Breslow thickness in males at diagno-
sis5,8,9,11,35,50,71,72  Several behavior-linked explanations have been proposed to cause these 
thinner tumors in females.
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Table 1. Studies with (predominantly) localized stage I and II cutaneous melanoma reporting an 
adjusted prognostic value for gender
Study, year 
(limitation of study 
population)
Country N Gender estimate adjusted for End-
point
Adj. Risk 
Estimate
95% CI / 
p-value
Karjalainen et al., 
198826
Finland 4,980 Breslow, Site DSS RR 0.67 0.57-0.8 *
Stidham et al., 19943 USA 6,383 Age, Breslow, Histology, Site, 
Clark
OS HR 0.78 - *
Karakousis and 
Driscoll, 199527
USA 659 Age, Breslow, Site, Year OS - - p=0.0008 *
Schuchter et al., 
199628
USA 488 Age, Breslow, Histology, Site, 
Invasion
DSS OR 0.5a 0.28-0.83 *
Kemeny et al., 19985
(Age <45 yrs)
USA 3,881 Age, Histology, Site, TNM OS HR 0.54a 0.44-0.64 *
Balch et al., 200129 USA 13,581 Age, Breslow, Site, Ulceration, 
Invasion
DSS RR 0.84 0.76-0.92 *
Masback et al., 200130 Sweden 711 Age, Breslow, Histology, Site, 
Ulceration, Year, Inflammation
OS OR 0.9 0.8-1.0
Azzola et al., 200331 Australia 3,661 Age, Breslow, Site, Ulceration, 
Clark, Mitotic Rate
DSS RR 0.69 0.55-0.87 *
Nagore et al., 200532 Spain 823 Breslow, Vascular invasion OS HR 0.59 0.40-0.88 *
Fortes et al., 200633 Italy 654 Age, Breslow, Histology, Ulcer-
ation, Mitotic Rate
DSS RR 0.57a 0.26-1,25
Downing et al., 200634 UK 3,127 Age, Breslow, Histology OS HR 0.67 0.56-0.80 *
Scoggins et al., 200615 USA/Can 1,829 Age, Breslow, SLN+ OS RR 0.69a 0.56-0.83 *
de Vries et al., 200835 Nether-
lands
10,538 Age, Breslow, Histology, Site, TNM RERd 0,53 a 0.48-0.61 *
Lasithiotakis et al., 
200836
Germany 4,785 Age, Breslow, Histol, Site, Ulcer-
ation, Clark, SLN+, Year
DSS HR 0.8 0.6-0.9 *
Metelitsa et al., 201037 Canada 3,479 Age, Breslow, Site, Clark DSS RR 0.61a 0.45-0.83 *
Xing et al., 2010 
(Stage I)38
USA 32,430 Age, Race, Marital status, Histol-
ogy, Site
DSS HR 0.67 a 0.60-0.75 *
(Stage II) USA 5,089 Age, Race, Marital status, Histol-
ogy, Site
DSS HR 0.67a 0.60-0.75 *
Rueth et al. 201039
(Age < 60 yrs)
USA 
(SEER)
8,647 Age, High vs Low riskb, Ulceration, 
Site
DSS HR 0.8a 0.8-0.9 *
Oberaigner et al. 
201040
Austria 1,607 Age, Stage, Follow-up*stage 
interaction
RERd 0.85 0.55-1.31
Brown et al. 201041
(Breslow > 1mm)
USA 2,335 Age, Breslow, Site, Ulceration, 
Clark, SLN+, NSN+ nr. of positive 
LNs
OS HR 0.76a 0.62-0.93 *
Hohneiser et al. 
201042
Germany 2,062 Age, Breslow, Site, Histology, Year, 
N-stage
OS HR 0.8a 0.7-0.9 *
Roach et al., 201043
(Breslow > 1 mm)
USA 551 Breslow, Site, SLN+, Ulceration, 
Lymphovascular invasion, Mitotic 
Rate
OS OR - P=0.004 *
Tseng et al. 201044
(head and neck MM 
only)
USA 27,097 Age, Breslow, Site within head/
neck, Histology, Ulceration, Clark, 
N stage, ethnicity, surgery type, 
radiation
OS HR 0.76 0.72-0.80 *
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Table 1. (Continued)
Study, year 
(limitation of study 
population)
Country N Gender estimate adjusted for End-
point
Adj. Risk 
Estimate
95% CI / 
p-value
USA 27,097 Age, Breslow, Site within head/
neck, Histology, Ulceration, Clark, 
N stage, ethnicity, surgery type, 
radiation
DSS HR 0.70 0.63-0.77 *
Collins et al. 201145
(patients who under-
went surgery)
USA 
(SEER)
142,653 Age, Stage, Site, Ulceration, 
Histology, satellites, LN meta’s, 
Year, Ethinicity
OS HR 0.71 0.68-0.73 *
Joosse et al., 20119 Germany 11,734 Age, Breslow, Site, Histology, N 
stage, M stage, Year
OS HR 0.69 0.64-0.74 *
 Germany 11,734 Age, Breslow, Site, Histology, N 
stage, M stage, Year
DSS HR 0.62 0.56-0.70 *
USA 
(SEER)
142,653 Age, Stage, Site, Ulceration, 
Histology, satellites, LN meta’s, 
Year, Ethinicity
DSS HR 0.65 0.62-0.68 *
Thompson et al. 
201146
AJCCc 13,296 Age, Breslow, Site, Ulceration, 
mitotic rate, Clark
DSS HR 0.69 0.61-0.79 *
De Vries et al. 201147 Nether-
lands
429 Age, Breslow, Ulceration, SLN+, 
Site
OS HR 0.6a 0.4-1.0
p=0.03
*
429 Age, Breslow, Ulceration, SLN+, 
Site
DSS HR 0.7a 0.4-1.0 
p=0.07
Mervic et al. 20118 Germany 7,338 Age, Breslow, Ulceration, Site, 
Clark, Histology, Decade of 
Diagnosis
DSS HR 0.8a 0.6-0.9 
p=0.002
*
Lee et al. 201148 Australia, 1,787 Thickness, Ulceration, Age, 
mitotic rate.
DSS HR 0.64a 0.46-0.89 *
Pollack et al. 201149 USA 
(SEER)
68,495 Age, ethnicity, stage, Breslow DSS HR 0.76 0.71-0.81 *
Joosse et al. 201211 Europe 
(EORTC 
trials)
2,672 Age, Breslow, Ulceration, Site, 
treatment, lymph node dissec-
tions
OS HR 0.70 0.59-0.83 *
2,672 Age, Breslow, Ulceration, Site, 
treatment, lymph node dissec-
tions
DSS HR 0.74 0.62-0.88 *
Joosse et al. Submit-
ted50
Australia 8,186 Age, Breslow, Ulceration, Site, Mi-
totic Rate, Histology, Clark, Year
DSS HR 0.64 0.55-0.75 *
* Risk Estimate is statistically significant at alpha=0.05 level
a Risk estimate was originally reported as males compared to females, here the inverted estimate and 95% CI is shown to 
enable comparison.  
b T2-3N0M0 vs T4N0M0 or T2-4N1M0
c AJCC study with data from USA, Australia, Italy, NL and EORTC
d Relative Excess Risk is a measure of the excess risk compared to the general population, of females relative to males.
Abbreviations: AJCC: American Joint Committee on Cancer, Can: Canada, CI: Confidence Interval, DSS: Disease-Specific 
Survival, EORTC: European Organisation for the Research Treatment of Cancer, HR: Hazard Ratio, LN: Lymph Node, MM: 
Malignant Melanoma, NSN+: Non Sentinel Node positivity, OR: Odds Ratio, OS: Overall Survival, RER: Relative Excess Risk, 
RR: Relative Risk, SEER: Surveillance Epidemiology and End Results, SLN+: Sentinel Lymph Node positivity, TNM: Tumor-
Node-Metastasis classification system, UK: United Kingdom, USA: United States of America
126
Chapter 3.2
Table 2. Stage III cutaneous melanoma studies reporting an adjusted prognostic value for gender.
Study, year 
(limitation of study 
population)
Country N Gender estimate adjusted for End-
point
Adj. Risk 
Estimate
95% CI / 
p-value
Balch et al. 200129 USA (AJCC) 1,151 Nr of LNs, micro- vs 
macrometastasis, ulceration, 
site, age, thickness, Clark
DSS RR 1.01 0.84-1.33
Agrawal et al. 200951
(macroscopic LNM 
after CLND)
USA 
(NY)
615 nr  of positive LNs, nr of LNs 
removed, size of largest LN, 
extracapsular extension, age, 
thickness, LN basin, Adjuvant 
RT, systemic therapy
DSS HR - P=0.20
Herman et al. 200952
(Lower extremity 
thick melanoma 
after CLND)
Poland 185 N-stage, LNM timing, 
ulceration, iliac nodes
DSS HR 0.50a P=0.045 *
Wiener et al. 201053
(SN+ patients)
Australia 
(MIA)
323 Nr of positive SNs, nr of positive 
NSNs, total SNs removed, age, 
thickness, ulceration, MR, site
DSS HR 0.64 0.41-1.00
Kruijff et al. 201054
(macroscopic LNM 
after CLND)
Nether-
lands
98 Nr of positive LNs, micro- vs 
macrometastasis, patients vs 
physician detected
DSS HR 0.3 P=0.004 *
Rutkowski et al. 
201055
Poland 849 Nr. of positive LNs, micro- vs 
macrometastasis, LN basin, 
Clark, age, ulceration
DSS HR 0.66a P=0.004 *
Pasquali et al. 201056
(after CLND)
Italy 190 Nr. of positive LNs, 
extracapsular extension, micro 
vs macrometastasis, thickness, 
ulceration, site, Clark, age
OS HR 0.65a 0.40-1.10
Xing et al. 201038 USA (SEER) 1,963 Site, histology, age, marital 
status, ethnicity
DSS HR 0.81a 0.70-0.93 *
Balch et al. 201057
(micrometastasis)
USA (AJCC) 1,872 Nr of positive LNs, thickness, 
ulceration, Clark, Site, age
DSS HR 0.80 p=0.03 *
1,070 See above, +MR DSS HR 0.86 p=0.30
(macrometastasis) 441 Nr of positive LNs, thickness, 
ulceration, Clark, Site, age
DSS HR 1.07 p=0.66
268 See above, +MR DSS HR 0.79 p=0.34
Bowles et al. 201058
(stage IIIa)
USA (TX) 136 Extracapsular extension, 
histology, age
DSS HR 0.68a 0.34-1.35
(stage IIIb) 324 Extracapsular extension, 
histology, age
DSS HR 0.82a 0.60-1.12
(stage IIIc) 300 Extracapsular extension, 
histology, age
DSS HR 0.70a 0.52-0.94 *
Joosse et al. 20109 Germany 1,321 Thickness, histology, site, age, 
YOD
DSS HR 0.80 0.66-0.96 *
Van der Ploeg et al. 
201159t
(SN+ patients)
Europe
(EORTC) 
1080 LN Tumor burden, Dewar 
criteria, NSN status, thickness, 
ulceration, site, Clark, age, 
center
DSS HR 0.76a 0.61-0.96 *
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Screening, especially clinical and self-skin examinations, has been shown to reduce 
melanoma thickness at diagnosis71,73. Most studies observed females to be more likely 
than males to participate in different kinds of screening activities74-78, possibly because 
(healthy) males are generally more reluctant to visit health workers due to social and 
cultural beliefs about masculinity79-83. Another cause explaining higher participation 
in screening activities might be the higher awareness of and knowledge about skin 
cancer in females84-88, which is indeed associated with thinner melanomas73. This higher 
awareness of melanoma might partly explain the higher proportion of self-detected 
melanomas in females compared to males88-93. This might also be related to the prepon-
derance of melanomas in female occurring on the limbs, more easily seen by the patient, 
in contrast to the melanomas on the trunk in men83. 
Some have hypothesized that these behavioral factors (awareness, self-skin examina-
tion, screening activities), cause a diagnosis delay in males, causing thicker melanomas. 
However, after patients noticed a suspicious skin lesion, there were actually no gender 
differences in the delay to seek professional help88,89,94. One study found that women 
are more likely to seek help for skin lesions, but when a patient judges a lesion to be 
‘suspicious’, males seek professional help more promptly82. No gender differences were 
observed for self-detection of disease recurrence, e.g. nodal metastases54,93. 
Even if gender differences in diagnosis delay exist, this might not be the major com-
ponent of melanoma thickness, as thickness was shown to depend more on the primary 
tumor growth rate than on diagnostic delays90. 
Table 2. (Continued)
Study, year 
(limitation of study 
population)
Country N Gender estimate adjusted for End-
point
Adj. Risk 
Estimate
95% CI / 
p-value
Berger et al.60
(after CLND)
USA (PA) 168 LN ratio, LN basin, LND type, 
thickness, ulceration, site, age, 
treatment
OS HR 0.78 0.48-1.27
Martinez et al. 201161 USA (SEER) 6,868 nr of positive LNs, thickness, 
ulceration, surgery, age, era
OS HR 0.79 0.73-0.86 *
DSS HR 0.80 0.73-0.88 *
Joosse et al. 201313 Europe 
(EORTC)
2734 nr. of positive LNs, micro- vs 
macrometastasis, thickness, 
ulceration, site, age, treatment 
OS HR 0.81 0.72-0.91 *
DSS HR 0.85 0.76-0.95 *
* Risk Estimate is statistically significant at alpha=0.05 level
a Risk estimate was originally reported as males compared to females, here the inverted estimate and 95% CI is shown to 
enable comparison.
Abbreviations: CLND: Complete Lymph Node Dissection, EORTC: European Organization for Research and Treatment of 
Cancer, LN: Lymph Node, LNM: Lymph Node Metastasis, MIA: Melanoma Institute Australia, MR: Mitotic Rate, NSN: Non 
Sentinel Nodes, NY: New York, PA: Pennsylvania, RT: Radiotherapy, , SEER: Surveillance Epidemiology and End Results, SN: 
Sentinel Node, SN+: Sentinel Node positive, TX: Texas, USA: United States of America, YOD: Year of Diagnosis
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Body site and behavior
The site of the primary tumor differs significantly by gender, i.e. males have more tumors 
on the trunk, females more on extremities, especially on the legs5,8,9,11,35,50,71,72,95,96. It is 
tempting to explain this finding by differences in sun exposure and clothing behavior 
across gender95. However, nevi in children follow highly similar gender-specific body 
site distributions (boys more nevi on the trunk; girls more nevi on the legs) independent 
of sun exposure or host characteristics95,97 which was even observed in children strictly 
protected from sun exposure by traditional religious costumes98. Thus, gender seems 
to influence the proneness of melanocytes to develop into nevi and melanomas at 
specific body sites independent of behavioral sun exposure95. This might be related to 
the ‘divergent pathway hypothesis’ with a possible gender-body site interaction related 
to presumed different etiological pathways to melanoma96. Overall, biological factors 
are at least partly responsible for the gender differences in anatomic distribution of 
melanoma although behavior might still play a role.
Adjusting the gender effect for thickness and body site
Three studies investigated the extent of adjustment of the gender Hazard Ratio’s (HRs) 
by other melanoma prognostic indicators3,9,50, and showed that of all available confound-
ers, only adjustment for Breslow thickness and body site caused a considerable shift of 
the gender HR for survival. We hypothesize that the adjustment caused by these two 
factors represents the ‘behavioral part’ of the explanation of the female survival advan-
tage. Therefore, although behavior does seems to explain a part of this phenomenon, 
a significant female advantage remains which is probably caused by biological factors. 
This is confirmed by a large body of evidence that after adjustment with these and other 
factors, a significant female advantage persisted in local melanoma (Table 1).
Summarizing, behavioral factors such as screening, melanoma awareness and self-
detection of skin lesions might cause gender differences in melanoma thickness, although 
the growth rate of the tumor itself might be a more important cause of thicker melano-
mas. Also, gender differences in body site distribution might be behaviorally determined, 
although a biological gender difference in proneness of melanocytes and nevi to develop 
into melanoma across different body sites does seem to exist. Adding Breslow thickness and 
body site into a multivariate model with gender does cause the female advantage to become 
smaller (i.e. shift towards a HR of 1) although a multitude of studies observed a persisting 
independent association of gender with survival after localized melanoma, suggesting that 
behavioral factors cannot fully explain this phenomenon.
Three other arguments contradicting the ‘behavioral hypothesis’ include (1) the fe-
male advantage persists in metastasized melanoma13 (2) gender differences also occur 
in controlled animal experiments99,100 and (3) The female advantage is highly comparable 
129
3.2
Possible Explanations for the Female Advantage in Melanoma
across different continents (table 1-3) despite large differences in sun exposure, cultural 
factors, health care systems, awareness and screening activities. 
Table 3. Stage IV cutaneous melanoma studies reporting an adjusted prognostic value for gender.
Study, year 
(limitation of study 
population)
Country N Gender estimate adjusted for End-
point
Adj. Risk 
Estimate
95% CI / 
p-value
Sirott et al. 199362
(trials)
USA (NY) 284 LDH level, serum albumin, 
platelet count, visceral 
involvement  
OS - - “significant” *
Ryan et al. 199363
(trials ECOG)
USA 635 Apetite, nausea/vomiting, fever, 
PS, nr of sites involved, Soft 
tissue or LN metastases, time to 
inclusion, ChT response
OS - - “significant” *
Barth et al. 199564 USA (CA) 1,521 Nr of metastases, DFI, 
preceding stage, thickness, site, 
Clark, YOD, age
OS - - p>0.10
Brand et al. 199765 Germany 442 Site of primary metastasis, nr. of 
sites involved, PS, surgery
OR - - “significant” *
Hofmann et al. 
199866
(Brain metastasis)
Germany 133 Nr. of metastases, surgery, ChT, 
ChT+RT, corticosteroids
OS RR 0.43 P<0.0001 *
Eton et al. 199867
(trials)
USA (Tx) LDH level, nr. of involved sites, 
serum albumin
OS HR 0.77 0.59-1.0
(p=0.02)
*
Unger et al. 200112
(trials SWOG)
USA 813 PS, Nr of sites involved, visceral 
involvement, DFI. Treatment, 
YOT
OS HR 0.90 0.76-1.05
Korn et al. 200868
(trials )
USA, 
Canada 
1,278 PS, Visceral metastases, Brain 
metastases, YOT
OS HR 0.78 P<0.0001 *
Xing et al. 201038 USA 
(SEER)
1,038 Primary and histology and site, 
age, ethnicity, marital status 
DSS HR 0.93 0.79-1.09
Joosse et al. 20109 Germany 1,602 site of metastasis, primary 
thickness, histology, site, age, 
YOD
OS HR 0.89 0.78-1.03
Wasif et al. 201169 USA 
(SEER)
4,201 M-stage, metastectomy, age, 
era.
OS HR 0.91 0.85-0.98 *
Schuhan et al. 201170
(pulmonary 
metastasis, surgical 
resection)
Germany 30 Resection completeness, 
extrapulmonary metastases
OS HR 0.32 0.12-0.85 *
Joosse et al. 201313 Europe 
(EORTC)
1,306 LDH level, nr. of involved sites, 
baseline sum of target lesion 
diameter, PS, nr. of TLs, M-stage 
site categories, age
OS HR 0.82 0.72-0.93 *
DSS HR 0.81 0.72-0.92 *
* Risk Estimate is statistically significant at alpha=0.05 level
Abbreviations: CA: California, ChT: Chemotherapy, DFI: Disease Free Interval, EORTC: European Organization for Research 
and Treatment of Cancer, LDH: lactate dehydrogenase, PS: Performance Score, RT: Radiotherapy, SEER: Surveillance 
Epidemiology and End Results, TL: Target Lesion, USA: United States of America,  YOD: year of diagnosis, YOT: year of trial
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Overall, although behavioral factors might cause part of the female survival advantage 
through thicker tumors and disadvantageous body site distribution in males, behavioral 
aspects cannot fully explain the female advantage in melanoma survival. 
BIOLOGICAL FACTORS
Different Tumors?
One possibility for a biological explanation is that males inherently develop more ag-
gressive tumors than females. We tested this in a large observational study, using mitotic 
rate which is considered a measure for tumor proliferation and thus aggressiveness50. 
We observed that mitotic rate was comparable between males and females after adjust-
ment for all other tumor and clinical factors. Also, the molecular and genetic make-up of 
melanomas does not seem to differ across gender as no differences were observed for 
mutation rates (or expression) of important genes in melanoma, i.e. BRAF101-106, NRAS104-
106, KIT107,108 and phosphorylated ERK and Cyclin D1, important downstream  products 
of the pathway of BRAF and NRAS108. The expression of X-linked cancer-testis antigens, 
which have been proposed as a possible explanation for gender survival differences25, 
were similar across gender25,109. The only exception is p53, which showed higher expres-
sion in males compared to females in one study110. 
Several researchers have attempted to classify melanoma into different categories. 
The divergent pathway hypothesis stated that there are ‘nevus-associated’ and ‘sporadic 
type’ melanomas111. However, no gender differences between these types were found112. 
Curtin et al. categorized melanoma in BRAF/NRAS mutated melanomas without chronic 
sun exposure and chronic sun exposed melanomas with mutations downstream in the 
same pathway113, however, no gender differences were found for BRAF or NRAS sta-
tus101-106. Anderson et al. described two groups of melanoma (1) predominantly males, 
lentigo maligna subtype, head and neck location and older age; and (2) predominantly 
females, superficial spreading subtype, lower extremity location and younger age. 
However, the increased survival in the first group contradicts the known female survival 
advantage114. 
One study in 52 melanoma tumors found that male tumors had a significantly higher 
intratumoral microvessel density (MVD), which was hypothesized to be caused by dif-
ferential angiogenic effects of sex steroids115. This intratumoral MVD however was not 
associated with tumor thickness, the ability to metastasize or tumor infiltration with 
immune cells e.g. macrophages or T-cells and therefore offers no clear explanation for 
gender differences in survival115.
Summarizing, no clear gender differences in the primary tumors have been found: mitotic 
rate does not truly differ across gender, nor do mutation rates of important genes. Evidence 
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of the role of gender in the divergent pathways model is unclear and often contradictory and 
although one study found a higher intratumoral MVD in males, the relationship with prog-
nosis is unclear. As tumor differences do not seem to be able to explain the female survival 
advantage, we will discuss several possible explanations related to host factors below. 
HOST DIFFERENCES
Hormonal explanations:
Estrogens
Estrogen is an obvious candidate to explain gender differences in melanoma survival. 
Concerning melanoma incidence, several reviews and meta-analyses addressing the 
influence of hormonal factors –including oral anticonceptives, hormonal replacement 
therapy, pregnancy, parity, age at menarche and menopause- concluded that there 
seems to be no association116-122.
Concerning melanoma progression after diagnosis In vitro research showed that 
estrogen inhibited invasion and growth of melanoma cell lines14,123,124. However, clinical 
evidence showed that circulating estrogen levels were not associated with disease pro-
gression14,125, nor did pregnancy influence melanoma prognosis116-118. In vitro tamoxifen 
inhibited melanoma progression, probably through non-estrogen-dependent path-
ways. However, tamoxifen showed no activity –either positive or negative- in advanced 
melanoma patients126. Only one study suggested that taking hormonal replacement 
therapy positively influenced survival in localized melanoma127. 
In most large observational studies, data on estrogen levels in female melanoma 
patients is  lacking. A proxy for menopausal status is to categorize patients by age with 
a cut-off point of 50 to 60 years beyond which women are presumed to be postmeno-
pausal. To our knowledge, 5 studies on (mainly) localized melanoma found the female 
advantage to disappear in older, presumably postmenopausal females5,8,26,36,128, but 14 
studies in both local and advanced melanoma found the female advantage to persist 
in presumed postmenopausal females1,3,9,11,13,30,35,50,55,64,129-131. An explanation for these 
contradicting findings might be that  the advantage does persist but declines in older 
females50, which could lead to different observations per study. Also, the drop of estro-
gen levels in postmenopausal women is partly negated by an increased production of 
estrogens in peripheral tissue, especially by adipocytes132,133. 
Summarizing, melanoma incidence and progression do not seem to be influenced 
by estrogens and most studies show that the female survival advantage persists in post-
menopausal age. Overall, there is little evidence of an association between melanoma and 
estrogen levels.
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Estrogen receptors
It has been hypothesized that not hormone levels, but rather the expression of es-
trogen receptors on melanoma cells influences the course of melanoma134. Estrogen 
Receptor Alfa (ERα) is rarely expressed in skin cells and was not consistently detected 
in melanoma or nevi135. However, Estrogen Receptor Beta (ERβ) is expressed on all skin 
cell types including nevi and melanoma cells135,136. ERβ is associated with inhibition of 
proliferation, invasion and apoptosis in several types of malignancies134,137,138. Also in 
melanoma, loss of ERβ is associated with malignant transformation: In ERβ knock-out 
mice melanoma grew significantly faster than in wild-type mice139 and in patients, 
lower ERβ expression in melanoma is associated with more malignant, thicker and 
metastasized tumors136-138,140,141. Furthermore, melanoma cells had lower ERβ expression 
than surrounding healthy tissue, and when this difference increased, tumor thickness 
increased138.
Sex seems to influence the expression of ERβ: In healthy skin, premenopausal females 
have higher ERβ expression compared to males and postmenopausal females137,138,140. 
Two studies demonstrated no significant gender difference in ERβ expression in mela-
noma cells or nevi135,136. However, one recent study observed an increased ERβ expres-
sion in melanomas of (especially premenopausal) women, as well as an increased loss of 
melanoma cell ERβ expression compared to healthy adjacent skin in men compared to 
premenopausal women138. This loss of ERβ expression compared with adjacent healthy 
tissue was associated with thicker tumors in men but not in women138. These data led 
De Giorgi et al. to hypothesize that a possible higher ERβ expression in premenopausal 
women might explain the survival advantage of this group compared to men and post-
menopausal women140. Although this could be a valid explanation for the gender dif-
ferences in survival, the numerous observations that the female advantage persists in 
postmenopausal women compared to men of the some age seem to contradict this 
hypothesis1,3,9,11,13,30,35,50,55,64,129-131.
Androgens
In the 1980´s, it was suggested that androgenic steroids might be a more logical expla-
nation than estrogens142,143, as estrogen-related factors did not correlate with melanoma 
survival (see above) and because there is a significant higher difference in androgen 
levels than estrogen levels across gender132,144. Androgen receptors were found in mela-
noma cells, with the highest intensity in melanoma metastases145. In a melanoma cell 
line, androgens significantly stimulated cell proliferation, which could be reversed by 
anti-androgens146. So far, little is known of the influence of androgens on melanoma, 
however available evidence suggests that should be considered as a potential explana-
tion for the female survival advantage.  
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The Immune System
Melanoma is considered a highly immunogenic tumor, which most likely actively in-
duces immunosuppression even at distant sites such as lymph nodes or visceral organs 
to promote distant metastases147,148. In melanoma, the immune system can be both a 
‘sword’ inducing tumor regression as a ‘ploughshare’, stimulating proliferation149. An 
example of using the ‘sword’ are the successful trials using CTLA-4-blockade, or ipili-
mumab, to simulate the immune system150,151. Vice versa, suppressing the ‘sword’ with 
iatrogenic immunosuppression increases melanoma risk152.
Clearly, gender influences the immune system. Estrogen stimulates immune responses 
(explaining higher resistance to infections but also a higher incidence of autoimmune 
diseases), while testosterone is immunosuppressive, leading to more vigorous cellular 
and humoral immune responses in females153. This leads to a higher resistance to in-
fections but also a higher incidence of autoimmune diseases in females154. In the skin, 
UV-radiation leads to higher inflammatory cutaneous responses in female than in male 
mice155 and three times higher UV-doses were required to induce immunosuppression in 
females compared to males144. Furthermore more efficient antigen-presenting cells and 
higher phagocytic activity of neutrophils and macrophages were observed in females144. 
Moreover, gender can matter in the effect of immune therapies: e.g. reducing T-regu-
latory function by inhibiting CD274 caused greater anti-melanoma immune response in 
female than male mice156. ERβ might also contribute to gender differences in melanoma-
associated immune responses, as estrogen-activated ERβ promotes the differentiation 
of Langerhans cells, important in tumor immunosurveillance in the skin140. One study 
found ERβ-deficient mice to grow melanoma tumors significantly faster than wild-type 
mice, an effect aggravated by prior UV radiation, which led the authors to conclude that 
immunological pathways were likely to mediate the ERβ-effect139.
Interestingly, after melanoma metastasis tot the liver was shown to differ across 
gender in a mouse model99, this gender effect was found to be attenuated by block-
ing Natural Killer cells activity in both sexes115. Therefore, NK-cells might be involved 
in gender differences in melanoma metastasis and prognosis. However, in contrast to 
human patients, in this mouse model only metastasis to the liver but not to other target 
organs differed across gender, limiting the applicability of this hypothesis to patients115. 
There is also evidence that the immune system cannot fully explain the gender dif-
ferences in melanoma. Miller and Mac Neil noted that several studies observed gender 
differences in melanoma progression in Severely Combined Immune Deficient (SCID) 
mice4. Other studies found inflammation to be a favorable prognostic factor but observed 
fewer inflammatory cells in female tumors30,157. There was also no difference observed 
across gender for tumor infiltrating lymphocytes (TILs; measured as brisk, non-brisk 
or absent)16,158 or tumor infiltrating neutrophils159. Furthermore, the observation that 
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gender did not modify the effect of immune therapy with ipilimumab contradicts the 
importance of immunity in gender survival differences150,151. 
Autophagy
Autophagy is a cellular process of degradation and recycling of cytoplasmic content and 
organelles which may promote tumor progression160. Melanoma cells use autophagy 
as a survival mechanism under stress conditions161 and a higher autophagic index was 
associated with shorter survival and less response to treatment in melanoma patients162. 
Although data is limited, gender seems to influence autophagy as reviewed by Lista 
et al160. This might be caused by hormonal factors as both androgens and estrogens 
have been linked with the regulation of autophagy160. Although a link seems to exist, 
so far the links between autophagy, gender and melanoma remain unclear and further 
research is needed.
Reactive Oxygen Species
Reactive Oxygen Species (ROS) are highly reactive molecules capable of damaging their 
surroundings through redox-type reactions163. In an earlier review, we proposed the 
known gender differences in the handling of ROS as a candidate explanation for gender 
differences in melanoma survival164. Summarized, males have a lower capacity to neu-
tralize ROS and ROS and its resulting oxidative stress have been implicated in promoting 
invasion, progression and metastasis through a wide variety of mechanisms164. 
Recently, additional supporting evidence for an important role of ROS in melanoma 
progression emerged. One mice study found a new UV-radiation-independent path-
way of BRAFV600E-driven melanoma carcinogenesis involving oxidative stress caused 
by increased pheomelanin synthesis165. Another review stated that melanoma cells’ 
remarkable resistance to many therapeutic agents might be caused by the fact that 
their healthy precursors, melanocytes, already have an intrinsic capacity to resist ROS147. 
Furthermore, a review proposed ROS as critical signal messengers in major pro-meta-
static signaling pathways, e.g. the MAP-Kinase pathway166. An in vitro study found that 
in melanoma, hypoxia releases ROS, which through stabilizing HIF-1α and activating the 
Met proto-oncogene activates motility, invasion, growth and vascular mimicry167. This 
study also confirmed the natural selection of ROS-resistant tumor cells in hypoxic envi-
ronments which we proposed in our review164. Furthermore, melanoma cell lines with 
higher expression of the main regulator of the antioxidant gluthatione, i.e. glutamate-
L-cysteine ligase catalytic subunit (GCLC) showed lower presence of intracellular ROS 
and also less cell proliferation, invasion and tumor growth. Moreover, in a small subset 
of melanoma patients GCLC expression predicted 5-year overall survival168 Overall, the 
authors concluded that a melanoma of low oxidative phenotype is associated with a 
better prognosis. 
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Finally, two recent studies confirmed that antioxidants can inhibit metastasis, as we 
reviewed before164. Both subcutaneous injection of pegylated catalase169, as pretreat-
ing metastatic cells in vitro with antioxidants before injection167 reduced pulmonary 
metastases in mice. 
Summarizing, ROS and oxidative stress seem to be key players in melanoma progression 
and metastasis. As males have a lower capacity to neutralize ROS, this might explain the 
gender differences in melanoma survival.
MMP-2
Matrix metalloproteinases (MMPs) are thought to play an important role in melanoma 
progression and invasion170. These proteolytic enzymes, MMP-2 in particular, can de-
grade and remodel the extracellular matrix (ECM) and basement membranes, thereby 
providing an essential step for primary tumor progression, invasion and hematogenous 
metastasis. MMP-2 expression is increased in primary and metastatic melanoma cells, 
especially in “invasive front” cells at the stromal tissue - tumor border170, and is associ-
ated with architectural disorder, atypia, progression, migration, invasion and hematog-
enous metastasis. MMP-2 is also synthesized by tumor-surrounding fibroblasts, possibly 
induced by the tumor itself170. 
Two studies showed that MMP-2 expression was an independent predictor of survival 
and that this prognostic effect was more profound in males than in females171,172. For 
example, MMP-2 positivity resulted in an absolute 36% decrease in 10-year disease-
specific survival in males compared to a 21% decrease in females171 and MMP-2-negative 
male patients had equal survival to MMP-2-negative female patients171,172, suggesting 
that MMP-2 expression caused a male disadvantage in survival.
Sex hormone-related differences in MMP-2 expression have been observed but are 
contradictory: estrogen caused a decrease in intra- and extracellular MMP-2 in fibro-
blast cultures173 however estradiol increased MMP-2 activity in human granulosa-lutein 
cells174. Interestingly, the inhibitor of MMP-2 i.e. TIMP-2 has been found to be more 
abundantly expressed in stromal cells of female melanoma patients175.
Unfortunately, MMP-2-inhibitors (e.g. marimastat) showed disappointing effects 
in melanoma patients170, e.g. in metastatic melanoma only very limited activity was 
observed176. However, MMP-2 expression might still be implicated in the gender differ-
ences in melanoma survival. 
Skin Physiology
Many physiologic aspects of the skin are influenced by gender. Males have a thicker der-
mis, females have a thicker epidermis and subcutaneous tissues, most likely mediated 
by estrogens177,178. Epidermis barrier function (stratum corneum integrity, transepider-
mal water loss) is better in females179 and skin pH level seems to be higher in females177. 
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Furthermore, estrogen increases collagen synthesis in the (epi)dermis133,180 and improves 
the extracellular matrix181. Some of these structural differences in the skin across gender 
might influence melanoma local progression, invasion and metastasis. However, as 
many of these differences in skin physiology differences seem estrogen-regulated and 
research showed that estrogen levels and menopausal age were not associated with 
melanoma prognosis, it seems unlikely that skin physiology differences are the main 
explanation for the gender differences in survival.
Vitamin D
Increasing evidence suggests Vitamin D to be associated with melanoma progression 
and survival. Sunlight induces production of Vitamin D in the skin. Its metabolite, 
1.25-hydroxyvitamin D3 or calcitriol, inhibits proliferation and increases apoptosis and 
cell differentiation in melanoma cells182,183. This effect is mediated by the binding to 
the intranuclear Vitamin D receptors (VDRs) affecting important melanoma signaling 
pathways such as the MAPK and the PI3K-AKT pathways182. In melanoma patients, higher 
Vitamin D serum levels at diagnosis were associated with a thinner tumors and lower 
melanoma relapse and death rates184 and a decreased VDR expression was correlated 
with melanoma proliferation, progression and metastasis185.  
In research on multiple sclerosis (MS), marked gender differences were observed for 
the therapeutic effects of Vitamin D: in mice, Vitamin D supplements decreased disease 
severity only in females, not in males, apparently caused by slower inactivation of cal-
citriol by CYP24A1 in females186. In MS patients ánd healthy subjects, the immunomodu-
latory effects of Vitamin D were observed to be stronger in females compared to males 
despite similar serum calcitriol levels187. The authors concluded that Vitamin D-based 
therapy might have a greater effect in women. 
In melanoma patients, no gender differences seem to exist in vitamin D serum levels188. 
However, the actual effect of Vitamin D might differ across gender irrespective of serum 
levels187. Indeed, one study suggested a link between gender, Vitamin D and melanoma: 
an inverse relationship between dietary Vitamin D and melanoma risk was found, with a 
stronger protective effect in males189. This seems counter-intuitive but possibly females 
had less to gain from extra dietary Vitamin D as their natural vitamin D already protected 
them more efficiently than in males. 
Summarizing, evidence is accumulating that Vitamin D is involved in melanoma progres-
sion and survival. Clearly, gender influences the metabolism and immunomodulatory effects 
of Vitamin D. It is therefore conceivable that Vitamin D is a mediator for the gender differ-
ences in survival. 
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Obesity
Research concerning obesity and melanoma focuses mainly on melanoma incidence, 
mostly reporting a significantly higher melanoma risk in obese patients compared to 
people of normal weight190-196. although other studies did not observe this association 
between melanoma and obesity197-200. Remarkably, a number of studies found gender 
differences in the effect of obesity: a USA case control study201, a large Norwegian co-
hort202 and a meta-analysis including 7 melanoma cohort studies203 all found weight or 
BMI to affect melanoma incidence only in males, which was recently confirmed in a large 
meta-analysis204. In line with these findings, no association with BMI and melanoma was 
found in the Million Women Study205. 
Although obesity does not seem to influence melanoma recurrence206, there is some 
laboratory evidence that obesity influences melanoma progression: diet-induced obe-
sity increased pulmonary metastasis in a melanoma mouse model207. 
Several metabolic processes and hormone levels might influence melanoma risk and 
progression in obese patients. Serum levels of the hormone leptin increase with obesity 
and are associated with melanoma208. Possibly, leptin increases melanoma proliferation 
through MAPK209 or Vascular Endothelial Growth factor (VEGF)210 pathway activation. 
Adiponectin is a hormone inversely associated with obesity and was found to be protec-
tive of several obesity-related cancers. This protection was sizeable but non-significant 
for melanoma197. Importantly, melanoma was observed to express adinopectin recep-
tors211. Hyperglycemia (high fasting glucose levels) is positively associated with both 
obesity and melanoma risk212. High glucose levels also play a role in oxidative stress, 
which might have procarcinogenic effects (see above)213. Estrogens might play a role as 
they are produced in fat tissue214. Indeed, one study found a possible interaction of the 
association between melanoma and obesity with menopause215.  
Summarizing, obesity seems to play a role in the incidence and possibly also in the pro-
gression of melanoma, possibly mediated by various metabolic and hormonal processes. 
Evidence suggests that males get a higher ‘penalty for melanoma’ for obesity compared to 
females. These links between obesity, gender and melanoma are a possible explanation for 
the observed female melanoma survival.
Treatment
Melanoma treatment allocation does not seem to differ by gender: gender did not influ-
ence surgical excision margins, delay to definitive surgery, the use of sentinel lymph 
node biopsy and subsequent complete lymph node dissection, the use of adjuvant 
therapies or surveillance protocols216,217.  
If biological factors cause gender differences in survival, this could also interfere with 
melanoma treatment. In the 1970’s, a better response to melanoma chemotherapy, 
especially dacarbazine, was reported in women130,142,218 although the male survival dis-
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advantage was mainly attributed to faster growing tumors rather than response to 
therapy219. A 1992 report showed a better response in women than in men when adding 
tamoxifen to dacarbazine treatment220, which was confirmed by a recent meta-analysis221. 
However, generally tamoxifen is not considered an effective melanoma therapy126. No 
gender differences in response or time to progression were observed for isolated limb 
perfusion using melphalan222. There were no differences in the female survival advan-
tage between patients receiving interferon compared to observation in EORTC trials for 
localized melanoma11 nor for stage III melanoma13. Treatment effects seem equal across 
gender for ipilimumab150 as well as for the BRAF V600E inhibitor vemurafenib223. Finally, 
when stratifying patients in categories of surgery for the primary tumor (i.e. biopsy, 
wide excision or amputation), equal female survival advantages in each category were 
observed45. 
Summarizing, the majority of studies found no gender differences in melanoma treatment 
effects.
CONCLUSION
In this review we attempted to present several explanations for the known female sur-
vival benefit in both localized and metastasized melanoma. Behavioral differences across 
gender might be able to partly explain these gender differences in survival but there 
seems to be a biological factor underlying the independent female survival advantage. 
There is no clear evidence that the primary tumor differs across gender in aggressive-
ness measured by mitotic rate, mutation status or in the divergent pathways model. Our 
literature search yielded several possible biological explanations influenced by gender 
and associated with melanoma, including estrogens, estrogen receptors, androgens, 
immune factors, autophagy, reactive oxygen species / oxidative stress, MMP-2, skin 
physiology, vitamin D and obesity. There was no evidence that therapeutic strategies 
influenced gender differences in survival. So far, most of the suggested explanations 
lack laboratory and clinical evidence. Therefore, more research is needed to unravel this 
intriguing phenomenon in melanoma. 
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The female advantage is highly consistent
In this thesis we show that the observation of dr. Clark in 1969 was correct: indeed, 
melanoma is “somewhat less malignant in the female when compared with the male”1. 
For local melanoma we can quantify this ‘somewhat less malignant’ to an approximate 
30% advantage in female patients compared to their male counterparts. After earlier 
work in the Netherlands Cancer Registry2 we showed in three unrelated databases this 
advantage to be highly consistent: in the unique population-based Munich Cancer 
Registry (MCR) with respect to its recording of recurrence and metachronous metastasis 
(chapter 2.1), females had a 31% advantage in overall survival (Hazard Ratio (HR) 0.69, 
with a 95% Confidence Interval (CI) 0.64-0.74) and 28% in disease-specific survival (HR 
0.62; 95%CI 0.56-0.70). In the four European Organization for Research and Treatment 
of Cancer (EORTC) randomized controlled trials with localized melanoma (chapter 2.2), 
this advantage in overall survival amounted to 30% (HR 0.70, 95% CI 0.59-0.83) and 26% 
in disease-specific survival (HR 0.74, 95%CI 0.62-0.88) Finally, in the Melanoma Institute 
Australia (MIA) database (chapter 2.4) females had a 36% disease-specific survival 
advantage (HR 0.64; 95% CI 0.55-0.75). When we investigated other endpoints, such as 
relapse-free survival, or distant metastasis free survival, the female advantage showed 
a comparable magnitude of approximate 30% (chapter 2.1 table 3 and chapter 2.2 
table 2). Moreover, when we compared our results to other large studies on localized 
melanoma, this advantage of approximately 30% was highly consistent: virtually all 
studies showed an estimate of the female survival advantage between 20% and 40% 
(chapter 2.2, table 4). 
The female advantage persists but decreases in more advanced melanoma
In advanced disease i.e. melanoma metastasized to lymph nodes (stage III) or distant 
organs (Stage IV), the female advantage persisted but with a smaller magnitude. In 
the MCR (chapter 2.1), females had a 20% disease-specific survival advantage in stage 
III (HR 0.80; 95% CI 0.66-0.96) and a borderline significant 11% advantage in stage IV 
(HR 0.89, 95% CI 0.78-1.03). In five EORTC trials (chapter 2.3) the female advantage 
for disease-specific survival in stage III melanoma was 15% (HR 0.85; 95% CI 0.76-0.95) 
and 19% in stage IV (HR 0.81; 95% CI 0.72-0.92). So, compared to the 30% advantage in 
localized melanoma, this advantage of 10-20% is considerably smaller in metastasized 
melanoma. Possibly, this also applies when the disease has metastasized even further: in 
the EORTC data, the female advantage disappeared in patient categories with the high-
est metastatic burden; for example, in patients with 3 or more sites of distant metastasis 
(HR 0.93; 95% CI 0.76-1.15) and in patients with 100 or more millimetres of measured 
diameters of the target lesions (HR 0.97; 95% CI 0.77-1.21). However, the interaction 
terms for these variables with gender were non-significant and therefore the estimates 
in these subgroups should be interpreted with caution.  
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If we consider the female advantage from localized melanoma to different stages of 
progression, we find a 30% advantage in localized melanoma, a 10-20% advantage in 
metastasized melanoma, and possibly no female advantage in those patients with the 
heaviest metastatic burden. Possibly, when expected survival becomes shorter because 
of more extensively disseminated disease, the underlying mechanism granting females 
a survival advantage is not able to have the same impact on prognosis as it does in 
localized, less aggressive melanomas. In other words: when the disease becomes too 
aggressive, even females can no longer withstand or delay it.
Only tumour thickness and tumour localization influence the gender effect on 
prognosis
This female survival advantage of 30% in localized melanoma and 10-20% in advanced 
melanoma was the result of adjusting survival analyses for all other available prognostic 
factors in each database, and therefore gender seems to be an independent prognostic 
indicator in cutaneous melanoma. Nevertheless, to understand possible underlying 
mechanisms, it remains interesting which of these other prognostic factors influence 
the gender effect on melanoma. In two studies, we investigated which other prognostic 
factors induce a change to the gender hazard ratio when added in a multivariate model 
alongside with gender. 
In the German MCR database, we checked for each endpoint which other variables 
caused a shift of 10% or more in the excess risk of dying of males. Only Breslow thickness 
caused a shift of this magnitude in overall and disease-specific survival after primary di-
agnosis (chapter 2.1, table 2). When investigating several other endpoints and survival 
after first recurrence of melanoma, only two variables caused this shift of ≥10% in the 
majority of investigated endpoints: again Breslow thickness and the localization (body 
site) of the primary melanoma (chapter 2.1, table 3&4). The results using the Australian 
MIA database yielded similar results: when adding the available variables in a forward 
step manner, the only two variables which showed any impact on the gender hazard 
ratio were, again, Breslow thickness and localisation of the primary tumour (chapter 
2.4, table 4). Together, these two variables caused a shift from a crude gender hazard 
ratio of 0.50 to 0.65 (95% CI 0.56-0.76). All other variables (age, ulceration, histologi-
cal subtype, mitotic rate, Clark level and year of diagnosis) did not affect the HR of the 
female advantage. 
Summarizing our findings, in two separate databases from two different continents, 
only Breslow thickness and localisation of the primary melanoma had a considerable in-
fluence on the gender difference in survival and progression. After adjustment of these 
variables, gender remained a significant independent predictor of melanoma survival. 
Remarkably, exactly these two variables have been linked to explanations involving 
patient behaviour for the female advantage in melanoma.
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Gender differences in behaviour are not the explanation
As extensively described in chapter 3.2, it is plausible that behavioural aspects influ-
ence the Breslow thickness of the primary melanoma. Participation in screening, clinical 
and skin examination and increased levels of knowledge about melanoma have all 
been associated with thinner melanomas at diagnosis3,4. It is known that females more 
often engage in screening activities5,6, have more knowledge about melanoma7-11 and 
are less reluctant to visit health care workers than males12,13. It is therefore likely that 
the thinner tumours observed in females are at least partly caused by earlier diagnosis 
caused by these behavioural factors. Several authors hypothesized earlier detection in 
females to be (part of ) the explanation of their superior survival compared to their male 
counterparts3,14,15. The rationale behind this is that earlier detection translates into both 
thinner tumours and earlier stages of melanoma at diagnosis (i.e. not yet metastasized). 
As explained above, indeed tumour thickness reduces the female survival advantage, i.e. 
adding in the model causes shift of the gender HR towards 1. Therefore, thinner Breslow 
thickness at diagnosis in females does seem to explain a part of the female advantage. 
The other variable often linked to behaviour is the localization of the primary tumour. 
It is well known that a striking difference across gender exists for the body site where the 
primary melanoma is found. In females, the lower extremities are the site where most 
melanomas are diagnosed, while males have far more melanomas diagnosed on their 
trunk2,4,16-19. It is conceivable that this is caused by differences in sun exposure behaviour 
across gender, e.g. skirts / shorts in females and no coverage of the upper body in males 
or differences in occupational sun exposure or differences in the use of sun protection20. 
However, researchers also found the same pattern of body distribution of nevi across 
gender, which was independent of sun exposure, was already present in early child-
hood19,21, even in children strictly protected from sun exposure by religious costumes22. 
Therefore, the gender differences in body site distribution of melanoma might not (only) 
be related to sun exposure behaviour, but also to some unknown mechanism causing 
gender differences in distribution of nevi and / or melanocytes.
As melanoma on the trunk is associated with more aggressive behaviour compared to 
melanomas on the (lower) extremities, the gender difference in primary localization has 
been put forward as a possible explanation for the female advantage in melanoma15,23. 
Indeed, in our studies in Munich and Australia, adjustment of the gender effect for 
survival or progression by localization of the primary tumour did cause a shift towards 1 
in the crude hazard ratios, i.e. it reduced the female survival advantage. However, in our 
studies, an independent gender difference in survival persisted after this adjustment 
(chapter 2.1, 2.2, 2.4), and therefore primary tumour localization cannot fully explain 
the female advantage in melanoma survival  which has also been observed by several 
other researchers17,24,25.
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If we look at the results from the MIA study in Australia, 30% of the total female advan-
tage was explained by Breslow thickness and tumour localisation (a shift from a crude 
HR of 0.50 to an adjusted HR of 0.65, chapter 2.4). If we regard Breslow thickness and 
primary tumour localization as two variables linked to behavioural differences across 
gender, as described above, then we could consider the 30% adjustment these two vari-
ables cause on the gender hazard ratio as the part of the female advantage caused by 
behaviour. This then leaves an independent prognostic effect of gender on melanoma, 
which should be caused by other mechanisms.  
Three further arguments support the hypothesis that behaviour cannot fully explain 
the female advantage in melanoma survival. Firstly, gender differences in melanoma 
metastasis have also been noted in controlled animal experiments26,27. Secondly, the 
gender difference in survival is highly consistent across continents: the same magnitude 
of an approximate 30% female advantage has been noted in Europe, Australia and The 
United States (chapter 3.2, table 1). This is even more remarkable when we consider 
gender differences in melanoma incidence across these continents: In Australia and 
New-Zealand, males have a higher melanoma incidence than females (age standardized 
incidence rates (ASR; World population) per 100,000 of 42 vs. 32, respectively), as well 
as in North America (ASR of 16 in males vs. 13 in females), however in Europe incidence 
is higher in females (ASR of 7.8 in females vs. 7.6 in males, see also chapter 1). So even 
when incidence ratios between males and females differ so greatly for these continents 
–which is probably caused by sun exposure and behavioural or cultural gender differ-
ences– the female advantage in survival remains highly consistent around the world. 
Thirdly, if the worse prognosis in males would be caused by delayed presentation to 
their doctors when disease is more often already metastasized, there should be no sur-
vival advantage for females in metastasized disease stages. However, we showed that 
gender does persist as an independent prognostic factor in metastasized melanoma 
(chapter 2.1, 2.3). 
Possible biological explanations: is it the tumour?
If behavioural differences do not explain the female advantage, it is likely that biological 
differences across gender are causing this phenomenon. First, we could consider the 
tumour itself: do males somehow get different, more aggressive tumours than females? 
In chapter 2.4, we used the MIA database to investigate whether tumours in males are 
inherently more aggressive than tumours in females as measured by tumour mitotic 
rate. We found that in a multivariate negative binomial regression model, mitotic rate 
did not differ between males and females (chapter 2.4, table 3). Therefore, being of 
male gender did not predispose patients to more aggressive tumours. Furthermore, 
adjusting the multivariate survival model for mitotic rate did not cause any change in 
the hazard ratio for gender, showing that there was no interaction between gender and 
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mitotic rate in predicting survival. Therefore, the aggressiveness of the primary tumour 
does not seem to be able to explain the female survival advantage in melanoma. The 
notion that the tumour itself does not really differ across gender is confirmed by several 
studies showing no gender differences in mutation rates of some important genes in 
melanoma (chapter 3.2), most notably in the BRAF gene28-33. Finally, as we discussed 
above, other primary tumour characteristics such as thickness, location on the body and 
ulceration do not (fully) explain the female survival advantage. 
Then, is it the host?
As there do not seem to be gender differences across the primary tumours which are 
able to explain the gender differences in survival, the other option is that differences 
in the host have an effect on melanoma: either males have some factor that promotes 
melanoma growth, invasion or metastasis, or females possess some factor that inhibits 
their melanomas to progress. 
In the literature, five theories have been put forward to be the answer to this mystery 
in melanoma. Firstly, based on observations and experiments, we theorized that the 
different handling across gender of reactive oxygen species and the consequent oxi-
dative stress might offer an explanation. We set out this hypothesis in chapter 3.1. In 
short, evidence is accumulating that reactive oxygen species are important mediators in 
melanoma progression and metastasis, through a wide range of mechanisms. Further-
more, it is known that females have a higher capacity of ROS-neutralizing mechanisms. 
Therefore, we speculated that this makes females better equipped to resist melanoma 
progression and metastasis. 
Secondly, Ladanyi et al. showed that female SCID mice showed less liver metastases 
after injecting melanoma cells in the spleen27. Recently the same group showed that this 
phenomenon was not influenced by treatment with sex steroids. However, this gender 
difference in liver metastasis was lost after blocking Natural Killer (NK) cell activity in 
both sexes, leading the authors to hypothesize that NK cells represent a critical host de-
fence mechanism against melanoma metastasis and might be implicated in the gender 
differences in survival of melanoma26. 
Thirdly, matrix metalloproteinases (MMP’s), especially MMP-2 have been implicated 
in melanoma progression, invasion and metastasis34. Two studies found that MMP-2 
positivity in tumours was associated with worse prognosis, with a far greater detrimen-
tal effect in males than females35,36. They observed poor prognosis of males with MMP-2 
positive tumours but equal prognosis for MMP-2 negative males and MMP-2 negative 
females. Therefore, they stated that MMP-2 tumour positivity might explain the gender 
differences in melanoma survival. 
The fourth and most often mentioned host-related explanation for the observed 
female advantage in melanoma are estrogen levels. This is supported by findings of 
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several studies that the female advantage disappears in postmenopausal age groups, 
when estrogen levels in female fall16,17,23,37,38. However, a far greater number of studies 
showed the opposite: postmenopausal females still had a survival advantage compared 
to their male counterparts in both localized and metastasized melanoma2,39-46, which 
is also supported by our findings in chapters 2.1, 2.2, 2.3 and 2.4. Other arguments 
against a role of estrogen levels in the female advantage include studies showing no 
association between estrogen levels and disease progression47,48, studies showing no 
influence of pregnancy on prognosis49,50 and the lack of effect of the estrogen inhibitor 
Tamoxifen on the prognosis and survival of melanoma51.  
Finally, de Giorgi et al. found that the of Estrogen Receptor β (ERβ) in melanoma cells 
was associated with melanoma progression and metastasis52. In another study of the 
same group (premenopausal) females had significant higher levels of ERβ expression 
compared to males53.  Furthermore, an increased loss of ERβ expression in tumour cells 
compared to healthy adjacent skin cells was found in males than in females53. Following 
these observations, the authors hypothesized that higher ERβ expression in women 
might inhibit melanoma proliferation, leading to a survival advantage compared to men 
with lower ERβ expression52. 
These five explanations for the gender phenomenon specifically mentioned in litera-
ture are reviewed in more detail in chapter 3.2. There we also mention several other 
possible explanations, which we will outline shortly below and which are discussed 
more elaborately in chapter 3.2 as well.  
As the female advantage seems irrespective of the hormonal status of the female host, 
androgen levels have been proposed as the explanation for this phenomenon54. Indeed 
androgen receptors have been found in melanoma cells, especially in metastases55.   
Above, we already mentioned NK cells as a possible host factor influencing melanoma 
progression and survival, but also other immune system factors might be involved. 
Melanoma is, even more than other types of cancer, considered a immunogenic tumour 
and immune factors can both stimulate melanoma progression and induce tumour 
regression56,57. Females are generally considered to have a stronger immune system than 
males: they produce more vigorous cellular and humeral immune responses58, have 
higher rates of auto-immune diseases59 and female mice produce a higher inflammatory 
response in the skin than male mice when exposed to UV radiation60. Considering these 
links between gender, immune homeostasis and melanoma, it is conceivable that im-
mune factors play a role in the female survival advantage in melanoma. 
Physiological differences across gender in the structure of the skin might also play 
a role in melanoma progression, especially in the early stages when the localized 
melanoma has to invade and migrate through the skin to be able to metastasize. Indeed, 
females have thicker epidermis and subcutaneous tissue61 and the epidermis barrier 
function in females is better than in males62. 
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An increasing amount of evidence is suggesting that Vitamin D inhibits melanoma 
progression: e.g. a retrospective study found higher serum levels of vitamin D at diag-
nosis to be associated with thinner tumours and lower relapse and death rates in mela-
noma patients63. In Multiple Sclerosis research,  gender has been found to profoundly 
influence the treatment effect of vitamin D: in mice, disease severity was decreased only 
in female animals64, and in human patients, immunomodulatory effects were stronger in 
females than in males, irrespectively of vitamin D serum levels65. Therefore, a potential 
protective effect of Vitamin D in melanoma could also be gender-dependent.
Multiple studies show that the incidence of melanoma is higher in obese people, 
but only in males66-69. Obesity may also affect melanoma survival: in a mouse model, 
melanoma pulmonary metastasis was increased in diet-induced obese mice70. As epide-
miological research concerning melanoma incidence and obesity shows these remark-
able gender differences, obesity may also affect melanoma progression and survival in 
a gender-dependent manner and could therefore contribute to the female advantage 
in melanoma survival.
Conclusion 
In this thesis we state that the female advantage in melanoma is not fully explained 
by behavioural differences across gender. Therefore, a biological difference across 
gender seems to cause this gender difference in survival, which is considerably larger 
in melanoma than in any other type of cancer. Further epidemiological and genetic 
research suggests that this biological difference does not so much involves the primary 
tumour itself, as this do not seem to differ between males and females. Therefore, we 
hypothesize that a biological difference in the host rather than in the tumour is granting 
females this advantage. 
As summarized above, there are several biological factors which both have been linked 
to melanoma progression and survival and show different effects across gender. These 
factors –reactive oxygen species, androgen levels, estrogen levels, estrogen receptor 
β, MMP-2, immune homeostasis, NK-cells, physiology of the skin, vitamin D and obe-
sity- might be involved in the underlying mechanisms causing the female advantage in 
melanoma progression and survival. However, future research is needed to confirm any 
of these factors to be (part of ) the mechanism which causes these gender differences 
in progression and survival. If we can find the cause of this 30% advantage of female 
patients in localized melanoma and 10-20% in metastasized melanoma, this might 
result in new treatment targets for melanoma. To identify this cause, we recommend all 
melanoma research to take gender into consideration, preferably by stratifying results 
by gender. If we find factors that either selectively favour female melanoma patients or 
cause a disadvantage in male patients, we might have a clue where to look to solve this 
gender mystery in melanoma. 
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SUMMARY
The aim of this thesis was to further investigate the gender differences in melanoma 
progression and survival. For this purpose we conducted four epidemiological studies 
using different databases, and two literature studies.
In chapter 2.1 we investigated the female advantage in survival of melanoma in the 
Munich Cancer Registry (MCR). The MCR uniquely registers not only cancer incidence 
and survival, but also cancer progression, i.e. lymph node and distant metastasis in the 
Bavarian region of Germany. This allowed us for the first time to study not only survival 
differences across gender, but also differences in progression and survival after progres-
sion of the primary melanoma. After adjustment of all other prognostic factors, female 
patients had a significant survival advantage compared to males for overall (31%) and 
disease-specific survival (38%). A female advantage of the similar magnitude was found 
for time to disease recurrence (32%), time to lymph node metastasis (42%) and time 
to distant metastasis (36%). No differences in the female advantage were found for 
metastasis to different target organs (brain, liver or lung). Furthermore, females also 
exhibited better survival after melanoma recurrence (19%), as well as after lymph node 
metastasis. For survival after distant metastasis, gender was only borderline significant. 
In conclusion, female gender was an independent favorable prognostic indicator in 
melanoma from diagnosis to death and in between for all pathways of metastasis. The 
only exceptions to this rule were the risk on having a local recurrence or in-transit / satel-
lite metastasis. Finally, when adjusting the crude female advantage for other prognostic 
indicators, the main confounders of the female advantage were Breslow thickness and 
body site localisation of the primary tumor. Other prognostic indicators, e.g. age and 
histological subtype had very little or no effect on the female advantage. 
In chapter 2.2 we further investigated the female advantage in melanoma using 
data from patients with localized melanoma (AJCC stage I and II) enrolled in four 
randomized controlled trials of the European Organisation for the Research and Treat-
ment of Cancer (EORTC) Melanoma Group. In contrast to the population-based study 
in chapter 2.1, complete information was available for all important confounders i.e. 
Breslow thickness, body site and ulceration. Again, we found a highly consistent female 
advantage for disease-specific and overall survival, as well as for the different endpoints 
describing disease progression (relapse-free survival and time to in-transit, lymph node 
and distant metastasis). When comparing our results to those published in literature, a 
highly consistent and robust independent female advantage emerged which amounted 
to approximately 30%. This was also highly consistent in virtually every subgroup as 
categorized by the different prognostic indicators.
In chapter 2.3 we used data from five EORTC randomized controlled trials concerning 
patients with AJCC stage III and IV melanoma to investigate the female advantage in me-
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tastasized melanoma. We found a consistent female advantage although slightly smaller 
than in localized melanoma, of 15-20%, even after adjustment for different confound-
ers indicating metastatic tumor load. This female advantage was found in overall and 
disease-specific survival as well as in relapse free survival and time to distant metastasis 
in stage III and progression-free survival in stage IV. Although non-significant, it seemed 
that the female advantage declined within subgroups of higher metastatic tumor load 
in stage IV. The magnitude of the female advantage was comparable to other studies 
in stage III and to another study based on trial data in stage IV patients. Other studies 
using population-based data showed a slightly lower female advantage, possibly due to 
a higher proportion of patients with a high metastatic load and therefore smaller female 
advantage. 
In chapter 2.4 we used the data from the Melanoma Institute Australia (MIA) to test the 
hypothesis that a more aggressive tumor in males, as measured by the mitotic rate, may 
be the reason behind the observed female survival advantage. However, when adjusted 
for other prognostic indicators, males did not have a significant higher mitotic rate in 
their primary tumors. Moreover, adding mitotic rate in a cox proportional hazard model 
did not affect the female survival advantage at all. Therefore, we concluded that males 
do not have a more aggressive phenotype of their primary tumor and therefore differ-
ences in the host are more likely to be the cause of their relative survival disadvantage. 
In chapter 3 we searched literature for possible explanations for the observed gender 
differences in melanoma survival. In chapter 3.1 we pose the hypothesis that a more ef-
ficient handling of reactive oxygen species by females explains their survival advantage. 
Reactive oxygen species (ROS) cause oxidative stress, which is increasingly implicated 
in tumor progression and metastasis by a wide range of mechanisms. This might be 
especially be true for melanoma compared to other types of cancer, as the healthy 
counterpart of the melanoma cell, the melanocyte, produces ROS in high quantities as 
a by-product of melanogenesis. Therefore, management of high ROS levels might be 
retained in melanoma cells, and play a key role in their progression and metastasis. As 
the female host better equipped to resist the ROS-induced oxidative stress caused by 
the melanoma cells, this might explain their lower rate of progression and metastasis 
and finally their higher survival rates.
In chapter 3.2 we discussed the hypothesis that behavioral differences (e.g. females 
visit their health care worker sooner than males and are therefore diagnosed earlier, 
or sun exposure behavior differences) explain the survival differences across gender. 
We conclude that this hypothesis cannot fully explain the female survival advantage. 
Subsequently, we presented alternative biological gender differences as explanations 
for the female survival advantage extracted from literature. Possible explanations had 
to be related to melanoma progression or survival and should exhibit a difference across 
gender. This yielded the following explanations: different types of tumors, hormonal fac-
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tors (estrogens, estrogen receptors, androgens), the immune system, skin physiology, 
vitamin D, obesity, autophagy and matrix metalloproteinase-2 (MMP-2). 
In conclusion, we showed that gender is a highly consistent, independent prognostic 
factor in melanoma, as well as for survival and different types of progression. This was 
true for localized and metastasized melanoma. Behavioral factors do not seem to be 
able to fully explain this prognostic value of gender. As males do not seem to have truly 
more inherently aggressive primary tumors, it seems likely that differences in the host, 
i.e. some female trait which inhibit melanoma progression or a male trait promoting 
melanoma progression, is causing these gender survival disparities. We suggested 
several biological factors as possible explanations for this phenomenon. Future research 
is needed to confirm if any of these factors is truly related to the female survival advan-
tage. If we unravel the mechanisms of this gender effect in melanoma, this may lead to a 
better understanding of melanoma biology and possibly new therapeutic targets. 
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Het melanoom van de huid is een kwaadaardige tumor uitgaande van melanocyten, 
de cellen die zich in de huid bevinden en dan vooral in moedervlekken. Dit type kanker 
komt steeds vaker voor in Europa en de Verenigde Staten en ook in Nederland blijft 
het aantal mensen wat melanoom krijgt elk jaar toenemen. Melanoom komt het meest 
voor in Europa, de Verenigde Staten en vooral in Australië en Nieuw-Zeeland. Een lo-
kaal in de huid gevonden melanoom kan goed behandeld worden door de tumor en 
een ruime marge gezonde huid eromheen chirurgisch te verwijderen. Een uitgezaaid 
melanoom heeft echter een zeer slechte prognose; een melanoom uitgezaaid naar een 
ander orgaan leidt vrijwel altijd tot het overlijden van de patiënt, vaak al binnen een jaar. 
Decennia lang was hier geen effectieve behandeling voor, echter recent zijn er enkele 
nieuwe medicijnen ontdekt die een kleine maar significante verlenging van leven geven 
bij patiënten met uitgezaaid melanoom. Het voordeel voor patiënten van deze nieuwe 
medicijnen is weliswaar klein maar het is hoopgevend dat er nu enkele middelen zijn 
goedgekeurd om uitgezaaid melanoom te behandelen en nu doorontwikkeld worden 
voor een beter en duurzaam effect.
De kans dat een lokaal melanoom uitzaait en dus echt levensbedreigend wordt, wordt 
bepaald door meerdere “prognostische factoren”, o.a. de dikte van het melanoom, of het 
wel of niet geulcereerd is, de leeftijd van de patiënt en de lokatie van de tumor op het 
lichaam. 
Dit proefschrift heeft als doel om een andere opvallende prognostische factor te 
onderzoeken: het geslacht van de patient. In dit proefschrift onderzoeken we de ver-
schillen tussen mannen en vrouwen in de progressie en de overleving van het mela-
noom van de huid en proberen hier een verklaring voor te vinden. Hiervoor voerden we 
vier epidemiologische studies uit in verschillende databases, en twee literatuurstudies. 
In hoofdstuk 2.1 onderzochten we het verschil in overleving van het melanoom 
tussen mannen en vrouwen in de Kankerregistratie van München (MCR). De MCR reg-
istreert alle nieuwe gevallen  van kanker in een derde deel van de deelstaat Beieren in 
Duitsland in meer dan 75 ziekenhuizen en klinieken. De MCR is uniek in vergelijking met 
andere kankerregistraties omdat het óók de progressie van kanker, zoals uitzaaiingen 
(metastases) naar lymfeklieren en andere organen registreert. Hierdoor konden we 
voor de eerste keer niet alleen de verschillen tussen mannen en vrouwen in overleving 
onderzoeken, maar ook de verschillen in progressie en overleving ná metastases. In de 
statististische analyses konden we aanpassen voor vele prognostische factoren van het 
melanoom. Dit zijn factoren die de kans op overleven na een melanoom beïnvloeden, 
bijvoorbeeld leeftijd, dikte, en lokatie van de eerste huidtumor. Na aanpassen voor 
deze en andere factoren hadden vrouwelijke patiënten een significant voordeel voor 
algehele overleving (31%) en ook  voor de melanoom-specifieke overleving (38%). Een 
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vergelijkbaar voordeel werd gezien voor het krijgen van een lymfeklier-uitzaaiing (42%) 
of een uitzaaiing naar een ander orgaan (36%). Als we alle uitzaaiingen samen namen 
was dit voordeel voor de vrouwen 32%. Er werden geen verschillen gevonden tussen 
mannen en vrouwen voor  welk orgaan het melanoom naar uitzaaide, bijvoorbeeld 
naar de hersenen, longen of lever. Vrouwen hadden wel een betere overleving ná hun 
eerste uitzaaiing (19%), dit goldt vooral als deze uitzaaiing in een  lymfeklier zat (20%). 
Voor de overleving ná een uitzaaiing naar andere organen was het overlevingsverschil 
tussen mannen en vrouwen net niet significant (11%, 95% betrouwbaarheidsinterval 
-3%-12%). De conclusie was dat geslacht een onafhankelijk prognostische factor is, 
met een duidelijk voordeel voor de vrouwen. Dit voordeel was zichtbaar in de totale 
“levensloop” van een melanoom: vanaf de diagnose, naar alle verschillende vormen 
van mogelijke uitzaaiingen, tot uiteindelijk het overlijden. Ook onderzochten we welke 
andere prognostische factoren van invloed waren op het vrouwelijke voordeel in over-
leving en progressie. Dit gold alleen voor de dikte van het melanoom en de plaats op het 
lichaam van de eerste tumor: alleen deze factoren zorgden -als zij werden toegevoegd 
in het multivariate model- voor een verschuiving van meer dan 10% van het vrouwelijk 
voordeel. Andere prognostische factoren, zoals leeftijd en het histologisch subtype, 
hadden geen invloed op het vrouwelijke voordeel. 
In hoofdstuk 2.2 onderzochten we het vrouwelijk voordeel voor de overleving en 
progressie van het melanoom in een database met patiëntgegevens uit vier geran-
domiseerde klinische trials voor de behandeling van een gelokaliseerd melanoom 
(stadium I en II). Deze vonden plaats  in de jaren 1984-2005 en werden uitgevoerd door 
de de Melanoma Group van de European Organisation for Research and Treatment of 
Cancer (EORTC). In deze database hadden we van alle deelnemende patiënten extra 
informatie over vele andere belangrijke prognostische factoren, te weten Breslow dikte 
en de lokalisatie en ook ulceratie van het primaire melanoom. Tevens was er uitgebreide 
en betrouwbare informatie beschikbaar over de progressie van de ziekte en overlev-
ing voor alle patiënten. Opnieuw vonden we een consistent en significant vrouwelijk 
voordeel voor ziekte-specifieke en totale overleving. Ook vonden we weer een voordeel 
voor de vrouwen als we keken naar progressie van de ziekte; te weten het krijgen van 
een eerste uitzaaiing, het krijgen van een in-transit uitzaaiing, uitzaaiing in de lymfeklier 
of in een ander orgaan. Nadat we al onze resultaten en de resultaten uit eerder gepub-
liceerde literatuur op een rijtje hadden gezet, zagen we een zeer consistent en robuust 
voordeel voor de vrouwelijke patiënten van ongeveer 30%. Dit bleek ook consistent in 
vrijwel elke prognostische subgroep.
In hoofdstuk 2.3 gebruikten we vijf gerandomiseerde trials van de EORTC met 
patiënten met een melanoom uitgezaaid naar de lymfeklieren (stadium III) of patiënten 
met een metastase op afstand (stadium IV). We vonden we een consistent vrouwelijk 
voordeel van 15-20%; iets kleiner dan bij patiënten met een nog niet uitgezaaid mela-
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noom. Dit voordeel bleef bestaan na aanpassing voor andere prognostische factoren die 
de “tumor load” weergaven, bijvoorbeeld het aantal uitzaaiingen, het aantal aangetaste 
organen, of de grootte van de metastases. Opnieuw was het voordeel zeer consistent 
voor de verschillende analyses voor overleving en progressie: vrouwen hadden een 
significant voordeel voor de totale en de ziekte-specifieke overleving, en ook voor het 
verder voortschrijden van de ziekte: de tijd tot een uitzaaiing naar een ander orgaan in 
stadium III en het verder groeien van uitzaaiingen in stadium IV. Hoewel niet significant 
leek het alsof het vrouwelijk voordeel steeds kleiner werd naarmate er meer of grotere 
uitzaaingen waren in stadium IV. De grootte van het vrouwelijk voordeel was vergeli-
jkbaar met eerder in de literatuur gepubliceerde resultaten voor zowel stadium III als 
stadium IV. 
In Hoofdstuk 2.4 gebruikten we data van het wereldbekende Melanoom Instituut 
Australia (MIA) in Sydney om de hypothese te testen dat het vrouwelijk voordeel in de 
prognose van melanoom veroorzaakt wordt door een agressievere tumor bij mannen, 
gemeten door het aantal celdelingen geteld onder de microscoop (‘mitotic rate’). Echter, 
na aanpassing voor de andere prognostische factoren was geslacht geen voorspellende 
factor voor een hogere of lagere mitotic rate. Bovendien zorgde het toevoegen van 
mitotic rate in een model dat de overleving van het melanoom voorspelde niet voor 
een aanpassing van het vrouwelijk voordeel hiervan. Daarom concludeerden we dat 
mannen – na correctie voor alle andere prognostische factoren- geen agressievere vorm 
van melanoom krijgen, en dat daarom niet de tumor zelf, maar verschillen tussen de 
‘gastheer’ van de tumor het voordeel van de vrouwen moeten verklaren. 
In hoofdstuk 3 onderzochten we de literatuur op mogelijke verklaringen voor de 
geslachtsverschillen in overleving van patiënten met een huidmelanoom. In hoofdstuk 
3.1 stelden we op basis van literatuuronderzoek de hypothese voor dat het efficiënter 
neutraliseren van zuurstofradicalen door vrouwen een verklaring is voor hun betere 
overleving van het melanoom. Te veel zuurstofradicalen zorgen voor een toename van 
oxidatieve stress. Het wordt steeds duidelijker dat deze zuurstofradicalen een belan-
grijke rol spelen in de progressie en metastasering van tumoren, en dan vooral van het 
melanoom:  zuurstofradicalen induceren DNA mutaties die de tumor meer kwaadaardig 
maken, spelen een rol in het uitselecteren van de meest resistente tumorcellen, stimul-
eren tumorgroei en invasie in omliggende weefsels, spelen een rol in het ontwijken van 
de tumor van het immuunsysteem, helpen tumorcellen om zich vanuit de bloedbaan 
in een ander orgaan te nestelen en activeren vele cellulaire processen die uitzaaiingen 
bevorderen. Vanuit de wetenschap die onderzoekt waarom vrouwen überhaupt langer 
leven dan mannen is al langer bekend dat vrouwen zuurstofradicalen beter kunnen 
neutraliseren dan mannen, waarschijnlijk omdat zij door een verschil in genen meer 
“anti-oxidanten” in hun cellen tot expressie brengen. De grotere verdedigingscapaciteit 
van vrouwen tegen deze zuurstofradicalen zou daarom een verklaring kunnen zijn voor 
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de verminderde progressie en betere overleving van het huidmelanoom dan bij man-
nen. 
In hoofdstuk 3.2 voerden we een literatuurstudie uit die meer dan 200 eerder ge-
publiceerde studies over het melanoom en de verschillen tussen mannen en vrouwen 
omvatte. Allereerst bediscussieerden we de hypothese dat het verschil in overleving 
tussen de geslachten kan worden verklaard door verschillen in gedrag. Zo zouden 
vrouwen mogelijk eerder naar de dokter gaan met klachten of (huid)afwijkingen en 
daardoor eerder gediagnosticeerd worden. Mogelijk zorgt ander gedrag ook voor ver-
schillen in blootstelling aan de zon. We concludeerden dat gedrag het verschil niet ten 
volle kan verklaren, onder andere omdat het vrouwelijk voordeel niet verdwijnt na het 
aanpassen voor prognostische factoren die met dergelijke gedragverschillen te maken 
hebben (zoals de dikte van het melanoom). Daarom zochten we verder in de literatuur 
voor alternatieve verklaringen gebaseerd op biologische verschillen tussen mannen en 
vrouwen die ook van invloed zijn op de progressie en overleving van het melanoom. Dit 
leverde een groot aantal mogelijke verklaringen op: 
- Verschillende tumortypes
- Hormonale factoren (oestrogenen, androgenen, oestrogeen-receptoren) 
- Het immuunsysteem
- Fysiologische verschillen van de huid
- Vitamine D metabolisme
- Obesitas
- Autofagie 
- Matrix metalloproteinase-2 (MMP-2). 
Conclusie
Samenvattend vonden we een zeer consistent en significant voordeel in de prognose 
van een melanoom voor  vrouwelijke patiënten in vergelijking met mannelijke. Dit 
gold voor voor zowel het gelokaliseerde als het gemetasteerde melanoom. Verschillen 
in gedrag lijken als verklaring hiervoor niet voldoende: als we de modellen aanpasten 
voor prognostische factoren die ook voor verschillen in gedrag zouden moeten cor-
rigeren bleef er een zeer consistent en significant voordeel van 30% bestaan voor de 
vrouwelijke patiënten. Ook vonden we geen aanwijzingen dat mannen een agressievere 
tumor kregen dan vrouwen. Daarom moeten we de verklaring zoeken in biologische 
verschillen tussen de gastheren. Hiervoor zijn er twee opties:
- óf een biologische eigenschap van vrouwen die ze beschermt tegen progressie van 
hun melanoom.
- óf een eigenschap van mannen die progressie van hun melanoom stimuleert of de 
weerstand tegen hun melanoom vermindert. 
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Samenvatting
We hebben hiervoor verschillende mogelijke verklaringen gevonden in de literatuur, 
zoals hierboven in hoofdstuk 3.2 aangegeven. Er is verder onderzoek nodig om de pre-
cieze verklaring voor dit fenomeen te vinden, zodat we de progressie van het melanoom 
van de huid beter begrijpen en deze kennis mogelijk kunnen gebruiken voor het vinden 
van nieuwe strategieën voor de behandeling van het (uitgezaaid) melanoom.
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Laat ik beginnen met u als lezer te bedanken. Er zijn immers twee mogelijkheden: óf u 
bent op pagina 1 begonnen met lezen en hebt het hele boekje uitgelezen tot hier en 
dan verdient u de grootste waardering. Óf - en dit is vele malen waarschijnlijker - u bent 
zo snel mogelijk naar het dankwoord gebladerd, en dan moet ik u bedanken dat u mij 
in de gelegenheid stelt om al die mensen te bedanken die mij geholpen hebben om dit 
proefschrift mogelijk te maken.  
Ik wil graag beginnen met het bedanken van mijn promotoren en co-promotor: Profes-
sor Jan-Willem Coebergh, Professor Lex Eggermont, Professor Tamar Nijsten en Dr. Esther 
de Vries. Promoveren is voor mij –op de laatste maanden na dan– nooit een stressvolle 
tijd geweest. De belangrijkste reden hiervoor is dat jullie me altijd veel vrijheid gaven 
om zelf mijn richting te kiezen in mijn onderzoek. Dit heeft voor mij geresulteerd in een 
echt ‘eigen’ proefschrift en gelukkig ook nog eens in een reeks mooie en succesvolle 
publicaties en presentaties. Veel dank hiervoor! 
Dan persoonlijk: Beste Jan Willem, niet alleen voor mij, maar voor al je onderzoekers 
ben je meer een vader dan promotor. Ik denk dat onze besprekingen voor 10% over mijn 
onderzoek gingen en voor 90% over ”overige onderwerpen”, variërend van algemene 
politieke (CDA-)beschouwingen tot de geschiedenis van Georgië en alles daartussen. 
Dank voor je bijzondere manier van begeleiding. Mocht ik ooit professor worden, dan 
zal ik mijn kamer naar jouw voorbeeld inrichten. 
Beste Tamar, bij jou begon dit proefschrift: jij was degene die me vanuit Leiden meege-
nomen hebt naar Rotterdam om te promoveren. Onder jouw stimulerende begeleiding 
zette ik mijn eerste stappen in de wereld van de epidemiologie en de statistiek. Dank 
je dat je het in me zag zitten. Gelukkig heb ik lang genoeg over mijn promotie gedaan 
zodat jij inmiddels professor werd en mijn promotor kan zijn. 
Beste Lex, ik weet nog goed dat we elkaar in het MGZ voor het eerst ontmoeten. 
Ik moest mijn hypothese en mijn onderzoek aan je uitleggen, je stelde een vuur aan 
vragen en hebt toen blijkbaar besloten dat ik goed genoeg was. Daarna heb ik altijd je 
steun ervaren. Ik vond het bijzonder dat de drukste man in Melanoom-Europa altijd als 
eerste zijn commentaar op een nieuw manuscript terugstuurde. Veel dank voor je hulp 
en de vele deuren die dankzij jou open gingen. 
Beste Esther, jij bent gedurende mijn hele promotie mijn directe steun en toeverlaat 
geweest. Dank voor je vele lessen in statistiek, epidemiologie, het schrijven van een 
manuscript, praatjes geven op congressen en al die andere dingen ik van jou als onder-
zoeker heb geleerd. Veel dank voor je deur die altijd open stond. Ik wens je het allerbeste 
in Colombia, maar hoop stiekem dat je wel weer terug komt.
Ik wil mijn kleine commissie, professor Mooi, professor Sleijfer en professor van Eijck 
bedanken voor het doorlezen en becommentariëren van dit proefschrift. Professor van 
Eijck wil ik ook bedanken voor zijn hulp bij het schrijven van hoofdstuk 3.1, de review 
over Reactive Oxygen Species, van dit proefschrift. 
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Een speciaal woord van dank gaat ook uit naar de onderzoekers op de afdeling Klini-
sche Pharmacologie en Toxicologie in het LUMC onder leiding van professor Guchelaar. 
Bij jullie begon mijn prille onderzoekscarrière als student en werd ik gegrepen door het 
onderzoek. Zonder die periode was dit proefschrift er nooit gekomen. Speciale dank 
gaat uit naar mijn kamer-met-uitzicht-op-een-container-genoten daar: Nielka, Judith, 
Jesse, Rogier en natuurlijk Els, veel dank voor het stimuleren van mijn nieuwsgierigheid 
naar wetenschappelijk onderzoek!
Dear Dieter Hölzel en Jutta Engel, many thanks for your invitation to come to Mün-
chen and for the ability to use your impressive database, leading to my first publication 
on this subject. Still, no other cancer registry that I know of registers so meticulously all 
metastatic events in cancer. For this you and your team deserve great admiration and 
are an example to the rest of Europe.
Dear researchers in the Melanoma Institute Australia; Professor Scolyer, Professor 
Thompson and Lauren Haydu: although we never met in person, you allowed me to use 
your famous melanoma database to study this subject. Many thanks for that, and thank 
you for your patience while waiting on my replies to your messages on the status of the 
manuscript...
Dear Stefan Suciu and Sandra Collette: I have very much enjoyed our succesful coöpe-
ration using the rich EORTC trial databases, which resulted in two nice and high-ranked 
publications! Stefan, your critical comments on the statistical methods forced me to 
step-up in my statistical knowledge and skills. This will prove invaluable in the rest of my 
career, for which I am very thankful. 
I want to thank the European Organization for Research and Treatment of Cancer 
(EORTC) Melanoma Group, for all your (financial) support and all the great meetings 
which I was able to visit accross Europe. I have learnt a great deal from the discussions 
with so many of you and have very much enjoyed the dinners and parties afterwards! A 
special thanks to the co-authors of the two papers using EORTC trial data: Ferdy Lejeune, 
Ulrich Kleeberg, Poulam Patel and Ulrich Keilholz, as well as to the present chairman 
Alessandro Testori and Treasurer Ghanem Ghanem: thank you for all your support. 
Mijn dank gaat ook uit naar al die jonge onderzoekers die ik in Nederland en Europa 
ben tegengekomen tijdens het schrijven van dit proefschrift. In het bijzonder Cynthia 
Holterhues, Loes Hollestein, en Robert van der Leest bij de dermatologie, Alexander van 
Akkooi en Stijn van der Ploeg bij de EORTC en Isabelle Soerjomataram, Henrike Karim-
Kos, Lifang Liu en Melina Arnold binnen het MGZ: veel dank voor alle samenwerking, 
overleggen, discussies, tips en samen bezoeken van congressen, inclusief de dineetjes 
en feestjes!   
Beste AE-135 kamergenootjes; Ilke, Anne en Luc: veel dank voor de gezellige tijd! Luc 
(Doctor Coffeng moet ik nu zeggen), tijdens mijn gehele MGZ-tijd zaten we bij elkaar 
op de kamer. Veel dank voor de ontspannende momenten en natuurlijk ook voor al je 
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hulp als ik mezelf weer in een gekke analyse had gewerkt die ik eigenlijk niet snapte. Ik 
vind het erg jammer dat je er vandaag niet bij kan zijn, voor nu veel succes in Seattle en 
hopelijk daarna weer tot ziens in Nederland! 
Onderzoeker zijn leek opeens heel makkelijk toen ik na drie jaar achter mijn computer 
vandaan kwam en de kliniek weer binnenstapte. Opeens waren patienten geen getal in 
SPSS meer maar een echte zieke persoon in een echt ziekenhuisbed. Gelukkig kwam ik 
in het leukste ziekenhuis van Nederland terecht met de gezelligste afdeling Interne Ge-
neeskunde. Alle collega arts-assistenten met wie ik samengewerkt heb: heel veel dank 
voor jullie steun in die eerste zware periode, en natuurlijk vooral voor alle gezelligheid 
en collegialiteit in de jaren dat ik nu in het Reinier de Graaf Gasthuis werk. Ik zou jullie 
bijna allemaal noemen hier maar dan is het risico te groot dat ik mensen vergeet. Ik kijk 
er naar uit velen van jullie nog heel vaak te ontmoeten in het medische wereldje! 
Ook de ‘bazen’ van de interne geneeskunde zorgden ervoor dat ik me in de kliniek snel 
thuis en veilig voelde. Veel dank voor al jullie steun en voor alles wat jullie me geleerd 
hebben. Dit geldt in het bijzonder voor de internisten van de afdeling oncologie en 
endocrinologie, de begeleiders op de consulten en de SEH, de intensivisten op de IC en 
natuurlijk de opleider Ward Posthuma.
Lieve familie: papa, mama, Eva, Niek, Wouter en Iris en alle aanhang: dank voor jullie 
steun en interesse voor alles wat ik de afgelopen jaren heb gedaan. Ik ben er trots op 
hoe we als gezin nu functioneren na soms moeilijke tijden en vind dat jullie daar al-
lemaal een groot compliment voor verdienen!
Lieve Peter, Addi en rest van de schoonfamilie: veel dank voor de warme opvang in de 
familie, interesse in wat ik doe, de gezelligheid en steun ook in moeilijke tijden. 
Lieve vrienden, teamgenoten bij de voetbal, vrienden bij het CD(J)A, en in het bijzon-
der de Winden en Jaar- en Dispuutsgenoten bij het G.L.H.D: dank voor jullie vriendschap. 
Ik hoop nog vele borrels, feestjes, discussies, windenweekenden en midden-oude-
mannen-weekenden voor de boeg te hebben! 
Lieve Chris en Louisa, dank voor jullie onvoorwaardelijke steun. Ik heb mogen ervaren 
dat ik altijd bij jullie mag aankloppen en dat is me heel veel waard. Ik hoop hetzelfde te 
kunnen betekenen voor jullie. Christiaan, ooit stonden we naast elkaar bij de decentrale 
selectie voor de studie, daarna stond ik naast je op bruiloft en vandaag sta je naast me 
op deze dag. Ik hoop dat we dit de rest van ons leven door kunnen zetten!
Lieve, lieve Suzan, ik besef me dat ik ongelofelijk veel geluk heb dat ik met jou samen 
mag zijn. Je vult me aan en bent mijn steun en toeverlaat in alles. Dank je voor al je hulp, 
ook bij dit proefschrift, maar vooral met al die andere dingen in mijn leven. Dank je dat 
je naast me staat vandaag. Ik hou van je en kijk uit naar een lange, avontuurlijke en 
gelukkige toekomst samen.  
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Summary of PhD training and teaching activities
Name PhD student:   Arjen Joosse
PhD period:    2008-2013
Erasmus MC Department:  Public Health
Promotors:    prof.dr. J.W.W. Coebergh, prof.dr. A.M.M. Eggermont, 
    prof.dr. T.E.C. Nijsten
Supervisor:    dr. E. de Vries
1. PhD training Year Workload
(Hours/ECTS)
Courses
- Multistate-models and models for competing risks, 
Department of Biostatistics, Erasmus MC Rotterdam
2009 0.6 ECTS
- Introduction to Data-Analysis, NIHES course, 
Erasmus MC Rotterdam
2010 1.0 ECTS
- Survival Analysis, NIHES course, Erasmus MC 
Rotterdam
2010 1.9 ECTS
Oral Presentations
- “NSAIDs and Cutaneous Melanoma Incidence”, 
International Dermato-Epidemiological Association 
(IDEA) congress, Nottingham
2008 1 ECTS
- “Pharmaco-epidemiology and Gender Differences in 
Cutaneous Melanoma”, semi-annual meeting of the 
EORTC Melanoma Group, Scheveningen
2008 0.5 ECTS
- “Melanoma Gender Differences in Survival”, EORTC 
Melanoma Group meeting, Brussels
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- “Melanoma Gender Differences; Population based 
Study in Munich”, EORTC Melanoma Group meeting, 
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- “Melanoma Gender Differences; Population based 
Study in Munich”, 7th World Congress on Melanoma 
and 5th congress of the European Association of 
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2009 0.5 ECTS
- “Female melanoma patients have a decreased risk 
of lymph node and visceral metastasis”, Skin Cancer 
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2010 0.5 ECTS
- “Reactive Oxygen Species and Melanoma: An Explana-
tion for Gender Differences in Survival?”,  ‘Oncologie is 
de Parel van de Ardennen’, Department of Dermatol-
ogy Meeting, Spa
2010 1 ECTS
- “Gender Differences in Progression for Localized 
Melanoma”, Perspectives in Melanoma XIV, Amster-
dam
2010 1 ECTS
- “The impact of gender on the outcome of malignant 
melanoma: Overview of seven EORTC phase III trials” 
semi-annual EORTC Melanoma Group meeting, 
Brussels
2011 0.5 ECTS
- “Lymph node ratio as a prognostic factor in stage III: 
Analysis in 3 EORTC adjuvant randomized controlled 
trials”, EORTC Melanoma Group semi-annual meet-
ing, Barcelona
2011 0.5 ECTS
- “Melanoma Gender Differences in Survival”, ‘Skin-
termezzo’ meeting, Department of Dermatology, 
Erasmus MC Rotterdam
2012 1 ECTS
- “The female advantage in melanoma survival”, 8th 
World Congress on Melanoma and 9th Congress of 
the European Association of Dermato-Oncology 
(EADO), Hamburg
2013 1 ECTS
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- “Zwakke Mannen (Bij melanoom dan)” Regional 
Melanoma Symposium, Comprehensive Cancer 
Center The Netherlands, Rotterdam. 
2013 0.5 ECTS
Poster Presentations
- “Reactive Oxygen Species and Melanoma: An 
Explanation for Gender Differences in Melanoma?”, 5th 
international congress of Gender Medicine, Tel Aviv
2010 1 ECTS
- “Reactive Oxygen Species and Melanoma: An Explana-
tion for Gender Differences in Melanoma?”, Perspec-
tives in Melanoma XIV, Amsterdam
2010 0.25 ECTS
- “The Impact of Gender on the Outcome of Malignant 
Melanoma”, American Society of Clinical Oncology 
(ASCO) Annual Meeting, Chicago
2011 1 ECTS
- “The female advantage in melanoma progression 
and survival: behavior or biology?”, Reinier de Graaf 
Hospital, Delft. 
2013 0.25 ECTS
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- 5th international congress of Gender Medicine, Tel 
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- Perspectives in Melanoma XIV, including semi-annu-
al EORTC Melanoma Group meeting, Amsterdam
2010 1 ECTS
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199
8
PhD Portfolio
2. Teaching activities
Supervising practicals
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